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1.	  Abstract	  
	  
c-­‐Myc	   is	   a	   transcriptional	   regulator	   required	   for	   the	   cellular	   response	   to	   proliferative	  
stimuli.	  The	  gene	  expression	  programs	  regulated	  by	  Myc	  in	  physiological	  settings	  remain	  
to	   be	   clarified.	   Here,	   we	   provide	   a	   complete	   characterization	   of	   Myc-­‐dependent	  
regulatory	   events	   in	   primary	   mouse	   B	   cells	   following	   activation	   by	   bacterial	  
lipopolysaccharide	   (LPS).	   Taking	   advantage	   of	   cells	   homozygous	   for	   a	   conditional	  
knockout	   allele	   of	   c-­‐myc,	   we	   induced	   deletion	   before	   LPS	   stimulation,	   followed	   by	  
genome	   wide	   profiling	   of	   mRNA	   levels	   and	   Myc-­‐DNA	   interactions.	   In	   contrast	   with	  
previous	   studies,	   in	   which	   Myc	   was	   proposed	   to	   directly	   drive	   transcriptional	  
amplification	  at	  all	  active	  loci	  (Nie	  et	  al.	  2012,	  Lin	  et	  al.	  2012),	  our	  study	  revealed	  that	  Myc	  
is	   required	   for	   the	   up-­‐	   and	   down-­‐regulation	   of	   distinct	   subsets	   of	   genes	   early	   after	  
stimulation,	   occurring	   prior	   to	   the	   global	   increase	   in	   RNA	   production.	   These	   gene	  
expression	   programs	   where	   partially	   overlapping	   with	   those	   regulated	   by	   Myc	   upon	  
oncogenic	  activation,	  a	  distinction	  made	  not	  only	  in	  B-­‐cells,	  but	  also	  in	  fibroblasts	  (Sabò	  et	  
al.,	  2014,	  Perna	  et	  al.	  2012).	  Our	  data	  also	  show	  that	  Myc	  dependent	  regulation	  can	  occur	  
at	   the	   level	   of	   RNA	  Polymerase	   II	   loading,	   as	  well	   as	   elongation.	   Altogether	   these	   data	  
provide	   an	   extensive	   picture	   of	   Myc'	  s	   action	   in	   response	   to	   a	   mitogenic	   stimulus,	  
highlighting	  the	  importance	  of	  Myc-­‐target	  genes	  in	  the	  remodeling	  of	  cellular	  physiology	  
and	  metabolism.	  Systematic	  work	  will	  be	  needed	   to	  unravel	  which,	  among	  all	   the	  Myc-­‐
regulated	  genes,	  are	  critical	  in	  mediating	  this	  chain	  of	  events.	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2.Introduction	  	  
	  
Myc,	   the	   product	   of	   the	   c-­‐myc	  proto-­‐oncogene,	   is	   one	   of	   the	  most	   studied	   proteins	   in	  
biomedical	  research.	  Myc	  normally	  integrates	  environmental	  signals	  in	  order	  to	  modulate	  
different	   cellular	   processes	   including	   proliferation,	   apoptosis,	   energy	   metabolism	   and	  
differentiation	   	   (Tansey,	   2014)	   .	   Disruption	   of	   its	   tight	   regulation	   leads	   to	   aberrant	   cell	  
cycle	   progression	   and	   carcinogenesis.	   Indeed	   Myc	   deregulation	   directly	   contributes	   to	  
malignant	  transformation	  in	  multiple	  cell	  types	  and	  is	  a	  hallmark	  of	  many	  human	  cancers	  	  
(Ciriello	  et	  al.,	  2013;	  Gabay	  et	  al.,	  2014;	  Meyer	  and	  Penn,	  2008).	  Oncogenic	  activation	  of	  
c-­‐myc	  can	  occur	  directly	  or	  indirectly.	  Chromosomal	  abnormalities	  of	  the	  myc	  locus,	  such	  
as	   gene	   translocation	   in	   Burkitt’s	   B	   cell	   lymphomas	   	   (Küppers	   &	   Dalla-­‐Favera,	   2001),	  
amplification	   in	   different	   carcinomas	   or	   insertional	   mutagenesis	   represent	   direct	  
mechanisms	  of	  Myc	  overexpression.	  In	  these	  genetic	  rearrangements,	  the	  protein	  coding	  
sequence	  of	  c-­‐myc	  may	   remain	   intact,	  differently	   from	  other	  proto-­‐oncogenes	   in	  which	  
changes	  in	  protein	  sequences	  are	  needed	  for	  oncogenic	  activation.	  	  Most	  frequently,	  Myc	  
is	   indirectly	  activated,	   since	  growth-­‐regulatory	  pathways	   that	   induce	  or	   stabilize	  Myc	   in	  
physiological	  conditions	  are	  themselves	  target	  of	  activating	  mutations	   (e.g.	  RAS,	  Wnt	  or	  
Notch	  signaling)	  (He	  et	  al.,	  1998;	  Palomero	  et	  al.,	  2006;	  Sears	  et	  al.,	  1999).	  In	  addition,	  in	  
many	   mouse	   models	   of	   Myc-­‐driven	   tumors,	   the	   tumor	   cells	   become	   addicted	   to	   Myc	  
overexpression,	   as	   inhibiting	   Myc	   can	   cause	   cell	   death,	   arrest	   and/or	   differentiation	  	  
(Felsher	   and	   Bishop,	   1999;	   Arvanitis	   &	   Felsher,	   2006;	   Jain	   et	   al.,	   2002;	   ).	   Thus,	  Myc	   is	  
usually	   required	   for	   tumour	  progression	  and	  maintenance	  also	  even	   if	   it’s	   not	  mutated	  
itself.	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2.1	  Myc	  
	  
2.1.1	  Myc’s	  discovery	  	  
	  
The	  discovery	  of	  Myc	  arose	  from	  studies	  on	  retroviruses	  associated	  with	  animal	  cancers.	  
In	  1911,	  the	  experiments	  of	  Peyton	  Rous	  showed	  that	  chicken	  leukemia	  and	  sarcomas	  are	  
transmissible	  through	  cell-­‐free	  filtrates.	   In	  the	  following	  50	  years	   it	  was	  established	  that	  
many	  animal	   tumors	   could	  originate	   from	  viral	   infections.	   	  During	   the	  1960s	  and	  1970s	  
different	  retroviruses	  were	  isolated	  from	  avian	  neoplasms	  and	  in	  particular,	  the	  strain	  of	  
virus	  called	  MC29	  was	  shown	  to	  transform	  myeloid	  cells	  in	  myelocytomas,	  a	  solid	  tumour,	  
or	   myelocytomatosis.	   The	   name	   gave	   to	   the	   genetic	   element	   responsible	   for	  
transformation	  was	  v-­‐myc	  from	  viral	  myelocytomatosis.	  The	  MC29	  virus	  MYC	  protein	  was	  
found	  to	  localize	  into	  the	  nucleolus	  of	  the	  target	  cell,	  suggesting	  a	  unique	  involvement	  in	  
gene	   regulation	   and	   nuclear	   function	   respect	   to	   other	   retroviral	   oncoproteins.	   Then,	   a	  
cellular	  homolog	  of	   this	  gene	   in	  uninfected	  vertebrate	  cells	  was	   found	  and	  called	  c-­‐myc	  
(Sheiness	  and	  Bishop,	  1979).	  Finally	  in	  1982,	  the	  c-­‐myc	  gene	  was	  cloned	  and	  characterized	  
opening	  an	  era	  of	  massive	  research	  efforts	  into	  understanding	  Myc’s	  structure,	  biological	  
functions	  and	  transcriptional	  regulation.	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2.1.2 Biological	  functions	  of	  Myc	  in	  cellular	  physiology	  	  
	  
Myc,	   in	   response	   to	   intracellular	   and	   extracellular	   stimuli	   such	   as	   cytokines,	   growth	  
factors	  and	  mitogens	   regulates	  a	  plethora	  of	  different	  biological	  processes.	   It	   is	   able	   to	  
induce	   cell	   cycle	   progression	   and	   growth,	   potentiate	   apoptosis,	   block	   differentiation,	  
increase	   genome	   instability,	   stimulate	   angiogenesis,	   stromal	   remodelling,	   inflammation	  
and	   thus	  drive	   transformation	   (Kelly	   et	   al.,	   1983;	   Eisenman,	  2001;	   Eilers	   and	  Eisenman,	  
2008)	   (Figure	   1).	  Myc	  may	   achieve	   these	  physiological	   and	  pathological	   outputs	  mainly	  
through	  regulation	  of	  gene	  expression.	  
	  
	  
Figure	  1	  Myc	  as	  an	  intracellular	  sensor	  of	  mitogenic	  stimuli.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Schematic	  representation	  of	  the	  biological	  effects	  of	  Myc	  activation.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(Source:	  modified	  from	  Sodir	  and	  Evan	  Journal	  of	  Biology	  2009	  8:77	  ©	  2009	  BioMed	  Central	  Ltd)	  	  
	  
!
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In	   somatic	   cells,	   the	  main	   function	  of	  Myc	   is	   the	   tight	   regulation	  of	  proliferation.	  Germ	  
line	  deletion	  of	  either	  N-­‐myc	  or	  c-­‐myc	  is	  lethal	  for	  the	  embryo	  beyond	  day	  10	  because	  of	  
abnormalities	   in	  organs	  development	  and	  tissue	  growth	   (Davis	  A.C.	  et	  al	  1993).	  For	   this	  
reason,	   conditional	  myc	   knockout	  mice	  were	   generated	   to	   study	  Myc	   function	   in	   adult	  
tissue.	  c-­‐myc	  deletion	  in	  fibroblasts,	  keratinocytes	  and	  B	  cells	  compromises	  G0	  to	  S	  phase	  
progression	  upon	  stimulation	  with	  	  serum	  or	  cytokines	  	  (de	  Alboran	  et	  al.,	  2001;	  Rabbitts	  
et	  al.,	  1985).	  On	  the	  other	  hand,	  Myc	  	  activation	  is	  sufficient	  to	  expedite	  cell	  cycle	  entry	  
and	  reduce	  the	  requirement	  for	  mitogenic	  signals	  to	  maintain	  the	  cycling	  state.	  The	  main	  
mechanism	   used	   by	   Myc	   to	   achieve	   this	   goal	   is	   the	   direct	   activation	   of	   cyclin/CDK	  
expression	  such	  as	  cdk4,	  cyclin	  D,	  E	  and	  inhibition	  of	  cell	  cycle	  checkpoints	  (Hermeking	  et	  
al.,	  2000;	  Yang	  et	  al.,	  2001).	  For	  example	  Myc	  induction	  of	  Cdk4-­‐cyclinD	  and	  Cdk2-­‐cyclinE	  
promotes	   Rb	   hyperphosphorylation,	   the	   release	   of	   E2F	   from	   Rb	   and	   thus	   the	   S	   phase	  
entry,	  which	  is	  also	  accelerated	  by	  a	  direct	  induction	  of	  E2F2	  by	  Myc	  	  (Hermeking	  et	  al.,	  
2000;	  Santoni-­‐Rugiu	  eta	  l.,	  2000;	  Mateyak	  et	  al.,1999).	  
An	   important	   aspect	   of	   cell	   physiology	   is	   the	   ability	   to	   coordinate	   growth	   with	   cell	  
division.	  	  Studies	  of	  Drosophila	  dmyc,	  the	  orthologous	  of	  myc,	  showed	  that	  cells	  without	  
dmyc	  decreased	  cell	  mass	  accumulation	  and	  size,	  while	  cells	  overexpressing	  it	  are	  bigger	  
than	   normal	   ones	   and	   more	   prone	   to	   progress	   in	   S	   phase	   to	   accelerate	   cell	   divisions	  	  
(Johnston	  et	  al.	  1999).	   	  Therefore,	  dmyc	   influences	  growth	  with	  changes	  in	  cell	  doubling	  
time	  suggesting	  a	  primary	  role	  in	  activation	  of	  the	  cell	  growth	  machinery.	  Studies	  in	  yeast	  
on	  growth	  showed	  that	  cell	  cycle	  mutants	  had	  impaired	  cell	  growth	  (altered	  cell	  size	  and	  
decreased	   in	  RNA	   content)	   independently	  of	   change	   in	   cell	   division	   	   (Fraser	   and	  Nurse,	  
1979).	   	   In	   primary	   B	   cells	   derived	   from	  Eμ-­‐myc	  mice	   and	   in	   human	  B	   cell	   lines	   such	   as	  
P493,	  it	  was	  demonstrated	  that	  ectopic	  c-­‐myc	  expression	  induces	  cell	  growth,	  that	  is,	  an	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increase	  in	  cell	  size	  and	  protein	  synthesis,	  independently	  from	  cell	  cycle	  phases	  	  (Iritani	  B	  
&	  Eisenman	  1999;	  	  Schuhmacher	  et	  al.,	  1999).	  	  Related	  to	  this,	  Myc	  promotes	  the	  increase	  
in	   ribosome	   biogenesis	   and	   production	   of	   metabolic	   enzymes	   in	   order	   to	   satisfy	   the	  
requirements	   of	   growing	   cells	   for	   ATP	   and	   metabolites	   	   (Johnston	   et	   al.,	   1999)	   (see	  
paragraph	  2.4.1).	  
Myc	  can	  also	  affect	  cellular	  differentiation.	  The	  presence	  or	  the	  absence	  of	  Myc	  can	  affect	  
this	  process	   in	  opposite	  ways,	  depending	  on	  the	  cell	  context	  and	  stage	  of	  development.	  
Down-­‐regulation	   of	  myc	   expression	   can	   engage	   differentiation	   in	   B	   cell	   and	   in	   human	  
promyelocytic	  leukemia	  cells	  (Schuhmacher	  et	  al.,	  1999;	  Bacon	  TA	  &	  Wickstrom	  E.	  1991).	  
In	   addition,	  Myc	   induction	  or	  overexpression	  blocks	  differentiation	   in	   various	   cell	   types	  
such	   as	   keratinocytes	   in	   vitro	   	   (Dang	   CV.,	   2013)	   and	   in	   vivo	   	   (Lin	   K.	   et	   al.,	   2000).	   The	  
physiological	   dowregulation	   of	   Myc	   is	   necessary,	   even	   if	   not	   sufficient,	   for	   B	   cell	  
differentiation	   	   (Lin	   K.	   et	   al.,	   2000;	   Murn	   et	   al.,	   2009).	   Indeed,	   ectopic	   expression	   of	  
Blimp1,	  a	  known	  inducers	  of	  plasma	  cell	  	  differentiation,	  induces	  	  also	  down-­‐regulation	  of	  
endogenous	  c-­‐Myc,	  correlating	  well	  with	  the	  cessation	  of	  proliferation	  that	  occurs	  during	  
terminal	   differentiation	   	   (Lin	   Y.,	   et	   al.	   1997).	   On	   the	   contrary,	   Myc	   can	   promote	  
differentiation	   of	   the	   stem	   cell	   compartment:	   in	   particular,	   Myc	   can	   push	   the	   exit	   of	  
hematopoietic	  stem	  cells	  (HSC)	  from	  the	  stem	  cell	  niche	  (Laurenti	  et	  al.,	  2008),	  and	  has	  a	  
similar	  effect	  on	  human	  epidermal	  stem	  cells,	  favouring	  entry	  into	  the	  transit	  amplifying	  
compartment	  and	  thereby	   initiating	  terminal	  differentiation	  (Gandarillas	  A.	  &	  Watt	  FM.,	  
1997).	  
Another	  aspect	  of	  Myc	  biology	  is	  its	  ability	  to	  sensitize	  cells	  to	  different	  apoptotic	  stimuli	  
rather	  than	  directly	  inducing	  apoptosis	  by	  itself.	  In	  B-­‐lymphocytes,	  for	  example,	  anti-­‐CD40	  
stimulation	  with	  consequent	  Myc	  induction	  promotes	  the	  surface	  expression	  of	  CD95	  and	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makes	  them	  susceptible	  to	  cell	  death.	  In	  addition,	  it	  was	  demonstrated	  in	  fibroblasts	  and	  
myeloid	   cell	   lines	   that,	   upon	   serum	   deprivation,	   overexpression	   of	   Myc	   can	   promote	  
apoptosis	   (Evan	  G.et	   al	   1992;	   Askew	  DS	   et	   al	   1991).	   In	   addition	   c-­‐Myc	   deficient	   B	   cells	  
were	   shown	   to	   be	   resistant	   to	   CD95	   induced	   cell	   death	   or	   staurisporine,	   another	  
apoptotic	  stimulus	  (de	  Alborán	  et	  al.,	  2003).	   	  On	  the	  contrary,	   it	  was	  shown	  that	  down-­‐
modulation	  of	  c-­‐myc	  expression	  correlates	  with	   induction	  of	  apoptosis	   in	  B	  cells	   (Wu	  et	  
al.,	   1996).	   Among	   the	  main	  mechanisms	   adopted	   by	  Myc	   to	   induce	   apoptosis	   are	   the	  
disruption	  of	  the	  equilibrium	  between	  pro-­‐apoptotic	  BH3-­‐only	  protein	  and	  anti-­‐apoptotic	  
proteins	  Bcl-­‐2	  and	  Bcl-­‐X	  (Hemann	  et	  al.,	  2005;	  Eischen	  CM	  et	  al.,	  2001)	  or	  the	  activation	  of	  
ARF-­‐MDM2-­‐p53	  axis	  during	   tumorigenesis	   (Eischen	  et	  al.,	  2001;	  Oster	  et	  al.,	  2002).	  The	  
ability	  of	  Myc	  to	  drive	  both	  programmed	  cell	  death	  and	  proliferation	   in	  a	  well-­‐balanced	  
way	  is	  a	  safeguard	  mechanism	  to	  prevent	  uncontrolled	  growth	  and	  tumour	  onset.	  	  
	  
2.1.3	  Structure	  of	  Myc	  proteins	  
	  
In	  mammalian	   cells,	   there	  are	   three	  different	  gene	   family	  members	  of	  Myc	  proteins,	  c-­‐
Myc,	  N-­‐myc,	  L-­‐myc,	  which	  share	  the	  same	  general	  topology	  with	  almost	  40%	  of	  sequence	  
homology	  and	   show	  very	   similar	   functions,	  but	  different	  patterns	  of	  expression	   (Bull	   et	  
al.,	  2001;	  Xu	  et	  al.,	  1991).	  The	  presence	  of	  multiple	  Myc	  family	  members	  may	  reflect	  the	  
different	  spatial	  and	  temporal	  requirements	  of	  Myc	  activity	  in	  development	  and	  in	  adult	  
tissues	   with	   a	   consequent	   overexpression	   of	   each	   protein	   in	   specific	   cancer	   types.	   In	  
particular,	  c-­‐Myc	  is	  usually	  overexpressed	  in	  most	  blood	  borne	  and	  solid	  tumors	  whereas	  
N-­‐myc	   is	   more	   selectively	   amplified	   in	   neuroblastoma	   and	   L-­‐myc	   in	   small	   cell	   lung	  
carcinomas	  (Nau	  et	  al.,	  1985;	  Weiss	  et	  al.,	  1997).	  The	  structural	  organization	  of	  Myc	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proteins	   is	   conserved	   through	   evolution	   and	   resembles	   the	   conformation	   of	   a	   typical	  
sequence-­‐specific	   DNA	   binding	   transcriptional	   regulator	   (Figure	   2).	   	   Among	   the	   three	  
paralogs	  (c,	  N,	  L-­‐myc)	  the	  main	  similarities	  lie	  in	  the	  conserved	  regions	  (Figure	  2).	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  2	  General	  architecture	  of	  MYC	  proteins.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
The	  main	  structural	  domains	  of	  MYC	  are	  shown	  schematically	  at	  the	  top	  of	  the	  figure.	  Transcriptional	  
activation,	  central	  portion,	  canonical	  nuclear	  localization	  sequence	  ‘N’	  and	  region	  of	  DNA	  binding	  via	  
interaction	  with	  MAX	  are	  reported.	  A	  representation	  of	  the	  different	  family	  members	  (C,	  N	  and	  L-­‐MYC)	  is	  
shown	  underlining	  the	  conservation	  of	  the	  sequences	  and	  the	  localization	  of	  Myc	  boxes	  even	  if	  the	  proteins	  
are	  different	  in	  length.	  (Source:	  Tansey,	  W.	  (2014).	  Hindawi	  Publishing	  Corporation	  New	  Journal	  of	  Science,	  
Volume	  2014,	  Article	  ID	  757534,	  27	  pages;	  Copyright	  ©	  2014	  William	  P.	  Ğansey.).	  
	  
	  
We	  can	  schematically	  subdivide	  Myc	  structure	  in	  three	  main	  parts,	  as	  described	  in	  details	  
in	  	  (Conacci-­‐Sorrell	  et	  al.,	  2014;	  Tansey,	  2014)	  (Figure	  3):	  
1-­‐ An	  amino-­‐terminal	  region	  constituting	  the	  transcriptional	  activation	  domain	  (TAD),	  
a	   region	   sufficient	   for	   trascriptional	   activation	   when	   fused	   with	   a	   DNA	   binding	  
domain	   (DBD),	   that	   contains	   the	   conserved	  Myc	   boxes	   (MBI,	  MBII)	   (Kato	   et	   al.,	  
1990).	  
2-­‐ A	  central	  portion	  rich	  in	  glutamic	  acid,	  threonine	  and	  proline	  residues	  (PEST)	  with	  
two	  conserved	  Myc	  boxes	  (MBIII	  and	  MBIV)	  and	  a	  nuclear	  localization	  sequences.	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3-­‐ A	  carboxy-­‐terminus	  domain	  of	  ≈	  100	  amino	  acids	  comprising	  the	  basic	  helix-­‐loop-­‐
helix-­‐leucine	  zipper	  (bHLH-­‐LZ)	  domain,	  which	  mediate	  protein-­‐protein	  interactions	  
and	  DNA-­‐binding	  (Blackwell	  T.K.,	  et	  al.,	  1990;	  Prendergast	  G.C.	  &	  E.B.	  Ziff,	  1991).	  	  
	  
Unlike	  the	  central	  region,	  which	  is	  still	  poorly	  understood,	  the	  other	  regions	  are	  very	  well	  
characterized.	   	   The	   N-­‐terminus	   TAD	   is	   required	   for	  Myc’s	   transforming	   activity	   in	   vitro	  	  
(Stone	   et	   al.,	   1987).	   Myc	   box	   I	   (MBI)	   is	   required	   for	   gene	   activation	   and	  
ubiquitination/proteasomal	  degradation	  of	  Myc.	  Point	  mutations	  in	  this	  domain	  (T58,	  S62	  
or	  S71)	  affect	  its	  half	  life	  (around	  20-­‐30	  min	  in	  many	  normal	  cells)	  and	  increase	  its	  stability	  
in	   many	   tumors	   	   (Salghetti	   et	   al.,	   1999).	   Myc	   box	   II	   (MBII)	   is	   necessary	   for	   Myc	  
transforming	  activity	  in	  vitro	  and	  in	  vivo,	  gene	  activation	  (Oster	  et	  al.,	  2002)	  and	  is	  a	  key	  
domain	   for	   binding	   of	   coactivators	   such	   as	   components	   of	   histone	   acetiltransferases	  
complex	  (TRAPP,	  GCN5,	  TIP60,	  TIP48)	  	  (McMahon	  et	  al.,	  1997).	  The	  MBI-­‐MBII-­‐TAD	  region	  
has	   an	   important	   role	   in	   trascriptional	   regulation	  because	   it	   is	   also	  bound	  by	  other	   co-­‐
factors	  of	  Myc	   such	  as	  p-­‐TEFb	   complex	  or	   the	  bromodomain	  protein	  BRD4	   (see	  below)	  
(Eberhardy	  SR	  &	  Farnham	  PJ.,	  2001;	  Rahl	  PB	  and	  Young	  R.,	  2014).	  
	  
	  
Figure	  3	  Organization	  of	  Myc	  structure	  and	  its	  interacting	  partners.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Different	  portions	  of	  Myc	  structure	  are	  very	  well	  described.	  Transcriptional	  binding	  partners	  of	  Myc	  are	  
indicated	  in	  violet	  and	  major	  ligases	  involved	  in	  Myc	  turnover	  are	  coloured	  in	  yellow.	  (Source:	  Modified	  
from	  Conacci-­‐Sorrell,	  et	  al.	  (2014).	  Cold	  Spring	  Harb	  Perspect	  Med	  4,	  a014357;	  Copyright	  @2014	  Cold	  
Spring	  Harbor	  Laboratory	  Press)	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In	   physiological	   conditions,	   Myc	   does	   not	   homodimerize	   (Prendergast	   G.C.	   &	   Ziff	   E.B.	  
1991)	  but,	  through	  the	  bHLH-­‐LZ	  domain	  at	  the	  C-­‐terminal,	  heterodimerizes	  with	  the	  same	  
domain	  of	  another	  bHLH-­‐LZ	  protein,	  Max	  (Blackwood	  E.M	  &	  Eisenman	  R.N.	  1991).	  They	  
form	   a	   complex,	  which	   bind	  major	   groove	   of	   the	   DNA	   by	   forming	   a	   fork-­‐like	   structure	  
(Ferre	  D’Amare	  et	  al.,	  1993;	  Ferre	  D’Amare	  et	  al.,	  1994).	  Helices	  1	  and	  2,	  part	  of	  bHLH-­‐LZ	  
of	  each	  monomer,	  create	  a	  hydrophobic	  core	  that	  stabilizes	  the	  dimeric	  structure,	  while	  
the	  leucine	  zipper	  regions	  form	  a	  coiled	  coil	  and	  lastly	  the	  zipper	  interactions	  determine	  
the	  dimerization	  specificity	  (Soucek	  et	  al.,	  1998).	  DNA	  binding	  occurs	  through	  recognition	  
of	   a	   consensus	   sequence	   “CACGTG”,	   called	   “	   Enhancer	  box”	   (E-­‐box)	  or	   variants	   thereof	  
(Lüscher	  B.	  and	  Larsson	  L.G,	  1999;	  Eilers	  M.	  &	  Eisenman	  R.N.	  2008)	  	  (Figure	  3;	  Figure	  4).	  
Interaction	   of	  Myc	   with	  Max	   is	   required	   for	   the	   correct	  Myc	   folding	   and	   its	   biological	  
activities	   such	   as	   regulation	   of	   gene	   expression,	  
proliferation,	   transformation	  and	  apoptosis	   (Amati	  
et	  al.	  1992;	  Amati	  et	  al.1993a;	  Amati	  et	  al.	  1993b).	  
The	  complex	  formation	  itself	   is	  an	  important	  point	  
of	  Myc	   regulation,	   since	  Max	   is	   expressed	   also	   in	  
the	   absence	   of	   Myc	   and	   can	   dimerize	   with	  
additional	   bHLH-­‐LZ	   such	   as	   Mnt	   or	   some	   Mad	  
members	   (O’Shea	   JM.	   &	   Ayer	   DE.,	   2013).	   These	  
members	  of	   the	  Max	  network	  behave	  much	   like	  
Myc	   and	   therefore	   they	   can	   compete	   for	  
available	   Max	   and	   for	   Myc/Max	   binding	   sites.	  	  
The	  physiological	  status	  of	  the	  cell	  may	  dictate	  the	  outcome	  of	  this	  competition	  (Ayer	  et	  
al.	  1993;	  Hurlin	  et	  al	  1997).	  	  In	  addition	  to	  the	  heterodimerization	  with	  Max,	  each	  steps	  of	  	  
Figure	  4	  X-­‐ray	  structure	  of	  MYC_MAX.	  	  	  	  	  	  	  	  	  
bHLHZ	  dimers	  bound	  to	  E-­‐box	  DNA	  sequences	  
(Source:	  Tansey,W.New	  Journal	  of	  Science	  
2014;	  Copyright	  ©	  2014	  William	  P	  .	  €ansey).	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the	   life	   of	   Myc	   protein	   is	   tightly	   regulated.	   Myc	   activity	   is	   controlled	   at	   the	   level	   of	  
transcription,	  post-­‐transcription,	  which	  involved	  mRNA	  stability,	  translation	  and	  by	  post-­‐
translational	  modification	  (PTMs)	  such	  as	  phosphorylation,	  acetylation,	  glycosylation	  and	  
ubiquitination	  	  (Oster	  et	  al.,	  2002;	  Hann	  SR.,	  2006;	  Farrell	  &	  Sears,	  2014;	  Salghetti	  et	  al.,	  
1999).	  
	  
2.2 Mechanisms	  of	  transcriptional	  regulation	  by	  Myc	  
	  
	  2.2.1	  Myc	  binding	  to	  the	  genome:	  sequence	  recognition	  and	  different	  modes	  of	  
Myc-­‐chromatin	  interactions	  	  
	  
Interaction	  with	  Max	   is	   necessary	   for	   the	   basic	   domain	   of	  Myc	   to	   bind	  DNA	   at	   the	   so-­‐
called	  E-­‐box	  sequences	  and	  drive	  gene	  expression	  (Kretzner	  et	  al.,	  1992;	  Amati	  et	  al.1992;	  
Amati	  et	  al.,	  1993a).	  In	  this	  regard,	  chromatin	  immunoprecipitations	  (ChIP)	  on	  CpG	  Island	  
arrays	   firstly	   confirmed	   that	   Myc	   and	   Max	   bound	   to	   identical	   promoters	   (Mao	   et	   al.,	  
2003).	   With	   the	   development	   of	   high	   throughput	   ChIP	   technologies,	   many	   labs	   have	  
identified	   in	   vivo	   the	  Myc	   DNA-­‐binding	   sites.	   	   The	   first	   features	   found	   to	   be	   enriched	  
among	   Myc-­‐binding	   sites	   was	   the	   CpG	   island	   (Fernandez	   et	   al.,	   2003;	   Lüscher	   and	  
Vervoorts,	   2012),	   which	   is	   associated	   with	   active	   chromatin	   	   (Deaton	   A.M.	   &	   Bird	   A.,	  
2011).	   Indeed,	   Myc-­‐bound	   promoters	   are	   always	   associated	   with	   an	   active	   chromatin	  
context	  delineated	  by	  precise	  histone	  marks	  (H3K4me3,	  H3K4me2,	  H3K27ac	  and	  so	  on),	  
presence	   of	   the	   basal	   transcriptional	   machinery	   and	   hypersensitivity	   to	   DNAase	   I	  
digestion	  	  (Fernandez	  et	  al.,	  2003;	  Zeller	  et	  al.,	  2006;	  Deaton	  and	  Bird,	  2011;	  Guccione	  et	  
al.	  2006;	  Sabò	  et	  al.,	  2014;	  Lin	  C.	  et	  al,	  2012).	  There	  are	  no	  cases	  in	  which	  Myc	  results	  to	  
bind	  heterochromatin	  even	  if	  E-­‐boxes	  are	  present	  	  (Lin	  C.	  et	  al.,	  2012;	  Sabò	  et	  al.,	  2014).	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Hence,	  sequence	  recognition	  by	  Myc	  is	  not	  possible	  before	  recognition	  or	  access	  to	  open	  
chromatin	  context.	  Thus,	  ChIP-­‐seq	  experiments	  performed	  in	  many	  systems,	  showed	  that	  
Myc	  binds	  open	  and	  active	  promoters	  and	  distal	  sites	  (Sabò	  et	  al.2014;	  Lin	  C.	  et	  al	  2012).	  
As	   an	   example,	   in	   serum	   stimulated	   fibroblasts,	   at	   low	   and	   physiological	   level,	   Myc	  
preferentially	   binds	   promoters	   already	   marked	   by	   H3K4me3,	   pre-­‐loaded	   RNAPolII	   and	  
contained	  E-­‐boxes	   sequences	   rather	   than	   sites	   that	   lack	   the	   E-­‐boxes	   (Perna	  et	   al	   2012;	  
Sabò	  et	  al	  2014).	  With	  increasing	  Myc	  levels,	  the	  number	  of	  bound	  promoters	   increases	  
and	  Myc	  starts	  also	  to	  bind	  distal	  sites	  	  (Lin	  C.	  et	  al	  2012;	  Sabò	  et	  al.	  2014).	  	  All	  of	  these	  
distal	   peaks	   are	   identified	   as	   active	   enhancers	   based	   on	   the	   presence	   of	   chromatin	  
features	   such	   as	   H3K4me1,	   me3,	   H3K27ac	  marks	   and	   high	   H3K4me1/H3K4me3.	   These	  
sites	  are	  already	  active	  before	  Myc	  overexpression	  and	  binding	  to	  them	  (Nie	  et	  al.,2012;	  
Lin	  C.	  et	  al.,	  2012;	  Sabò	  et	  al.,	  2014).	   In	  this	  context,	  Myc	  can	  also	  bind	  lower	  affinity	  E-­‐
boxes	   (variants	   or	   non	   canonical)	   and	   also	   other	   sequences	   indicating	   that	   Myc/Max	  
binding	  to	  the	  DNA	  could	  be	  less	  sequence	  specific	  (Guccione	  et	  al.,	  2006;	  Fernandez	  et	  
al.,	  2003).	  At	  the	  highest	  Myc	  levels,	  as	  in	  tumors	  or	  cell	  lines,	  Myc	  can	  be	  cross-­‐linked	  at	  
virtually	   all	   active	   promoters	   and	   enhancers	   of	   the	   genome,	   a	   phenomenon	   called	  
‘invasion’	   (Lin	  C.	   et	   al.	   2012).	   	   This	  widespread	  binding	   to	   the	  genome	   is	   therefore	   less	  
selective	  and	   includes	  E-­‐boxes	   variants	   that	  have	   lower	  affinity	   for	  Myc-­‐Max	   in	   vitro	   or	  
other	  sequences	  (Lin	  C.	  et	  al.,	  2012).	  	  
Our	  lab	  recently	  proposed	  a	  general	  model	  of	  Myc	  binding	  to	  DNA,	  possibly	  valid	  also	  for	  
other	   transcription	   factors	   (Sabò	   A.	   &	   Amati	   B.,	   2014;	   Kress	   et	   al	   2015).	   	   Myc/Max	  
recruitment	  to	  chromatin	  can	  be	  explained	  through	  successive	  steps	  (Figure	  5).	  As	  already	  
mentioned,	  the	  packing	  of	  DNA	  into	  an	   inaccessible	  heterochromatic	  state	  prevents	  the	  
Myc/Max	  binding	  (Figure	  5a).	  When	  positive	  determinants	  for	  recruitment	  such	  as	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histone	   marks	   and	   cofactors	   are	   present,	   the	   heterodimer	   starts	   to	   interact	   with	  
chromatin	   facilitated	   by	   contacts	   with	   chromatin-­‐associated	   protein	   or	   the	   basal	  
transcriptional	  machinery	  (Figure	  5b).	  The	  Myc/Max	  dimer	   is	  then	  engaged	  on	  DNA	  in	  a	  
sequence	   independent	  manner,	  allowing	   local	  scanning	  (Figure	  5c).	  After	  DNA	  scanning,	  
Myc	  may	  stabilize	  on	  high	  affinity	  binding	  sites	  (Figure	  5d).	  	  This	  kind	  of	  binding	  mode	  is	  
also	  supported	  by	  the	  structural	  studies	  of	  bHLH-­‐LZ	  proteins	  such	  as	  Myc-­‐Max	  with	  DNA	  
backbone	  (Sauvé	  et	  al.,	  2007).	  In	  particular,	  after	  formation	  of	  an	  initial	  complex	  partially	  
folded,	   basic	   region	   of	   bHLH-­‐LZ	   dimer	   screens	   DNA	   in	   search	   of	   favouring	   interactions	  
(DNA-­‐assisted	   folding).	  Afterwards,	   through	   the	  binding	   to	  an	  E-­‐Box,	   the	  basic	   region	   is	  
stabilized	  in	  its	  α-­‐helical	  conformation;	  whereas	  if	  it	  doesn’t	  happen,	  the	  complex	  lacks	  its	  
conformational	  stability	  (Sauvé	  et	  al.,	  2007).	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  5	  Schematic	  model	  for	  Myc/Max	  interaction	  with	  chromatin.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Different	  modes	  of	  Myc-­‐chromatin	  interactions	  are	  represented	  in	  details	  on	  the	  left	  of	  the	  picture.	  Two	  
examples	  of	  Myc	  ChIP-­‐seq	  tracks	  for	  high	  affinity	  Myc	  binding	  site	  (Ncl,	  nucleolin)	  and	  low	  affinity	  binding	  
site	  (Pax5,	  paired	  box	  5)	  in	  mouse	  B	  cells	  are	  reported	  on	  the	  right.	  (Source:	  Kress	  et	  al	  2015,	  Nature	  
Reviews	  Cancer	  (2015);	  Copyright	  ©	  2015,	  Rights	  Managed	  by	  Nature	  Publishing	  Group:)	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In	   summary	   we	   proposed	   that	   that	   Myc/Max	   heterodimer	   is	   firstly	   recruited	   to	   open	  
chromatin	   domain,	   such	   as	   active	   promoters	   and	   enhancers	   via	   interactions	   with	  
cofactors	  and	  then,	  almost	  simultaneously,	   the	  complex	  scan	  DNA	  and	  stabilize	  on	  high	  
affinity	  binding	  sites.	  These	  binding	  modes	  lead	  to	  a	  continuum	  of	  DNA-­‐binding	  intensities	  
and	   they	  can	  be	  maintained	  at	   low	  medium	  and	  high	  Myc	  expression	   levels	   (Figure	  5e)	  
(see	  paragraph	  2.2.3).	  	  
	  
2.2.2	  Cooperation	  between	  Myc	  and	  others	  transcription	  factor	  
	  
Analysis	   of	   ENCODE	   (Encyclopaedia	   of	   DNA	   Elements)	   ChIP-­‐seq	   datasets	   demonstrated	  
that	  only	  a	  subset	  of	  Myc/Max	  sites	  actually	  binds	  to	  canonical	  and	  non-­‐canonical	  E-­‐boxes	  
(Soufi	  et	  al.,	  2015;	  Neph	  et	  al.,	  2012).	  Around	  40%	  of	  Myc-­‐binding	  sites,	  especially	  when	  
outside	   promoters,	   lack	   E-­‐boxes	   and	   are	   localized	   in	   a	   more	   relaxed	   sequence	  
environment	  leading	  to	  the	  hypothesis	  that	  on	  those	  sites	  Myc	  could	  have	  been	  recruited	  
through	   indirect	   DNA	   binding	   	   (Soufi	   et	   al.,	   2015).	   In	   general,	   two	   TFs	   can	   bind	   to	  
neighbouring	  sites	  (co-­‐binding)	  or	  one	  TF	  can	  bind	  to	  another	  that,	  in	  turn,	  binds	  directly	  
to	  DNA	   (tethered	  binding).	   The	  analysis	  of	   the	  binding	  motifs	  different	   from	  E-­‐boxes	   in	  
Myc	  ChIP-­‐seq	  experiments	  shown	  significant	  enrichment	  for	  other	  TFs	  binding	  sites	  that	  
can	  indirectly	  tether	  Myc	  to	  chromatin	  such	  as	  CTCF,	  GA-­‐binding	  protein-­‐	  α	  chain	  (GABPA)	  
and	   activating	   protein	   1	   (AP1)	   (Wang	   J.	   et	   al.,	   2012),	   but	   the	   relevance	   of	   these	  
observations	   remains	   to	  be	  addressed.	   	   In	   terms	  of	   co-­‐binding,	  Myc	  was	   shown	  also	   to	  
interact	  with	  many	  TFs.	  These	  Myc	  partners	   found	  with	  motif	  analysis	  were	  AP-­‐2,	  HIF1,	  
Sp1,	  YY1,	  NF-­‐Kb.	  (Lüscher	  and	  Vervoorts,	  2012;	  Oster	  et	  al.,	  2002;	  Wang	  J.	  et	  al	  2012).	  AP-­‐
2	   can	   antagonize	  Myc-­‐mediated	   transcriptional	   activation	   by	   competing	  with	  Myc/Max	  
for	  DNA	  binding	  to	  target	  promoters	  of	  genes	  mainly	  involved	  in	  apoptosis	  or,	  in	  absence	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of	   overlapping	   DNA	   binding	   sites,	   it	   can	   specifically	   interact	   with	   Myc	   preventing	  
Myc/Max	  complex	  from	  DNA	  binding	  and	  so	  inhibit	  Myc	  functional	  activation	  (Gaubatz	  et	  
al.,	  1995).	  Under	  low	  oxigen	  conditions	  which	  usually	  characterized	  a	  tumor	  environment,	  
the	   transcriptor	   factor	   HIF-­‐1	   can	   cooperate	   with	   Myc	   	   to	   control	   the	   expression	   of	  
metabolic	  genes	  including	  those	  	  encoding	  for	  	  glycolytic	  enzimes	  (Dang	  et	  al.,	  2008).	  	  In	  
order	  to	  promote	  uncontrolled	  cell	  cycle	  progression	  (Zeller	  et	  al.,	  2006),	  overexpressed	  
Myc	  may	  cooperate	  with	  E2F1.	  In	  addition,	  it	  was	  reported	  that	  Myc,	  STAT	  and	  E2F1	  may	  
interact	  with	  different	  portion	  of	  p300/CBP	  suggesting	  that	  these	  TFs	  can	  at	  least	  in	  part	  
cooperate	  by	  co-­‐recruitment	  of	  p300/CBP	  (Bedford	  et	  al.,	  2010).	  
Finally,	  Myc	  can	  also	  co-­‐bind	  DNA	  with	  TFs	  and	  negatively	  affects	  their	  activities,	  such	  as	  
in	  the	  case	  of	  Myc	  interaction	  with	  Sp1	  and	  Miz1	  (see	  also	  paragraph	  1.2.6	  for	  Miz1).	  As	  
an	  example	  a	   study	  of	  p21	   Cip1	   promoter	  which	   is	   a	   repressed	  Myc	   target,	   outlined	   the	  
presence	  of	  several	  Sp1	  binding	  sites.	  Myc	  binds	  the	  zinc	  finger	  domain	  of	  Sp1	  and	  may	  
form	  a	  complex	  with	  Sp1/Sp3.	   	  Since	  Sp1	   is	   required	  for	  p21	  transcription,	   it	   is	  possible	  
that	   Myc	   may	   down-­‐regulate	   p21	   transcription	   by	   sequestering	   Sp1	   out	   of	   promoters	  
(Gartel	  et	  al.,	  2001).	  	  
	  
2.2.3	  Global	  versus	  selective	  transcriptional	  control	  by	  Myc	  
	  
Even	  if	  there	  is	  a	  vast	  amount	  of	  literature	  describing	  RNA	  profiling	  studies	  in	  response	  to	  
modulation	  of	  Myc	  levels,	  the	   identification	  of	  a	  definitive	  Myc	  signature	   is	  still	  missing.	  
One	  reason	  is	  that	  Myc	  per	  se	  is	  a	  mild	  transcription	  factor,	  inducing	  only	  2-­‐3-­‐fold	  change	  
in	   mRNA	   expression	   levels.	   Next,	   since	   Myc	   is	   able	   to	   interact	   with	   several	   other	  
transcription	  factors	  as	  described	  above,	  a	  very	  complex	  network	  is	  orchestrated.	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Paradoxically	  with	   the	   advent	   of	   next	   generation	   sequencing	   for	   genome-­‐wide	   studies,	  
different	  views	  of	  Myc	  gene	  regulation	  have	  emerged.	   	  Two	  recent	  papers	   (Lie	  C.	  et	  al.,	  
2012;	   Nie	   et	   al.,	   2012)	   describe	   a	   new	   way	   of	   Myc	   action	   in	   transcription	   and	   they	  
introduce	  the	   	   ‘transcriptional	  amplifier	  model’.	  According	   to	   that	  model,	  Myc	  does	  not	  
work	   as	   a	   sequence	   specific	   transcriptional	   activator	   or	   repressor	   of	   specific	   gene	  
programs	   (as	  classically	   thought)	  but	   it	   functions	  as	  a	  direct	  activator	  or	  amplifier	  of	  all	  
the	  genes	  already	   ‘on’	   in	  a	   given	   cell	   type	  either	  at	  physiological	  or	  pathological	   levels.	  
Indeed,	  in	  LPS-­‐activated	  B	  cells,	  embryonic	  stem	  cells	  (Nie	  et	  al.,	  2012)	  and	  tumour	  cells	  
(Lie	   C.	   et	   al.,	   2012),	   Myc	   is	   highly	   expressed	   and	   able	   to	   invade	   all	   open	   regulatory	  
elements	  of	   the	  genome	  both	  promoters	   and	  enhancers.	   This	  phenomenon	  of	   invasion	  
was	  directly	  associated	   to	  an	  higher	   level	  of	  RNA	  per	   cells	   in	   these	  Myc	  overexpressing	  
cells	   compared	   to	   cells	   with	   low	  Myc	   (co-­‐called	   “RNA	   amplification”).	   However,	   these	  
observations	   are	   also	   compatible	  with	   an	   alternative	  model	   by	  which	  Myc	   can	   activate	  
and	   repress	   selected	   target	   genes,	   with	   RNA	   amplification	   occurring	   as	   a	   secondary	  
consequence.	  Indeed,	  in	  our	  work	  (Sabò	  et	  al.,	  2014),	  we	  demonstrated	  that	  Myc	  either	  in	  
tumours	  or	  normal	  cells,	  with	  or	  without	  invasion	  on	  all	  active	  elements	  of	  the	  genome,	  
can	   selective	   up	   or	   down-­‐regulate	   genes.	   These	   genes	   mainly	   control	   growth,	  
metabolism,	  cell	  size,	  protein	  translation,	  ATP	  content	  and	  mitochondrial	  mass	  increase.	  
All	  of	  these	  physiological	  changes	  can	  lead	  to	  a	  global	  transcriptional	  rate	  increase,	  which	  
is	   deciphered	   in	   higher	   amount	   of	   RNA	   (das	   Neves	   et	   al	   2010;	  Marguerat	   and	   Bähler,	  
2012).	  In	  relation	  with	  this,	  we	  reported	  that	  Myc	  chromatin	  invasion	  and	  its	  specific	  gene	  
regulation	  could	  or	  not	  imply	  into	  a	  cell	  metabolic	  switch	  which	  in	  turn	  feedback	  on	  RNA	  
amplification	   (Sabò	  et	  al.,	  2014).	  As	  an	  example,	  upon	  serum	  stimulation	  of	   fibroblasts,	  
Myc	  does	  not	  invade	  all	  active	  chromatin	  but	  is	  essential	  for	  cell	  cycle	  entry	  and	  activation	  
of	  a	  set	  of	  Myc-­‐dependent	  serum	  response	  (MDSR)	  genes,	  which	  precedes	  the	  increase	  in	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RNA	  levels	  and	  cell	  size	  (Figure	  6).	  Upon	  supra-­‐physiological	  expression	  of	  Myc	  in	  already	  
proliferating	  fibroblasts,	   invasion	  of	  active	  chromatin	  with	  selective	  gene	  regulation	  was	  
observed	   without	   further	   RNA	   amplification	   (Figure	   6).	   	   On	   the	   other	   hand,	   in	   Myc	  
overexpressing	   tumors	   such	   as	   in	   the	   Eμ-­‐myc	   model,	   Myc	   regulates	   transcription	   of	  
selective	  genes	  but	  its	  widespread	  binding	  to	  active	  chromatin	  and	  total	  RNA	  increase	  are	  
concomitant	   processes	   making	   difficult	   to	   unravel	   their	   cause-­‐to-­‐effect	   relationships.	  	  
Returning	  to	  the	   idea	  that	  Myc	  can	  regulate	  specific	  genes,	  Walz	  et	  al.,	  2014	  showed	   in	  
cancer	  human	  cell	   lines	   that,	   concomitant	  with	   the	  enhanced	  degree	  of	  Myc-­‐regulatory	  
elements	  binding	  due	  to	  Myc	  abnormal	  expression,	  there	  is	  a	  direct	  Myc	  gene	  activation	  
and	  repression	  in	  this	  last	  case	  through	  the	  suppression	  of	  Miz1-­‐target	  genes.	  	  Thus,	  this	  
second	  model,	  more	  close	  to	  a	  classical	  view	  of	  Myc	  action,	  re-­‐established	  the	  importance	  
of	   specific	   Myc	   target	   genes	   independently	   of	   Myc	   chromatin	   invasion	   and	   RNA	  
amplification.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  6	  Summary	  of	  events	  occurring	  after	  mitogenic	  stimulation	  and/or	  Myc	  overexpression.	  
Comparative	  studies	  on	  mitogen-­‐stimulated	  cells	  such	  as	  serum	  stimulated	  fibroblasts	  and	  LPS	  activated	  B	  
cells	  or	  Myc	  overexpressing	  cells	  such	  as	  3T9	  MycER	  and	  Eμ-­‐myc	  tumour	  B	  cells	  shown	  that	  RNA	  
amplification	  and	  chromatin	  invasion	  are	  separable	  phenomena.	  (Source:	  Kress	  et	  al	  2015;	  Nature	  Reviews	  
Cancer	  (2015)	  doi:	  10.1038/nrc3984;	  Copyright	  ©	  2015,	  Rights	  Managed	  by	  Nature	  Publishing	  Group:)	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2.2.4	  Myc-­‐dependent	  activation:	  Interplay	  between	  Myc	  and	  RNAPolII	  
	  
The	  importance	  of	  Myc/Max	  binding	  to	  the	  DNA	  through	  interactions	  with	  other	  effector	  
proteins	  is	  very	  well	  documented.	  Since	  ChIP-­‐seq	  experiments	  shown	  Myc	  binding	  mainly	  
on	   pre-­‐engaged	   RNAPol2	   promoters,	   it’s	   possible	   that	  Myc	   could	   be	   recruited	   on	   DNA	  
through	   components	  of	   the	   general	   transcriptional	  machinery	   such	   as	   TFII-­‐I	   (Roy	  et	   al.,	  
1993)	  and	  in	  addition	  through	  other	  transcriptional	  molecules	  or	  complexes.	  For	  example,	  
Myc	   is	   known	   to	   interact	   with	   many	   histone-­‐acetyltransferases	   (HATs)	   and	   HAT-­‐
containing	  complexes	  such	  as	  GCN5/PCAF,	  Tip60,	  p300/CBP,	  as	  well	  as	  with	  the	  adaptor	  
protein	   TRAPP	   (transformation-­‐	   transactivation	   domain-­‐associated	   protein),	   itself	   a	  
subunit	   of	   the	   GCN5/PCAF	   and	   Tip60	   complexes	   (McMahon	   et	   al.,	   1997;	   Lance	   RT.	   &	  
Tansey	  WP,	  2015).	  All	  of	   these	   interactions	  are	  thought	  to	  result	  mainly	   in	  core	  histone	  
acetylation	   (Frank	   SR.	   et	   al.,	   2001),	   which	   is	   likely	   to	   contribute	   to	   Myc-­‐dependent	  
transcriptional	  activation.	  However,	   It	   ‘s	  not	  really	  clear	  how	  all	   these	  cofactors	  work	   in	  
order	  to	  promote	  a	  functional	  transcriptional	  regulation.	  Furthermore,	  Myc	  also	  recruits	  
the	  core	  Mediator	  through	  the	  SAGA	  complex	  containing	  the	  acetyltransferases	  GCN5	  (Liu	  
X	   et	   al	   2008)	   and	   interacts	   with	   WD	   repeat-­‐containing	   protein	   (WDR5)	   an	   H3K4me3	  
associated	   protein	   for	   the	   binding	   to	   its	   target	   sites	   in	   the	   genome	   (Thomas	   LR	   et	   al.	  
2015).	   Myc	   has	   also	   been	   reported	   to	   recruit	   different	   components	   of	   the	   SWI/SNF	  
complex,	  a	  multiprotein	  apparatus	  that	  activates	  transcription	  by	  remodelling	  chromatin	  
in	  an	  ATP-­‐dependent	  manner.	  In	  particular,	  the	  bHLHZip	  domain	  of	  Myc	  directly	  interacts	  
with	  hSNF5,	  key	  component	  of	  SWI/SNF	  complex	  and	   this	   interaction	  permits	   the	  Myc-­‐
mediated	  expression	  of	  reporter	  genes	  (Cheng	  et	  al	  1999).	  In	  conclusion,	  the	  transcription	  
activation	   function	   of	   Myc	   involves	   at	   least	   in	   part	   the	   recruitment	   of	   histone	  
acetiltransferase	  and	  chromatin	  remodelling	  complexes.	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Another	   regulatory	   step	   of	   the	   activation	   of	   target	   genes	   by	   Myc	   is	   the	   promoter	  
recruitment	  and	  clearance	  of	  RNA	  polymerase	  II	  (RNAPolII)	  (Cole	  M	  and	  Cowling	  V.	  2008;	  
Oster	  et	  al.,	  2002).	  Even	  though	  Myc	  regulates	  the	  transcription	  of	  rRNA	  and	  tRNA	  genes	  
by	  RNA	  polymerase	  I	  and	  III	  respectively,	  the	  vast	  majority	  of	  Myc	  target	  genes	  are	  mRNA-­‐
encoding	   genes	   transcribed	   by	   RNAPolII.	   Transcription	   factors	   can	   regulate	   their	   target	  
genes	   by	   affecting	   transcriptional	   initiation	   (RNAPolII	   recruitment)	   or	   transcriptional	  
elongation	  (pause	  release	  and	  RNAPolII	  elongation).	  In	  particular,	  the	  C-­‐terminal	  domain	  
(CTD)	   of	   RNAPolII	   undergoes	   a	   cycle	   of	   phosphorylation	   and	   dephosphorylation	   during	  
the	   various	   steps	   of	   transcription.	   RNAPolII	   is	   recruited	   to	   promoters	   in	   a	  
hypophosphorylated	  form	  (transcriptional	  initiation)	  and	  then	  is	  phosphorylated	  on	  Ser5	  
by	  the	  transcription	  factor	  TFIIH.	  Subsequently,	  RNAPolII	  produces	  a	  short	  transcript	  and	  
a	  pause	  factor	  induces	  a	  pausing	  usually	  20-­‐50	  bp	  downstream	  of	  the	  transcriptional	  start	  
site.	  	  Specific	  signals	  and	  cofactors	  then	  stimulate	  transcriptional	  elongation	  via	  RNAPolII	  
phosphorylation	   on	   Ser2	   by	   P-­‐TEFb	   complex.	   Transcriptional	   termination	   is	   finally	  
stimulated	   by	   recognition	   of	   polyadenylation	   site	   sequence	   by	   factors	   associated	   with	  
RNAPolII	  during	  elongation.	  A	  CTD	  dephosphorylation	  occurs	  at	   the	   termination	  step	   to	  
also	  promote	  a	  new	  cycle	  of	  transcription	  (Cole	  M	  and	  Cowling	  V.	  2008).	  All	  genome-­‐wide	  
studies	  so	  far	  (Lie	  et	  al.2012;	  Nie	  et	  al	  2012;Sabò	  et	  al.2014;	  Walz	  et	  al.2014)	  agree	  with	  
the	  fact	  that	  TSS-­‐associated	  Myc	  binding	  sites	  are	  pre-­‐marked	  not	  only	  by	  open	  chromatin	  
but	   also	   by	   the	   presence	   of	   RNAPolII.	   	   Even	   if	  Myc	   has	   been	   reported	   to	   enhance	   the	  
loading	  of	  the	  polymerase	  on	  target	  promoters	  (Martinato	  et	  al.	  2008),	  other	  data	  suggest	  
that	   it	   mainly	   modulates	   transcriptional	   elongation	   by	   recruiting	   the	   P-­‐TEFb	   complex	  
(cyclin	  T1	  and	  Cdk9)	  which	  phosphorylates	   the	  carboxy-­‐terminal	  domain	  of	  RNAPolII	  on	  
Ser2	  favouring	  transcriptional	  elongation	  (Rahl	  et	  al.	  2010;	  Lin	  C.	  et	  al.2012;	  Bouchard	  et	  
al.,	  2004)	  (Figure	  7).	  The	  role	  of	  Myc	  on	  RNAPolll	  elongation	  is	  at	  the	  basis	  of	  the	  general	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amplifier	   model	   according	   to	   which	   increased	   Myc	   binding	   leads	   to	   increased	   rate	   of	  
RNAPolII	   elongation	   and	   consequently	   higher	   levels	   of	   transcribed	  mRNAs	   (Rahl	   et	   al.,	  
2010;	  Wolf	  et	  al.,	  2014;	  Rahl	  PB	  and	  R.Young	  2013).	  However,	  the	  general	  increase	  in	  the	  
transcriptional	   RNAPolII	   activity	   of	   a	   cell	   undergoing	   metabolic	   activation	   and	   cell	   size	  
expansion	   is	   a	   highly	   conserved	   process,	  which	   pre-­‐dates	  Myc	   in	   evolution	   (Marguerat	  
and	   Bähler,	   2012;	   das	   Neves	   et	   al.,	   2010;	   Lloyd	   A.,	   2013).	   	   The	   growth	   in	   cell	   size	  
correlates	   with	   RNA	   amplification	   but	   the	   cause-­‐to	   effect	   relationship	   between	   these	  
changes	   is	   still	   unclear	   and	   how	   changes	   in	   transcriptional	   elongation	   of	   Myc’s	   target	  
genes	  take	  part	  to	  these	  processes	  need	  to	  be	  elucidated.	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
Figure	  7	  Chromatin	  remodelling	  and	  promoter	  clearance	  of	  RNAPolII	  for	  Myc	  induced	  
transcriptional	  activation.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Myc-­‐Max	  dimer	  recruits	  acetyltransferases,	  which	  modify	  chromatin	  in	  an	  open	  and	  active	  state.	  Then,	  Myc	  
can	  induced	  pause	  release	  of	  RNAPolII	  on	  the	  mRNA	  targets	  by	  recruiting	  the	  P-­‐TEFb,	  which	  phosphorylates	  
RNAPolII	  on	  Ser2	  and	  so,	  promotes	  transcriptional	  elongation.	  (Source:	  Transcription-­‐independent	  functions	  
of	  MYC:	  regulation	  of	  translation	  and	  DNA	  replication	  Michael	  D.	  Cole	  and	  Victoria	  H.	  Cowling	  (2008)	  Nature	  
Reviews	  Molecular	  Cell	  Biology;	  Copyright	  ©	  2008,	  Rights	  Managed	  by	  Nature	  Publishing	  Group).	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2.2.5	  Myc-­‐dependent	  repression	  	  
	  
Even	   if	   the	  mechanisms	  of	  Myc-­‐mediated	  transcriptional	  repression	  are	   less	  understood	  
compared	   to	   the	  ones	  of	  activation,	  many	  studies	   indicate	   that	  Myc	  may	   repress	  genes	  
with	  anti-­‐proliferative	  properties	  such	  as	  cell	  cycle	  inhibitors,	  cell	  adhesion	  molecules	  and	  
tumour	   suppressive	   miRNAs	   (Tansey,	   2014).	   	   For	   example	   Myc	   can	   induce	   EZH2	  
expression,	   a	  member	   of	   the	   polycomb	   complex,	   directly	   or	   through	   the	   repression	   of	  
miRNAs	  such	  as	  miR-­‐26a	  and	  miR-­‐26b	  which	  are	  negative	  regulators	  of	  Ezh2	  (Koh	  et	  al.,	  
2011;	   Sander	   et	   al.,	   2008).	   The	   existence	   of	   direct	  Myc	  mediated	   repression	   has	   been	  
recently	   questioned	   and	   gene	   repression	   by	  Myc	   ascribed	   to	   technical	   artefacts	   of	   the	  
normalization	  of	  gene	  expression	  data	  (Lovén	  et	  al.,	  2012).	  Indeed,	  when	  considering	  cells	  
with	  different	  level	  for	  RNA	  (such	  as	  cells	  with	  High	  Myc	  versus	  cells	  with	  Low	  Myc),	  the	  
normalization	  of	  RNA	  profiles	  to	  the	  average	  expression	  or	  to	  the	  reference	  housekeeper	  
genes,	  as	  is	  commonly	  done	  in	  gene	  expression	  studies,	  would	  be	  inappropriate	  because	  
genes	  that	  are	  simply	  less	  induced	  compared	  to	  the	  average	  population	  are	  classified	  as	  
‘repressed’.	   In	   light	   of	   this,	   the	   authors	   of	   the	   amplification	   models	   propose	   the	  
measurements	   of	   RNA	   levels	   for	   cell	   equivalent	   in	   order	   to	   compare	   and	   analyze	   gene	  
expression	  datasets	  (Lin	  et	  al.	  2012;	  Nie	  et	  al.	  2012;	  Lovén	  et	  al.,	  2012;	  Wolf	  et	  al.2014).	  	  
Since	  the	  transcriptional	  output	  scale	  proportionally	  with	  cell	  size	  (Marguerat	  and	  Bähler,	  
2012),	   we	   demonstrated	   that	   the	   concept	   of	   repression	   is	   still	   valid	   in	   the	   context	   of	  
bigger	   cells	   overexpressing	   Myc	   (Sabò	   et	   al	   2014).	   A	   known	   mechanism	   of	   repression	  
driven	  by	  Myc	  is	  via	  its	  association	  with	  Miz1	  (Figure	  8).	  Miz1	  is	  a	  zinc–finger-­‐containing	  
protein	   that	  binds	   ‘initiator’	   elements	   (INR)	   close	   to	   the	   transcription	   start	   site	   (TSS)	  of	  
selected	   genes	   and	   induces	   their	   expression.	   When	   complexed	   with	   Myc	   through	  
interaction	  with	  its	  C-­‐terminal	  helix–loop–helix	  domain,	  Miz1,	  loss	  the	  interactions	  with	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its	  co-­‐activators,	  the	  histone	  acetiltransferase	  p300	  and	  nucleophosmin	  Npm1	  (Staller	  et	  
al.	   2001;	  Wanzel	   et	   al	   2001).	   Nucleophosmin	   can	   also	   be	   displaced	   from	  Miz1	   by	   the	  
ribosomal	  protein	  RPL23,	  transcriptionally	  induced	  by	  Myc	  (Wanzel	  et	  al.	  2008).	  Myc	  can	  
also	  recruit	  the	  DNA	  methyltransferase	  Dnmt3a	  that	  methylates	  the	  promoters	  of	  Miz1-­‐
target	   genes	   	   (Herkert	   and	   Eilers,	   2010)	   (Figure	   8).	   Therefore,	   both	  MYC	   and	  MIZ1	   are	  
transcriptional	   activators	   that	   form	   a	   repressive	   complex	   upon	   binding	   to	   each	   other.	  
Indeed,	   it	  has	  been	  proposed	  that	  the	  ratio	  of	  MYC	  and	  MIZ1	  bound	  to	  each	  promoters	  
correlates	   with	   the	   direction	   of	   transcriptional	   response	   (Walz	   et	   al.2014).	   	   This	   ‘anti-­‐
activation’	   mode	   through	   which	   Myc	   acts	   on	   Miz1	   is	   a	   mechanism	   of	   Myc–mediated	  
repression	  reported	  also	  for	  Myc	  and	  Sp1,	  C/EBPα	  and	  other	  transactivators	  described	  in	  
the	  previous	  paragraph	  (Gartel	  et	  al	  2001).	  Finally,	  Myc	  can	  also	  repress	  transcription	  via	  
recruitment	   of	   histone	   deacetylases	   (HDACs)	   to	   chromatin,	   inducing	   deacetilation	   and	  
thus	   nucleosome	   compaction,	   a	   chromatin	   environment	   refractory	   to	   transcription	  
(Kurland	  &	  Tansey	  2008).	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  8	  Myc	   transcriptional	   repression	  mediated	  by	  Miz1	  and	  HDACs/Dnmt3a	   recruitment	   to	  
chromatin.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Schematic	   representation	   of	   Myc	   transcriptional	   repression	   by	   Miz1	   and	   histone	   deacethilases	  
HDACs/Dnmt3a.	   (Source:	  Modified	   from	  Barbara	  Herkert	  and	  Martin	  Eilers	  Genes	  Cancer.	  2010	   Jun;	  1(6):	  
580-­‐6;	  ©	  The	  Author(s).	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2.3 Myc	  role	  in	  lymphocytes	  
	  
The	   humoral	   immunological	   response	   depends	   on	   plasma	   cells,	   the	   sole	   producers	   of	  
antibodies.	  Thus,	  activation	  of	  mature	  B	  cells,	  secretion	  of	  antibody	  and	  survival	  of	  plasma	  
cells	  needs	   to	  be	   tightly	   regulated.	  Cellular	  development	  and	  commitment	   in	   the	  B	   cell	  
lineage	  takes	  place	  in	  the	  bone	  marrow,	  originating	  from	  hematopoietic	  stem	  cells	  (HSCs)	  
(Figure	  9).	  Rearrangement	  of	   immunoglobulin	  heavy-­‐chain	  (IgH)	  gene	  segments	  in	  pro-­‐B	  
cells	   leads	   to	   precursor	   (pre)-­‐B	   cells.	   After	   a	   phase	   of	   active	   proliferation,	   pre-­‐B	   cells	  
rearrange	  their	  antigen	  receptors	  and	  migrate	  to	  the	  periphery	  (spleen	  and	  other	  lymph	  
nodes)	  as	  quiescent	  G0	  lymphocytes.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  9	  Antigen	  independent	  B	  cell	  development	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Schematic	  view	  of	  B	  cells	  commitment	  starting	  from	  pluripotent	  stem	  cell	  in	  the	  bone	  marrow.	  Naïve	  B	  cells	  
IgM+	  exit	  from	  bone	  marrow	  and	  they	  mature	  in	  the	  spleen	  mainly	  as	  long-­‐live	  follicular	  B	  cells	  and	  in	  a	  
minor	  part	  as	  naïve	  marginal	  zone	  B	  cells	  which	  remain	  in	  the	  spleen	  as	  non-­‐circulating	  cells.	  T1	  and	  T2	  B	  
cells	  are	  two	  transitional	  stages	  before	  complete	  maturation.	  (Source:	  Shapiro-­‐Shelef	  M.	  &	  Calame	  K.,	  
(2005).	  Regulation	  of	  plasma	  cell	  development.	  Nature	  Rev	  Immunol.	  5,	  230-­‐242.	  Copyright	  ©	  2005,	  Rights	  
Managed	  by	  Nature	  Publishing	  Group).	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Here,	   the	   cells	   undergo	   further	  maturation	   and	   become	   follicular	   and	  marginal	   zone	   B	  
cells.	  At	  this	  point,	  marginal	  zone	  B	  cells	  remain	  in	  the	  spleen	  as	  naïve	  non-­‐circulating	  cells	  
whereas	   follicular	   B	   cells	   may	   circulate	   in	   the	   periphery	   until	   they	   die	   or	   encounter	  
antigens	   and	   undergo	   additional	   maturation.	   Upon	   contact	   with	   the	   foreign	   antigen,	  
marginal	   zone	   B	   cells	   and	   subsequently	   follicular	   B	   cells	   differentiate	   into	   plasma	   cells,	  
(mostly	   short-­‐lived	   plasma	   cells),	   and	   some	   activated	   follicular	   B	   cells	   can	   form	   the	  
germinal	  center,	  a	  specialized	  area	  which	  permit	  development	  of	  B	  cells	  memory	  through	  
rounds	  of	  proliferation,	  cycles	  of	  somatic	  antigen	  receptor	  diversification	  (SHM)	  and	  class	  
switch	   recombination	   of	   immunoglobulin	   (CSR)	   (McHeyzer-­‐Williams	   LJ.	   et	   al.,	   2001).	  
Before	  encountering	  the	  antigen,	  all	  the	  subtypes	  of	  mature	  B	  cells	  shown	  a	  small	  size,	  a	  
high	  nuclear	   to	   cytoplasmic	   ratio	  and	  are	   in	  a	  poised	  metabolic	   status,	  where	  RNA	  and	  
protein	   synthesis	  are	  maintained	  at	  basal	   levels	   (Shapiro-­‐Shelef	  M.	  &	  Calame	  K.,	  2005).	  
On	  the	  other	  hand,	  both	  short-­‐lived	  and	   long-­‐lived	  plasma	  cells	  are	  characterized	  by	  an	  
increase	   in	   protein	   synthesis	   and	   RNA	   production	   to	   sustain	   cell	   division	   and	   clonal	  
expansion	   (Rajewsky	   K.	   1996).	   All	   of	   these	   steps	   can	   be	   recapitulated	   in	   vitro	   until	   cell	  
death	  after	  plasma	  cells	  differentiation	  (Figure	  10).	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  10	  Schematic	  representation	  of	  B	  cell	  fate	  from	  antigen	  activation	  to	  plasma	  cell	  
differentiation	  in	  vitro.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Clonal	  expansion,	  differentiation	  and	  cell	  death	  occurs	  within	  4	  days	  after	  stimulation.(Source:	  Modified	  
from	  Garcia-­‐Manteiga	  J	  M.	  et	  al	  Metabolomics	  of	  B	  to	  Plasma	  Cell	  Differentiation	  J.	  Proteome	  Res.	  2011,	  10,	  
4165–4176.	  Copyright	  ©	  2011,	  American	  Chemical	  Society)	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B	   cells	   can	   be	   activated	   either	   via	   B-­‐cell	   receptor	   in	   an	   antigen-­‐specific	   manner,	   or	  
through	   Toll-­‐like	   receptors	   (TLRs)	   that	   recognize	   specific	   microbial	   products	   such	   as	  
lipopolysaccharide	   (LPS).	   Upon	   ligation,	   TLRs	   and	   also	   BCR	   receptors,	   induce	   B	   cells	  
proliferation	   and	   memory	   B	   cell	   development	   through	   activation	   of	   Rel/NF-­‐ĸB	  
transcription	  factors.	  In	  unstimulated	  cells,	  NF-­‐ĸB	  dimers	  reside	  in	  the	  cytoplasm	  and	  are	  
maintained	   inactive	   by	   inhibitory	  molecules,	   collectively	   termed	   inhibitors	   of	   ĸB	   (IķBs).	  
NF-­‐κB	  translocation	  into	  the	  nucleolus	  with	  subsequent	  binding	  to	  the	  DNA	  results	  from	  
the	   activation	   of	   kinases	   that	   phosphorylate	   IķBs,	   signaling	   their	   ubiquitination	   and	  
degradation	  (Karin	  M	  &	  Ben-­‐Neriah	  Y.,	  2000).	  There	  are	  two	  distinct	  pathways	  (type	  1	  and	  
type	   2	   NF-­‐κb)	   regulating	   phosphorylation	   of	   IκB	   proteins	   that	   result	   in	   the	   release	   of	  
specific	  and	  distinct	  Rel	  dimers	  (Zandi	  E.	  &	  Karin	  M	  1999;	  Dejardin	  et	  al.,	  2002).	  CD40,	  a	  
ligand	  of	  BCR	  receptors,	  controls	  type	  1	  and	  type	  2	  of	  NF-­‐Kb	  signalling	  pathway,	  whereas	  
TLRs	  engagement	   trigger	  only	   type	  1	  NF-­‐kb	   (Zarnegar	  et	  al.	   2004).	   Even	   if	  BCR	  and	  TLR	  
activation	   induce	  similar	  cellular	  response	  there	  are	  some	  differences	   in	  gene	  activation	  
programs	  (	  Dadgostar	  et	  al.,	  2002;	  Zarnegar	  et	  al.,	  2004	  Gerondakis	  et	  al.,	  2007).	  CD40L	  
activation	   for	   example	   induces	   the	   type	   2	   NF-­‐κB	   pathway	   and	   thus	   the	   expression	   of	  
genes	  involved	  in	  adhesion,	  migration,	  and	  germinal	  center	  formation,	  a	  property	  that	  LPS	  
lacks	  (Zarnegar	  et	  al.,	  2004).	  Whereas	  the	  signalling	  pathway	  cascades	  acting	  during	  B	  cell	  
activation	  are	  very	  well	  described,	  a	  complete	  picture	  of	  the	  transcriptional	  mechanisms	  
and	  epigenetic	  changes	  occurring	  before	  proliferation	  and	  functional	  immune	  response	  is	  
still	  not	  available.	  Initial	  mitogenic	  stimulation	  of	  B	  cells	  leads	  to	  the	  induction	  of	  primary	  
response	   genes	   (PRGs)	  which	   are	   usually	   turned	   on	  within	  minutes	   (Fowler	   et	   al.2013)	  
such	   as	   the	   immediate	   early	   response	   genes	   c-­‐myc,	   c-­‐fos	   and	   c-­‐jun.	   Very	   recently,	   a	  
genome	  wide	  study	  compared	  the	  BCR	  and	  TLR	  –mediated	  activation	  response	  of	  B	  cells	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and	   showed	   a	   partial	   overlap	   between	   the	   two	   transcriptional	   response	   at	   very	   early	  
stages	  of	  activation.	  Remarkably,	   in	  this	  common	  signature	  there	  was	  the	  prevalence	  of	  
known	  Myc	  induced	  genes	  (Fowler	  et	  al.	  2015).	  
Also	  T	  cells	  undergo	  a	  growth	  phase	  upon	  stimulation	  of	  antigen	  receptors,	  accumulation	  
of	   cell	   biomass	   and	   rapid	   proliferation	   associated	   with	   transcriptional	   metabolic	  
reprogramming	  to	  increase	  the	  bioenergetics	  and	  the	  biosynthetic	  demand.	  It	  was	  shown	  
that	   Myc	   drives	   this	   metabolic	   reprogramming	   in	   activated	   T	   lymphocytes	   coupling	  
glutaminolysis	   to	   polyamine	   biosynthesis	   to	   enhanced	   the	   polyamine	   demand	   required	  
for	   proliferation	   (Wang	   et	   al.,	   2011).	   Since	   these	   changes	   in	   T	   cell	   metabolism	   were	  
observed	  within	  3	  to	  10	  hr	  of	  stimulation,	  the	  metabolic	  effects	  of	  Myc,	  either	  direct	  or	  
indirect,	   were	   very	   rapid	   and	   indipendent	   to	   S-­‐phase	   entry.	   Myc	   expression	   is	   also	  
transient	   and	   it	   is	   demonstrated	   that	   one	   transcription	   factor,	   AP-­‐4	   part	   of	   its	   target	  
genes,	   is	   induced	   to	   sustain	   T	   cells	   activation.	   in	   the’post	   Myc	   phase’	   through	   the	  
expression	  of	  genes	  mainly	   involved	   in	  metabolism	  (Chou	  C.	  et	  al.	  2014).	  Thus,	  Myc	   is	  a	  
primary	   response	   gene	   rapidly	   induced	   upon	   lymphocyte	   activation.	   Altogether,	   the	  
metabolic	   switch	   from	   quiescent	   to	   activated	   cells	   is	   controlled	   by	   a	   complex	   gene	  
regulatory	   network,	   different	   combinations	   of	   transcription	   factors	   being	   required	   to	  
maintain	  B-­‐cell	  and	  plasma	  cell-­‐specific	  programs.	  	  	  
In	   the	   simplest	   view,	   the	   key	   factors	   sustaining	   the	   B	   cell	   phenotype	   are	   Pax5,	   Bcl6,	  
Bach2,	  PU.1	  and	  IRF8,	  whereas	  the	  terminal	  differentiation	  is	  driven	  by	  IRF4,	  Blimp-­‐1	  and	  
XBP1	   (Shapiro-­‐Shelef	  and	  Calame,	  2005)	   (Figure	  11).	  Each	   transcription	   factors	   is	   stage-­‐
specific	   and	   may	   repress	   those	   factors	   that	   are	   required	   for	   the	   alternative	  
developmental	   state,	   creating	   mutually	   exclusive	   gene-­‐expression	   programs.	   In	   this	  
scenario,	  Myc	  shows	  different	  pattern	  of	  expression:	  it	  is	  expressed	  at	  very	  low	  levels	  in	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mature	   B	   cells,	   is	   rapidly	   induced	   upon	   antigen	   activation,	   and	   then	   repressed	   during	  
plasma	  cell	  differentiation	  (de	  Alboran	  et	  al	  2001;	  Lin	  C.	  et	  al.,	  2000;	  Murn	  et	  al.,	  2009).	  In	  
vitro,	   Myc-­‐deleted	   B	   cells	   	   are	   impaired	   in	   the	   mitogenic	   respose	   upon	   CD40+	   IL4	  
treatment	  with	  a	  delay	  in	  activation	  and	  cell	  cycle	  progression	  	  (de	  Alboran	  et	  al.,	  2001).	  
Myc	  stimulates	  not	  only	  proliferation	  but	  also	  development	  of	  B	  cells	  through	  an	  increase	  
in	   intracellular	   Ca2+	   	   (Habib	   et	   al.,	   2007)	   inducing	   thus	   the	   expression	   of	   Myc	   and	  
Ca2+.induced	  genes.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  	  11	  Changes	  in	  the	  trascription	  factor	  networks	  from	  B	  cells	  to	  plasma	  cells.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
BCL-­‐6	  (B-­‐cell	  lymphoma	  6),	  MTA3	  (metastasis-­‐associated	  1	  family,	  member	  3),	  MITF	  (microphthalmia-­‐
associated	  transcriptionfactor)	  and	  PAX5	  (paired	  box	  protein	  5)	  —defend	  B	  cell	  identity	  by	  repressing	  
BLIMP1	  (B-­‐lymphocyte-­‐induced	  maturation	  protein	  1),	  XBP1	  (X-­‐box-­‐binding	  protein	  1)	  and	  	  IRF4	  (interferon-­‐
regulatory	  factor	  4).	  In	  plasma	  cells,	  BLIMP1	  represses	  B-­‐cell	  gene-­‐expression	  programmes.	  This	  mutual	  
repression	  prevents	  the	  unelicited	  formation	  of	  plasma	  cells	  in	  the	  germinal	  centre	  and	  prevents	  the	  
reversion	  of	  plasma	  cells	  to	  a	  B-­‐cell	  stage.	  	  (Source:	  Shapiro-­‐Shelef	  M.	  &	  Calame	  K.,	  (2005).	  Regulation	  of	  
plasma	  cell	  development.	  Nature	  Rev	  Immunol.	  5,	  230-­‐242.	  Copyright	  ©	  2005,	  Rights	  Managed	  by	  Nature	  
Publishing	  Group).	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In	  conclusion,	  Myc	  induction	  has	  an	  important	  role	  during	  lymphocyte	  activation	  (Quade	  
et	  al.,	  1983;	  Eilers	  and	  Eisenman,	  2008;	  Wang	  et	  al.,	  2011).	  In	  mitogen-­‐stimulated	  B	  cells,	  
P493	   and	   Eμ-­‐myc	   B	   cells,	   metabolic	   growth	   which	   includes	   cellular	   size	   and	   prothein	  
synthesis	   increase	   is	   a	   very	   well	   described	   process	   concomitant	   to	   Myc-­‐induced	  
proliferation	   	   (de	   Alboran	   et	   al.2001;	   Iritani	   B	   &	   Eisenman	   1999;	   Schuhmacher	   et	   al.,	  
1999).	  	  
	  
2.4 Myc	  regulated	  genes	  	  
	  
Over	  the	  past	  two	  decades	  many	  studies	  aimed	  to	   identify	  the	  genes	  that	  mediate	  Myc	  
biological	  activities	  in	  physiological	  and	  pathological	  contexts.	  According	  to	  many	  studies	  
the	   functional	   categories	  mainly	   affected	  by	  Myc	   activity	   are	   cell	   growth	   (including	   cell	  
size	   and	   biomass	   accumulation),	   RNA	   processing,	   ribosome	   biogenesis	   and	   protein	  
synthesis,	   metabolic	   processes	   (such	   as	   glycolysis,	   glutaminolysis,	   amino	   acid	   and	  
nucleotide	  biosynthesis).	  
	  
2.4.1 Myc	  activated	  genes:	  role	  in	  growth,	  metabolism	  and	  RNA	  processing	  
	  
Ectopic	  expression	  of	  Myc	  leads	  to	  activation	  of	  many	  mRNAs	  involved	  in	  different	  aspect	  
of	  cell	  physiology,	  which	  will	  be	  separately	  discussed	  below.	  
	  
-­‐Ribosome	  biogenesis	  and	  protein	   synthesis.	   In	  different	  model	   systems,	  Myc	  promotes	  
the	   RNAPolII-­‐mediated	   transcription	   of	   mRNAs	   encoding	   various	   ribosomal	   proteins,	  
which	  are	  part	  of	  a	  general,	  cell-­‐type	  independent	  core	  Myc	  target	  gene	  signature	  (Ji	  et	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al.,	  2011).	  Myc	  also	  induces	  the	  expression	  of	  translation	  initiation	  factors	  (such	  as	  eIF2A	  
and	  eIF4E)	  and,	  in	  the	  absence	  of	  Max,	  RNAPolIII-­‐mediated	  synthesis	  of	  tRNA	  (Rosenwald	  
et	  al.	  1993;	  Gomez-­‐Roman	  et	  al.	  2003).	  	  
Myc	   can	   also	   control	   directly	   the	   transcription	   of	   genes	   involved	   in	   mRNA	   cap	  
methylation.	   The	  Myc	   target	   eIF4F,	   for	   example,	   is	   responsible	   for	   the	   recognition	   and	  
enhanced	   translation	   of	   cap-­‐methylated	   mRNAs	   contributing	   to	   the	   broad	   increase	   in	  
protein	  synthesis	  (Jones	  et	  al.,	  1996;	  Cole	  and	  Cowling,	  2008;	  Koromilas	  et	  al.,2009).	  
	  
-­‐Nucleotide	  biosynthesis.	   In	   several	   cell	   types	   such	  as	  B	   cells,	   fibroblasts	  and	   liver	   cells,	  
Myc	   overexpression	   globally	   induces	   expression	   of	   genes	   involved	   in	   nucleotide	  
biosynthesis	  (Liu	  et	  al.,	  2008).	  In	  serum-­‐stimulated	  fibroblasts,	  for	  example,	  several	  MYC-­‐
dependent	   serum	   response	   genes	   encode	   key	   enzymes	   in	   purine	   and	   pyrimidine	  
biosynthetic	   pathways,	   including	   ribonucleoside-­‐diphosphate	   reductase	   subunit	   M2	  
(RRM2),	   amidophosphoribosyltransferase	   (PPAT),	   GAR	   transformylase	   (GART)	   and	   CAD	  
(Perna	  et	  al.,	  2012).	  As	  shown	  in	  activated	  T	  lymphocytes,	  Myc	  can	  up	  regulates	  glycolytic	  
enzyme	   such	   as	   LDH-­‐A	   (lactate	   dehydrogenase)	   and	   GLUT1	   (glucose	   transporter)	  
providing	  important	  precursor	  also	  for	  nucleotide	  metabolism	  (Wang	  et	  al.,	  2011).	  Myc	  is	  
also	   described	   as	   a	   master	   regulator	   of	   the	   de-­‐novo	   purine	   biosynthetic	   pathway:	  
phosphoribosyl	   pyrophosphate	   synthase	   (PRPS2)	   was	   translationally	   regulated	   by	   Myc	  
whereas	  enzymes	  of	  PRPS2	  pathway	  were	  transcriptionally	  activated	  by	  MYC	  in	  Eμ-­‐myc	  B	  
cells,	   most	   likely	   contributing	   to	   the	   global	   enhancement	   of	   RNA	   production	   (Sabò	   et	  
al.2014).	  This	  was	  directly	  proven	  in	  an	  independent	  study	  showing	  that	  deletion	  of	  Prps2	  
in	  the	  same	  model	  eliminated	  the	  general	  increase	  in	  cellular	  RNA	  levels	  that	  is	  normally	  
observed	  in	  pre-­‐tumoral	  and	  tumoral	  B	  cell	  stages	  	  (Cunningham	  et	  al.,	  2014).	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-­‐RNA	  processing	  and	  stability.	  Myc	  may	  also	  contribute	  to	  RNA	  processing	  and	  stability.	  It	  
can	  directly	   induce	  expression	  of	  alternative	  splicing	   factors	  serine/arginine-­‐rich	  splicing	  
factor	  1	  (SRSF1)	  or	  interferes	  with	  the	  splicing	  machinery	  (Das	  et	  al.,	  2012).	  In	  this	  regard,	  
during	   lymphomagenesis	  Myc	   can	   promote	   proper	   splicing	   of	   precursor	   mRNAs	   by	   up	  
regulating	  protein	  arginine	  N-­‐methyltransferase	  5	  (PRMT5)	  and	  other	  genes	  encoding	  for	  
components	   of	   the	   core	   small	   nuclear	   ribonucleoprotein	   particle	   (snRNP)	   (Koh	   C.M	   .et	  
al.2015).	   In	   addition,	   MYC	   can	   also	   regulate	   RNA	   stability	   factors	   such	   as	   nuclear-­‐
interacting	  protein	  1	  (SNIP1).	  It	  was	  shown	  in	  various	  cell	  lines	  that	  SNIP1	  might	  interfere	  
with	   the	   transcriptional	   activation	   of	   some	   Myc	   target	   genes	   regulating	   their	   mRNA	  
stability	  (Fujii,	  M.	  et	  al.	  2006).	  	  
Our	  data	  confirm	  the	  Myc-­‐dependent	  activation	  of	  many	  of	  these	  genes	  in	  B-­‐cells.	  
	  
2.4.2 Myc-­‐repressed	  genes	  
	  
The	  first	  identified	  target	  genes	  of	  Myc-­‐mediated	  repression	  was	  c-­‐myc	  itself,	  suggesting	  a	  
negative	   auto-­‐regulatory	   feedback	   (Penn	   et	   al.,	   1990).	   Myc	   can	   down-­‐regulate	   either	  
mRNAs,	  as	  described	  below,	  and/or	  specific	  miRNAs	  	  (Jackstadt	  R	  &	  Hermeking	  H.,	  2014).	  	  
	  
-­‐Negative	  regulators	  of	  proliferation.	  Myc	  promotes	  cell	  cycle	  progression	  through	  down-­‐
regulation	  of	  cell	  cycle-­‐inhibitory	  genes	  such	  as	  CDK1A	  (p21CIP1),	  CDKN2B	  (p15INK4b)	  (Gartel	  
et	  al.,2001;	  Staller	  et	  al.,	  2001).	  The	  mechanism	  of	   repression	   is	  based	  on	   the	  ability	  of	  
Myc	  to	  prevent	  Miz1	  from	  activating	  transcription	  of	  these	  genes.	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-­‐Cell	   adhesion	   molecules.	   Myc	   can	   repress	   a	   group	   of	   genes	   involved	   in	   cell	   adhesion	  
(Inghirami	  et	  al.	  1990)	  as	  the	  integrin	  β1	  (Itgb1),	  a	  subunit	  of	  the	  integrin	  complex.	  Since	  
this	  integrin	  mediate	  cell-­‐cell	  interactions	  as	  well	  as	  contact	  to	  the	  extracellular	  matrix,	  its	  
dowregulation	   may	   facilitate	   the	   exit	   of	   stem	   cells	   from	   the	   niche	   and	   subsequent	  
differentation	  (Herkert	  B.	  &	  Eilers	  M.,	  2010).	  
	  
2.4.3	  Myc	  target	  genes	  as	  therapeutic	  opportunities	  	  
	  
Myc	  expression	  is	  estimated	  to	  be	  deregulated	  in	  up	  to	  70%	  of	  human	  cancers.	  	  In	  order	  
to	  find	  an	  effective	  therapeutic	  treatment	  for	  these	  Myc	  overexpressing	  tumours,	  many	  
strategies	   have	   been	   proposed:	   inhibition	   of	  Myc	   expression,	   interruption	   of	  Myc-­‐Max	  
dimerization	   or	   DNA	   binding	   and	   also	   the	   possibility	   to	   interfere	   with	   key	   Myc	   target	  
genes	  or	  transcriptional	  co-­‐factors.	  	  More	  than	  ten	  years	  ago,	  a	  dominant	  negative	  form	  
of	   Myc	   (called	   Omomyc)	   was	   generated	   in	   order	   to	   block	   Myc	   driven	   transcriptional	  
activation	   (Soucek	   et	   al	   1998).	   It	   was	   shown	   that	   Omomyc	   could	   reverse	  Myc-­‐induced	  
tumorigenesis	   in	  vitro	  and	   in	  vivo	   (Soucek	  et	  al	  2002;	  Soucek,	  Nasi	  &	  Evan	  2004).	  While	  
Omomyc	  was	  shown	  to	  homodimerize	  with	  all	  three	  Myc	  proteins	  (c-­‐Myc,	  N-­‐myc,	  L-­‐myc)	  
competing	  with	  the	  binding	  with	  Max	  and	  sequestering	  Myc	  in	  complexes	  with	  low	  DNA	  
affinity	  (Soucek	  et	  al	  1998),	  its	  precise	  mode	  of	  action	  in	  vivo	  remains	  to	  be	  addressed.	  	  	  
Considering	   that	   Omomyc	   or	   Myc	   inhibitory	   drugs	   can	   lead	   to	   side	   effects	   such	   as	  
proliferation	   arrest	   of	   normal	   tissues	   (Soucek	   et	   al.,	   2008),	   other	   strategies	   have	   been	  
investigated	   to	   precisely	   affect	   selected	   Myc	   functions	   in	   tumour	   cells.	   In	   this	   regard,	  
Myc-­‐regulated	  genes	  such	  as	  lactate	  deidrogenase	  (LDHA),	  ornithine	  decarboxylase	  (ODC)	  
or	  glutaminase	  (GLS)	  have	  been	  targeted	  by	  shRNAs	  or	  drug-­‐like	  molecules	  in	  vivo.	  In	  	  
	   42	  
	  
particular,	  shRNA-­‐based	  LDH-­‐A	  knockdown	  in	  different	  tumors	  cell	  lines	  compromised	  the	  
ability	  of	  these	  cells	  to	  proliferate	  under	  hypoxia,	  promoting	  a	  decrease	  in	  tumorigenesis	  
(Fantin	  et	  al	  2006).	  	  
Since	  also	  miRNAs	  are	  very	  well	  known	  to	  be	  Myc	  targets,	  some	  studies	  focused	  on	  their	  
targeting.	  The	  expression	  and	  activity	  of	  Myc	  itself	  are	  under	  the	  control	  of	  miRNAs	  and	  
different	  classes	  of	  miRNAs	  can	  be	  induced	  or	  repressed	  by	  Myc	  (Jackstadt	  R	  &	  Hermeking	  
H.,	  2014).	   It	  was	   shown	  that	  expression	  of	  miRNA-­‐26a,	  which	   is	  a	  Myc,	   regulated	  gene,	  
induce	  inhibition	  of	  liver	  cancer	  cells	  in	  vitro	  and	  in	  vivo	  (Kota	  et	  al.2009).	  
In	  conclusion,	  we	  underlined	  the	  importance	  of	  a	  putative	  Myc	  core	  signature	  in	  normal	  
cells	  and	  we	  identified	  also	  in	  stimulated	  B	  cells	  Myc	  regulated	  genes	  associated	  with	  the	  
described	  pathways.	  Since	  these	  genes	  that	  impinge	  on	  the	  normal	  physiology,	  are	  often	  
deregulated	  in	  cancer,	  their	  further	  characterization	  will	  be	  very	  useful	  for	  the	  treatment	  
of	  Myc-­‐driven	  cancers.	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2.5	  Aim	  
	  
Myc	  plays	  a	  central	  role	  in	  the	  activation	  of	  B	  cells	  in	  response	  to	  growth-­‐stimulatory	  
cues.	  However,	  the	  gene	  expression	  programs	  mobilized	  by	  Myc	  under	  those	  
circumstances	  remain	  largely	  unknown.	  The	  aim	  of	  this	  work	  was	  to	  unravel	  these	  
programs	  following	  LPS-­‐mediated	  activation	  of	  primary	  mouse	  B	  cells,	  by	  combining	  gene	  
expression	  profiling	  with	  the	  mapping	  of	  Myc-­‐binding	  sites	  along	  the	  genome.	  We	  took	  
advantage	  of	  a	  conditional	  knockout	  allele	  of	  the	  c-­‐myc	  gene,	  allowing	  the	  rigorous	  
identification	  of	  Myc-­‐dependent	  events,	  and	  of	  advanced	  RNA-­‐	  and	  chromatin-­‐profiling	  
techniques	  based	  on	  next-­‐generation	  sequencing	  (RNA-­‐seq	  and	  ChIP-­‐seq).	  Having	  
provided	  us	  with	  a	  complete	  Myc-­‐dependent	  gene	  expression	  program	  in	  activated	  B-­‐
cells,	  our	  work	  sets	  the	  basis	  for	  a	  functional	  characterization	  of	  critical	  downstream	  
effectors	  in	  the	  same	  biological	  setting.	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3.	  Materials	  &	  Methods	  
	  
3.1	  Mouse	  strains	  	  
	  
c-­‐myc	   flox/flox	   mice	   in	   the	   C57BL/6	   background	   were	   obtained	   	   from	   	   the	   	   Trumpp	  	  
Laboratory	  	  (Trumpp	  et	  al.,	  2001).	  	  Mice	  at	  7–10	  weeks	  of	  age	  were	  used.	  
	  
3.2	  Primary	  mouse	  B	  cells	  	  
	  	  	  	  	  	  	  	  	  	  	  	  
Naïve	  mouse	  B-­‐cells	  were	  isolated	  with	  the	  B	  cell	  isolation	  kit	  (MACS	  Miltenyi	  Biotech	  Cat.	  
no.	   130-­‐090-­‐862)	   from	   the	   spleen	   of	  wt	   and	   homozygous	   c-­‐mycf/f	   conditional	   knockout	  
animals	  (Trumpp	  et	  al	  2001).	  After	  smashing	  of	  spleens	  and	  some	  steps	  of	  filtering	  of	  the	  
mixed	  cell	  population,	  erithroid	  cells	  were	  lysates.	  Progressively	  cells	  not	  belonging	  to	  the	  
B	   cell	   lineage,	   i.e,	   T	   cells,	  macrophages,	   dendritic	   cells	   or	   granulocytes	  were	   labeled	  by	  
using	  a	  cocktail	  of	  biotin-­‐conjugated	  antibodies	  against	  CD-­‐43,	  CD4	  and	  Ter-­‐119	  and	  then	  
captured	  with	  an	  anti-­‐biotin	  monoclonal	  antibodies	  conjugated	  to	  magnetic	  Micro	  Beads	  
to	  be	  depleted	  from	  the	  cell	  suspension.	  	  	  
After	  isolation,	  splenocytes	  were	  exposed	  to	  a	  recombinant	  Tat-­‐Cre	  protein	  (50µg/ml	  for	  
1h	  in	  optimem	  +1%	  fetal	  bovine	  serum)	  	  (Peitz	  et	  al.,	  2002)	  in	  order	  to	  induce	  deletion	  of	  
the	   c-­‐mycf/f	   allele.	   Tat-­‐cre	   protein	   was	   homemade	   purified	   according	   to	   the	   protocol	  
published	  in	  Peitz	  et	  al.2002.	  After	  1h	  of	  incubation	  at	  37°C	  Tat-­‐cre	  was	  washed	  out	  and	  
cells	   were	   then	   grown	   in	   suspension	   in	   DMEM	   medium	   (Dulbecco’s	   Modified	   Eagle	  
Medium)	   and	   IMDM	   medium	   (Iscove’s	   Modified	   Dulbecco’s	   Medium)	   in	   ratio	   1:1	  
containing	  10%	  fetal	  calf	  serum	  (FCS)	  (Globefarm	  Ltd,	  Cranleigh,	  UK),	  2	  mM	  L-­‐glutamine	  
(Invitrogen	  Life	  Technologies,	  Paisley,	  UK),	  1%	  of	  non-­‐essential	  amino	  acids	  (NEAA),	  1%	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penicillin/streptomycin	  and	  25	  uM	  β	  mercaptoethanol	  (Gerondakis	  et	  al.,	  2007).	  12h	  after	  
seeding,	   splenocytes	   were	   stimulated	   with	   lipopolysaccharide	   LPS	   	   (50ug/ml;	   SIGMA	  
L6237)	  to	  induce	  cell	  activation.	  
	  
3.3	  Proliferation	  and	  Cell	  Size	  analysis	  
	  
Starting	  from	  a	  cell	  density	  of	  500000	  cells/ml,	  cell	  proliferation	  was	  monitored	  counting	  
the	  cells	  with	  Trypan	  Blue	   to	  exclude	  dead	  cells.	   To	  measure	  cell	   size,	  500000	   live	   cells	  
were	  resuspended	  in	  500	  µl	  of	  PBS	  with	  Propidium	  iodide	  (PI)	  to	  exclude	  dead	  cells	  from	  
the	  analysis	  and	  40000	  total	  events	  were	  collected	  using	  a	  FACsCalibur	  machine	  (Becton	  
Dickinson).	  Data	  were	  then	  analyzed	  by	  using	  FlowJo	  software	  (TreeStar)	  and	  the	  mean	  of	  
PI	  negative	  population	  scored.	  	  
	  
	  3.4	  Caspase	  3/7	  assay	  and	  Trypan	  blue	  exclusion	  assay	  	  
	  
In	  order	  to	  evaluate	  apoptosis,	  caspase	  activity	  was	  measured	  using	  the	  Caspase-­‐Glo	  3/7	  
luminescence	   kit	   (Promega)	   with	   Glomax	   luminometer	   following	   manufacturer’s	  
instruction.	   The	   assay	   provides	   a	   proluminescent	   caspase-­‐3/7	   DEVD-­‐aminoluciferin	  
substrate	  and	  luciferase	  in	  a	  reagent	  optimized	  for	  caspase-­‐3/7	  activity,	  luciferase	  activity	  
and	   cell	   lysis.	   Adding	   the	   single	   Caspase-­‐Glo®	   3/7	   Reagent	   in	   an	   "add-­‐mix-­‐measure"	  
format	   results	   in	  cell	   lysis,	   followed	  by	  caspase	  cleavage	  of	   the	  substrate.	  This	   liberates	  
free	   aminoluciferin,	   which	   is	   consumed	   by	   the	   luciferase,	   generating	   a	   "glow-­‐type"	  
luminescent	  signal.	  The	  signal	  obtained,	  normalized	  to	  the	  cell	  numbers,	   is	  proportional	  
to	  caspase-­‐3/7	  activity	  given	  a	  measure	  of	  apoptosis	  cell	  death.	  The	  cells	  were	  in	  parallel	  
counted	  with	  Trypan	  blue	  to	  exclude	  dead	  cells	  and	  calculate	  the	  percentages	  of	  death.	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3.5	  Cell	  cycle	  analysis	  and	  cell	  sorting	  
	  
Cells	  were	   incubated	  with	   33	   µM	  BrdU	   for	   a	   pulse	   labeling	   of	   30	  min.	   Cells	  were	   then	  
harvested,	  washed	  with	  PBS	  and	  ice-­‐cold	  ethanol-­‐fixed.	  Upon	  DNA	  denaturation	  using	  2N	  
HCl,	   cells	   were	   stained	   with	   an	   anti-­‐BrdU	   primary	   antibody	   (BD	   Biosciences)	   and	   anti-­‐
mouse	  FITC	  conjugated	  secondary	  antibody	  (Jackson	  Immunoresearch).	  DNA	  was	  stained	  
by	  resuspending	  the	  cells	   in	  2.5	  µg/ml	  Propidium	  Iodide	  (Sigma)	  overnight	  at	  4°C	  before	  
FACS	   analysis.	   All	   samples	   were	   acquired	   on	   a	   FACS	   Canto	   II	   (BD	   Biosciences)	   flow	  
cytometer.	  At	   least	  15,000	  events	  were	  acquired	  and	   the	  analysis	  was	  performed	  using	  
FlowJo	  X	  software.	  For	  sorting,	  cells	  were	  resuspended	  at	  the	  appropriate	  time	  points	  in	  
Macs	   Buffer	   (0.5	   %	   BSA,	   2mM	   EDTA	   in	   PBS)	   and	   sorted	   for	   size	   at	   the	   FAcsAir	   of	   our	  
Campus	  service	  facility.	  
	  
3.6	  Markers	  staining	  with	  FACS	  
	  
Cells	  were	   stained	  with	   the	   appropriate	   antibodies	   (listed	   below)	   in	   1%BSA	   in	   PBS	   and	  
incubated	  for	  1h	  at	  4°C:	  
-­‐ IgM	   APC,	   B220	   eFluo450,	   Cd19	   PE-­‐Cy7,	   CD44	   PE	   (1:200	   dilution),	   CD38	   APC	  
(Biolegend;	  1:400	  dilution),	  CD138	  Bv510	  (BD;	  1:100	  dilution)	  	  
Afterwards,	  cells	  were	   fixed	   in	  1%	  FA	   in	  PBS	   for	  10’	  at	   room	  temperature,	  washed	  with	  
PBS	   and	   stored	   at	   4°C	   before	   FACS	   acquisition.	   	   All	   samples	   were	   then	   analyzed	   with	  
FlowJo	  X	  software.	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3.7	  Immunoblot	  analysis	  
	  
5	  x106	  B-­‐cells	  were	  lysed	  with	  RIPA	  Buffer	  (20	  mM	  HEPES	  at	  pH	  7.5,	  300	  mM	  NaCl,	  5	  mM	  
EDTA,	  10%	  Glycerol,	  1%	  Triton	  X-­‐100,	  supplemented	  with	  protease	  inhibitors	  Mini,	  Roche	  
and	  phosphatase	   inhibitors	  0.4	  mM	  Ortovanadate,	   10	  mM	  NaF)	   and	   sonicated.	  Cleared	  
lysates	  were	  electrophoresed	  and	  immunoblotted	  with	  the	  indicated	  primary	  antibodies:	  
c-­‐Myc	  Y69	  (ab32072)	  from	  Abcam,	  Vinculin	  (V9264)	  from	  Sigma,	  total	  H3	  (ab1791)	  from	  
Abcam,	   H3panAc	   (06-­‐599)	   and	   H4panAc	   (06-­‐866)	   from	   Millipore.	   We	   also	   performed	  
histone	   acid	   extraction	   as	   described	   by	   abcam	   protocol:	   cell	   lysate	   was	   obtained	   with	  
Triton	  extraction	  buffer	  and	  o/n	  HCl	  incubation	  was	  then	  performed	  to	  extract	  histones.	  
Chemiluminescent	   detection,	   after	   incubation	   of	   the	   membranes	   with	   appropriate	  
secondary	  antibodies,	  was	  done	  through	  a	  CCD	  camera	  using	  the	  ChemiDoc	  System	  (Bio-­‐
Rad).	  Quantification	  of	  protein	   levels	  was	  done	  using	   the	   Image	  Lab	  Software	   (Bio-­‐Rad,	  
version	  4.0).	  
	  
3.8	  Isolation	  genomic	  DNA	  
	  
Cells	  pellet	  (1.5*10^7)	  were	  collected	  at	  different	  time	  points	  (0h,	  24h,	  48h,	  72h	  post	  LPS	  
stimulation)	  and	  DNA	  was	  extracted	  with	  the	  Nucleospin® 	   tissue	  kit.	  The	  genomic	  DNA	  
was	  finally	  eluted	  in	  50	  μl	  of	  BE	  buffer	  (5mM	  Tris/HCl,	  pH	  8.5).	  	  The	  analysis	  of	  the	  c-­‐myc	  
deletion	  efficiency	  was	  performed	  on	  10	  ng	  of	  genomic	  DNA	  isolated	  from	  wt	  or	  c-­‐myc	  Δ	  
cells	  using	  quantitative	  PCR	  with	  the	  primers	  pair	  5’flox-­‐3’flox	  (Trumpp	  et	  al,	  2001).	  Data	  
were	  normalized	  to	  Nucleolin	  amplicon.	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3.9	  RNA	  extraction	  and	  analysis	  (RT-­‐qPCR	  	  and	  RNAseq)	  	  
	  
Total	  RNA	  (at	  least	  from	  2.5*	  10^6	  cells)	  was	  purified	  onto	  RNeasy	  columns	  (Qiagen)	  and	  
treated	   on-­‐column	   with	   DNase	   (Qiagen).	   Complementary	   DNA	   	   (cDNA)	   was	   prepared	  	  	  
using	  	  ImProm-­‐IITM	  reverse	  transcription	  kit	  	  	  (Promega)	  and	  10	  ng	  of	  cDNA	  were	  used	  for	  
each	  real-­‐time	  PCR	  reaction.	  cDNA	  was	  	  detected	  by	  fast	  SyberGreen	  Master	  Mix	  (Applied	  
Biosystems)	  on	  CFX96	  Touch™	  Real-­‐Time	  PCR	  Detection	  System	  (Biorad).	  We	  normalized	  
gene	  expression	  to	  TBP	  and	  	  	  expressed	  	  	  values	  	  	  relative	  	  	  to	  	  	  control	  using	  	  	  the	  	  ddCT	  	  	  
method.	  For	  quantitative	  PCR	  primers,	  see	  primers	  list	  below.	  
Another	  method	  highly	  accurate	  for	  quantifying	  expression	  levels	  as	  determined	  by	  qPCR	  
is	   RNA-­‐seq;	   the	   last	   permits	   not	   only	   to	   look	   at	   changes	   in	   gene	   expression	   during	  
development	  or	  under	  different	  conditions	  but	  also	  to	  catalogue	  all	  species	  of	  transcripts,	  
mRNAs,	   small	   RNAs	   and	   non-­‐coding	   RNAs,	   alternative	   gene	   spliced	   transcripts,	   post-­‐
transcriptional	   modifications,	   gene	   fusion	   and	   mutations/SNPs.	   Briefly,	   total	   RNA	   is	  
converted	   to	   a	   library	  of	   cDNA	   fragments	  with	   adaptors	   attached	  at	   one	  or	   both	  ends.	  
Each	  molecule	  is	  then	  sequenced	  in	  a	  high-­‐throughput	  manner	  to	  obtain	  short	  sequences,	  
called	   reads	   from	  one	   (single-­‐end	   sequencing)	   or	   both	   ends	   (pair-­‐end	   sequencing).	   The	  
reads,	  typically	  30-­‐400	  bp	   length	  compatible	  to	  the	  sequencing	  technology,	  are	  mapped	  
on	   a	   reference	   genome	   to	   reveal	   a	   transcriptional	   map	   where	   the	   number	   of	   reads	  
aligned	  on	  each	  gene,	  called	  counts,	  gives	  a	  measure	  of	  its	  level	  of	  expression	  (Figure	  12)	  
(Trapnell	  et	  al.,	  2010;	  Wang	  et	  al.,	  2009,	  Morin	  et	  al.,	  2008).	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Figure	  12	  Steps	  of	  a	  typical	  RNA-­‐seq	  experiment.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Long	  RNAs	  are	  first	  converted	  into	  a	  library	  of	  cDNA	  	  fragments	  through	  either	  RNA	  fragmentation	  or	  DNA	  
fragmentation,	  then	  adaptors	  (blue)	  are	  added	  to	  each	  cDNA	  fragment	  and	  short	  sequence	  are	  obtained	  
from	  each	  cDNA	  using	  high-­‐throughput	  sequencing	  technology.	  Subsequently	  the	  sequence	  reads	  are	  
aligned	  with	  the	  reference	  genome	  or	  transciptome	  ,	  and	  classified	  as	  three	  types:	  exonic	  reads,	  junction	  
reads	  and	  poly(A)	  end-­‐reads.	  These	  three	  types	  are	  used	  to	  generate	  a	  base-­‐resolution	  expression	  profile	  
for	  each	  gene,	  as	  illustrated	  at	  the	  bottom;	  yeast	  ORF	  with	  one	  intron	  is	  shown.(Source:	  Wang	  Z.	  et	  al.,	  
Nature	  review	  Genetics,	  (2009);	  Copyright	  ©	  2009,	  Rights	  Managed	  by	  Nature	  Publishing	  Group).	  
	  
	  
In	  this	  work,	  for	  the	  RNA-­‐seq	  experiment,	  total	  RNA	  from	  8*106	  B	  cells	  was	  purified	  and	  
0.5	   µg	   were	   then	   treated	   with	   Ribozero	   rRNA	   removal	   kit	   (Epicentre)	   and	   EtOH	  
precipitated.	   RNA	   quality	   and	   removal	   of	   rRNA	   were	   checked	   with	   the	   Agilent	   2100	  
Bioanalyser	   (Agilent	   Technologies).	   Libraries	   for	   RNA-­‐Seq	  were	   then	   prepared	  with	   the	  
TruSeq	  RNA	  Sample	  Prep	  Kits	  v2	  (Illumina)	  following	  manufacturer	  instruction	  (except	  for	  
skipping	   the	   first	   step	   of	  mRNA	   purification	  with	   poly-­‐T	   oligo-­‐attached	  magnetic	   bead)	  
with	  the	  paired-­‐end	  option.	  50bp	  reads	  were	  obtained	  from	  the	  Illumina	  sequencer.	  The	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RNAseq	  experiment	  was	  performed	  in	  3	  technical	  replicates	  for	  time	  0h	  and	  in	  single	  for	  
all	  the	  other	  samples.	  
	  
3.10	  Chromatin	  Immunoprecipitation	  and	  sequencing	  	  
	  
Splenic	  B	  cells	  were	  resuspended	  in	  PBS	  at	  room	  temperature	  and	  fixed	  by	  addition	  of	  1%	  
formaldehyde	  for	  10 min.	  Fixation	  was	  stopped	  by	  addition	  of	  0.125 M	  glycine.	  Cells	  were	  
washed	  in	  PBS,	  resuspended	  in	  SDS	  buffer	  (50	  mM	  Tris	  at	  pH	  8.1,	  0.5%	  SDS,	  100	  mM	  NaCl,	  
5	  mM	  EDTA,	  and	  protease	   inhibitors)	  and	  stored	  at	   -­‐80	  °C	  before	  further	  processing	  for	  
ChIP.	  Chromatin	  was	  sonicated	  and	  processed	  as	  described	  in	  (Frank	  et	  al.,	  2001)	  except	  
for	  blocking	  protein	  A-­‐Sepharose	  beads	  with	  tRNA	  (Sigma)	  instead	  of	  salmon	  sperm	  and	  
purifying	  immunoprecipitated	  DNA	  through	  Qiaquick	  columns	  (Qiagen)	  instead	  of	  phenol-­‐
cloroform	  extraction.	  We	  combine	  chromatin	  immunoprecipitation	  with	  high-­‐throughput	  
DNA	  sequencing	  (ChIP-­‐seq)	  in	  order	  to	  obtain	  high	  resolution	  and	  genome-­‐wide	  analysis	  
of	   DNA-­‐protein	   interactions.	   For	   ChIP-­‐Seq	   analysis	   of	   Myc	   and	   RNAPol2	   lysates	   from	  
30x106	   B-­‐cells	   or	   50X106	   were	   immunoprecipitated	   with	   10	   μg	   of	   the	   corresponding	  
antibody	  (see	  below).	   Immunoprecipitated	  DNA,	  after	  several	  washes,	  was	  eluted	   in	  TE-­‐
2%	   SDS	   and	   crosslinks	  were	   reversed	   by	   incubation	   overnight	   at	   65	   °C.	   DNA	  was	   then	  
purified	  by	  Qiaquick	  columns	  (Qiagen)	  and	  quantified	  using	  Qubit	  TM	  	  dsDNA	  HS	  Assay	  kits	  
(Invitrogen).	   1.5-­‐2	   ng	   ChIP	   DNA	   was	   end-­‐repaired,	   A-­‐tailed,	   ligated	   to	   the	   sequencing	  
adapters	   and	   amplified	   by	   17-­‐cycles	   of	   PCR,	   size	   selected	   (200-­‐300bp)	   according	   with	  
TruSeq	   ChIP	   Sample	   Prep	   Kit	   (Illumina).	   We	   run	   Agilent	   2100	   Bioanalyser	   (Agilent	  
Technologies)	   to	   evaluate	   ChIP-­‐seq	   library	   quality	   checking	   for	   size	   distribution	   and	  
contamination	  by	  adapter	  primers	  and	  then	  proceed	  with	  HiSeq2000	  sequencing	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3.11	  Antibodies	  for	  ChIP	  
	  
The	  following	  antibodies	  were	  used	  for	  ChIP:	  Myc	  N262	  (Santa	  Cruz,	  sc-­‐764)	  and	  RNAPII	  
N20	  (Santa	  Cruz,	  sc-­‐899).	  
	  
3.12	  List	  of	  Primers	  	  
	  
Primers	   for	   ChIP	   and	   mRNA	   analysis	   were	   previously	   designed	   in	   the	   lab	   by	   using	  
computer	  assisted	  primer	  design	  software	  (Primer	  3).	  The	  list	  of	  primers	  used	  is	  below:	  
Primers	  for	  ChIP:	  
	  
	   	  Gene	  	   Forward	  	   Reverse	  
AchR	   AGTGCCCCCTGCTGTCAGT	   CCCTTTCCTGGTGCCAAGA	  
Smyd2	   CCGCGTACCTGGCGAAGC	   GCCTGCGTGCTCACCGTG	  
Ncl	   GGCGTGGTGACTCCACGT	   CGAAATCACCTCTTAAAGCAGA	  
pus	  7	   GCTGCACCGCGTGGAGAC	   GGCTGGTGGGATAACCCGT	  
	  
	  
	  
Primers	  for	  RT-­‐PCR:	  
	  
	   	  
Gene	  	   Forward	  	   Reverse	  
TBP	   TAATCCCAAGCGATTTGCTG	  	   CAGTTGTCCGTGGCTCTCTT	  	  
Myc	  	   TTTTTGTCTATTTGGGGACAGTG	   CATCGTCGTGGCTGTCTG	  
Smyd2	   TGGTTGTTTTGGGGGAGAACT	   AGCTTGTCCAGATGTGACTCA	  
Gart	   CGTCATTGCTGGAATTGCT	   TTGGGCATCTCTGCTGTCT	  
Ncl	   GGCGTGGTGACTCCACGT	   	  CGAAATCACCTCTTAAAGCAGA	  
Xbp1	   AAGAACACGCTTGGGAATGG	   ACTCCCCTTGGCCTCCAC	  
BCL6	   CTGCAGATGGAGCATGTTGT	   CACCCGGGAGTATTTCTCAG	  
Blimp1	   TGGCAAGATCAAGTATGAGTGC	   CCAAGTAGTGTTTCTGCAGGTG	  
junb	   ATCAGCTACCTCCCACATGCA	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   TACGGTCTGCGGTTCCTCTTT	  
Ikba	  	  	  	  	  	  	  	  	  	  	   CTTGGCTGTGATCACCAACCAG	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  CGAAACCAGGTCAGGATTCTGC	  
Slc16a1	  	  	  	  	  	  	  	  	  	   GGATATCATCTATAATGTTGGCTGTC	   GCTGCCGTATTTATTCACCAA	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Primers	  for	  PCR	  on	  gDNA:	  
	  
Gene	  	   Forward	  	   Reverse	  
myc	  fl/fl	   TCTAGACTTGCTTCCCTTGCTGT	   	  TTCCTGTTGGTGAAGTTCACGT	  
	  
myc	  ∆	   AAATAGTGATCGTAGTAAAATTTAGCCTG	   ACCGTTCTCCTTAGCTCTCACG	  
Ncl	   GGCGTGGTGACTCCACGT	   CGAAATCACCTCTTAAAGCAGCA	  
	  
	  
Primers	  genotyping:	  
	  
	   	  Gene	  	   Forward	  	   Reverse	  
myc	  	   CACCGCCTACATCCTGTCCATTC	   TACAGTCCCAAAGCCCCAGCCAAG	  
	   	   	  
	  
3.14	  Computational	  analysis	  
	  
3.14.1	  Next	  generation	  sequencing	  data	  filtering	  and	  quality	  assessment	  
	  
ChIP-­‐seq	  and	  RNA-­‐seq	  NGS	   reads	   sequenced	  with	   the	   Illumina	  HiSeq2000	  were	   filtered	  
using	   the	   fastq_quality_trimmer	   and	   fastq_masker	   tools	   of	   the	   FASTX-­‐Toolkit	   suite	  
(http://hannonlab.cshl.edu/fastx_toolkit/).	   Their	   quality	   was	   evaluated	   and	   confirmed	  
using	   the	   FastQC	   application:	   (www.bioinformatics.babraham.ac.uk/projects/fastqc/).	  
Then	   we	   use	   our	   homemade	   pipeline	   called	   HTS	   flow	   for	   analysis	   of	   both	   ChIP	   and	  
RNAseq	  data.	   	  The	  pipeline	   include	  primary	  analysis	  which	  means	  quality	  control	  of	   the	  
raw	   reads	   followed	  by	   filtering	   and	   alignment	   to	   the	   reference	   genome	   and	   secondary	  
analysis	  which	  concerns	  differential	  gene	  expression,	  peak	  calling	  or	  footprint	  calling.	  
	  
3.14.2	  ChIP-­‐seq	  data	  analysis	  
	  
ChIP-­‐seq	  NGS	   reads	  were	  aligned	   to	   the	  mouse	   reference	  genomes	   (mm9)	   through	   the	  
BWA	  aligner	   using	   default	   settings	   (Li	   and	  Durbin,	   2009).	   After	   this,,	   peaks	  were	   called	  
using	  the	  MACS	  software.	  Only	  peaks	  with	  p-­‐value	  <1e-­‐8	  were	  retained.	  Normalized	  reads	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count	  within	  a	   genomic	   region	  were	  determined	  as	   the	  number	  of	   reads	  per	  million	  of	  
library	  reads	  (total	  number	  of	  aligned	  reads).	  	  
MACS	  was	  also	  used	  to	  perform	  saturation	  analysis	  (as	  a	  control	  of	  false	  negatives)	  and	  to	  
determine	   an	   estimated	   false	   discovery	   rate	   (as	   a	   control	   of	   false	   positives)	   for	   each	  
experiment.	   In	   the	  saturation	  analysis,	   the	   fraction	  of	  peaks	  confirmed	  with	  80%	  of	   the	  
reads	  was	  determined.	  False	  discovery	  rate	  was	  determined	  as	  the	  proportion	  of	  negative	  
vs	   positive	   peaks	   where	   negative	   peaks	   were	   identified	   by	   calling	   MACS	   on	   the	   input	  
samples,	  using	  the	  ChIP	  as	  reference.	  
Peak	  enrichment	  was	  determined	  as	  log2	  (ChIPw	  -­‐	  inputw),	  where	  ChIPw	  and	  inputw	  are	  the	  
normalized	  counts	  of	  reads	  in	  the	  peak	  region	  in	  the	  ChIP	  and	  in	  the	  corresponding	  input.	  	  
Peaks	   were	   mapped	   to	   reference	   genes	   and	   annotated	   as	   intragenic,	   intergenic,	   or	  
promoter	  on	  the	  basis	  of	  the	  genomic	  position	  of	  each	  peak’s	  midpoint:	  
-­‐promoter:	   the	   peak	   position	   is	   within	   -­‐2Kb	   upstream	   and	   1Kb	   downstream	   from	   an	  
annotated	  refgene	  start	  coordinate	  or	  TSS	  
-­‐Intragenic:	  the	  peak	  position	  is	  inside	  an	  annotated	  refgene	  (>	  1	  Kb	  from	  the	  TSS	  to	  its	  3’	  
end).	  
-­‐Intergenic:	  the	  peak	  position	  doesn’t	  match	  neither	  the	  criterion	  for	  being	  intragenic	  nor	  
promoter.	  
Qualitative	  and	  quantitative	  heatmaps	  of	  ChIP-­‐seq	  enrichment	  for	  the	  indicated	  factor	  or	  
modification	   were	   determined	   using	   compEpiTools	   package,	   a	   tool	   for	   computational	  
epigenomics	   developed	   for	   the	   analysis,	   integration	   and	   simultaneous	   visualization	   of	  
various	  epigenomics	  data	  types	  across	  multiple	  genomic	  regions	  in	  multiple	  samples.	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To	   investigate	   if	   Myc	   binding	   intensity	   could	   affect	   regulation	   of	   gene	   expression	   we	  
stratified	  Myc	  peak	  enrichments	  in	  3	  quantiles:	  
-­‐for	  the	  2h	  LPS	  time	  point,	  log2	  enrichment	  was	  divided	  in:	  low	  intensity	  if	  lower	  or	  equal	  	  
to	  7.71,	  	  medium	  intensity	  if	  between	  7.71	  and	  10.	  05,	  high	  intensity	  if	  higher	  than	  10.05	  
-­‐	  for	  the	  4h	  LPS	  time	  point,	  log2	  enrichment	  was	  divided	  in:	  low	  intensity	  if	  lower	  or	  equal	  
to	  7.52,	  medium	  intensity	  if	  between	  7.52	  and	  9.84,	  high	  intensity	  if	  higher	  than	  9.84	  
-­‐	  for	  the	  8h	  LPS	  time	  point,	  	  log2	  enrichment	  was	  divided	  in:	  low	  intensity	  if	  lower	  or	  equal	  
to	  7.11,	  medium	  intensity	  if	  between	  7.11	  and	  9.63,	  high	  intensity	  if	  higher	  than	  9.63.	  
	  
3.14.3	  RNA-­‐seq	  data	  analysis	  
	  
NGS	  reads	  were	  aligned	  to	  the	  mm9	  mouse	  reference	  genome	  using	  the	  TopHat	  aligner	  
(version	   2.0.6)	   with	   default	   parameters	   (Trapnell	   et	   al.,	   2009).	   Read	   counts	   were	  
associated	   to	   each	   exon	   using	   the	   HTSeq	   software	  
(http://www.huber.embl.de/users/anders/HTSeq/doc/overview.html).	   The	   expression	   of	  
a	  transcript	  X	  (eRPKM)	  was	  estimated	  as	  the	  reads	  per	  kilobase	  over	  the	  total	  number	  of	  
aligned	  reads	  considering	  only	  exonic	  reads:	  
	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
where	  r(X!"#$)	  is	  the	  number	  of	  reads	  mapped	  to	  exons	  of	  X	  ,	  RExon	  	  is	  the	  sum	  of	  reads	  
mapped	  to	  all	  exons	  (of	  all	  transcripts)	  in	  the	  experiment,	  and	  	  s(XExon)	  is	  the	  total	  length	  
(in	  kilobases)	  of	  exons	  in	  X.	  We	  estimated	  the	  expression	  of	  a	  gene	  with	  more	  than	  one	  
isoform	  as	  the	  mean	  of	  the	  expression	  of	  its	  isoforms.	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3.14.3i	  Identification	  of	  differentially	  expressed	  genes	  
	  
Differentially	   expressed	   genes	   (DEGs)	   were	   identified	   using	   the	   Bioconductor	   Deseq2	  
package.	  	  In	  order	  to	  call	  DEGs	  when	  multiple	  isoforms	  are	  present,	  the	  rounded	  mean	  of	  
counts	   over	   the	   isoforms	   is	   used.	   Considering	   only	   protein	   coding	   genes	   and	   after	  
removing	  the	  very	  low	  expressed	  genes	  (that	  never	  reached	  eRPKM	  of	  1	  in	  any	  condition	  
analyzed),	  we	  obtained	  a	   set	  of	  11614	  expressed	  genes	  and	  we	  defined	  DEGs	  as	   genes	  
whose	  q-­‐value	  relative	  to	  the	  control	  is	  lower	  than	  0.05.	  	  
The	   different	   categories	   of	   Myc	   dependent	   LPS	   response	   and	   Myc	   independent	   LPS	  
response,	  were	  identified	  as	  following:	  
• Myc-­‐dependent	   genes	   were	   defined	   as:	   regulatory	   group	   1	   or	   Myc-­‐dependent	  
induced	   (DEGs	   in	   wt	   OR	   myc∆/Δ	   cells	   with	   qvalue<=0.05	   &	   log2FCwt>0.58	   &	  
log2FCwt>(log2FCflox+0.58)	  which	  means	  genes	  significatively	  more	  up	  in	  wt	  than	  
in	   c-­‐myc∆/Δ	   cells);	   regulatory	   group	   2	   (DEGs	   in	   wt	   OR	   c-­‐myc	   ∆/Δ	   cells	   with	  
qvalue<=0.05&	   log2FCwt>0.58	   &	   log2FCwt<(log2FCflox-­‐0.58)	   which	   are	   genes	  
significatively	   more	   up	   in	   c-­‐myc∆/Δ	   than	   wt	   cells);	   regulatory	   group	   3	   or	   Myc-­‐
dependent	  repressed	  (DEGs	  in	  wt	  OR	  myc	  ∆/Δ	  cells	  with	  qvalue<=0.05	  &	  log2FC<-­‐
0.58	  &	   log2FCwt<(log2FCflox-­‐0.58)	  which	   are	   genes	   significatively	  more	  down	   in	  
wt	  than	   in	  c-­‐myc∆/Δ	  cells);	  regulatory	  group	  4	  (DEGs	   in	  wt	  OR	  c-­‐myc∆/Δ	   	  cells	  with	  
qvalue<=0.05	   &	   log2FCwt<-­‐0.58	   &	   log2FCwt>(log2FCflox+0.58)	   which	   are	   genes	  
significatively	  more	  down	  in	  myc∆/Δ	  than	  in	  wt	  cells).	  
• Myc-­‐independent	  genes	  were	  defined	  as	  DEGs	   in	  wt	  OR	  c-­‐myc	   ∆/Δ	   cells	  with	   the	  
same	  fold	  change,	  but	  considering	  only	  fold	  changes	  bigger	  than	  0.58	  and	  +-­‐	  0.3	  as	  
threshold:	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-­‐regulatory	   group	   5	   or	  Myc-­‐independent	   induced	   (DEGs	   in	   wt	   OR	   c-­‐myc∆/Δ	   cells	  
with	   qvalue<=0.05	   &	   log2FCwt>0.58	   &	   log2FCflox>0.58	   &	  
log2FCwt<=(log2FCflox+0.3)	   &	   log2FCwt>=(log2FCflox-­‐0.3)	   which	   are	   genes	  
positively	  regulated	  not	  in	  a	  myc	  dependent	  manner);	  
-­‐regulatory	  group	  6	  or	  Myc-­‐independent	  down	  (DEGs	  in	  wt	  OR	  c-­‐myc∆/Δ	  cells	  with	  
qvalue<=0.05	   &	   log2FC<-­‐0.58	   &	   log2FC<-­‐0.58	   &	   log2FCwt<=(log2FCflox+0.3)	   &	  
log2FCwt>=(log2FCflox-­‐0.3)	   which	   are	   genes	   negatively	   regulated	   not	   in	   a	   myc	  
dependent	  manner).	  
• No_DEGs	   (qvalue>0.05	   in	   wt	   AND	   c-­‐myc	   ∆/Δ	   &	   -­‐0.4<log2FCwt<0.4	   &	   -­‐	  	  	  	  
0.4<log2FCflox<0.4	  which	  are	  genes	  that	  didn’t	  change	  their	  expression	  in	  the	  two	  
fenotypes).	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3.14.4	  Stalling	  index	  analysis	  
	  
In	  order	  to	  study	  promoter-­‐proximal	  pausing	  of	  Pol	   II,	  a	  post-­‐initiation	  regulatory	  event,	  
we	  calculate	  the	  RNA	  polymerase	  II	  stalling	  index	  (SI,	  also	  called	  elongation	  rate)	  (Rahl	  et	  
al.,	  2010;	  Frank	  et	  al.,	  2001).	  It	  is	  the	  ratio	  between	  the	  read	  counts	  on	  the	  promoter	  (TSS	  
±300	  bp	   interval)	  and	  the	  read	  counts	   in	  the	  gene	  body	  (the	   interval	  between	  TSS	  +301	  
and	   3,000	   bp	   after	   the	   TSS).	   These	   values	   were	   normalized	   both	   to	   library	   size	   (total	  
number	  of	  reads)	  and	  to	  the	  length	  of	  the	  interval,	  and	  only	  genes	  with	  GB>600	  bp	  and	  
with	  a	  RNAPII	  ChIP-­‐seq	  peak	  in	  the	  region	  [TSS	  -­‐	  2,000;	  TSS	  +	  1,000	  bp]	  were	  considered.	  
	  
3.14.5	  Motif	  analysis	  
	  
To	   identify	   motifs	   of	   TFs,	   the	   enrichment	   of	   position	   weight	   matrices	   (PWMs)	   was	  
computed	   on	   the	   set	   of	   sequences	   corresponding	   to	   the	   +/-­‐75bp	   regions	   around	   the	  
summit	  of	  Myc	  peaks	  on	  promoters	  of	   the	  genes	  of	  each	  different	  category	  of	  DEGs.	   In	  
order	   to	   find	   a	   significant	   enrichment	   (zscore	   at	   least	   ≥3)	   we	   considered	   a	   genomic	  
background	  characterized	  by	  sequences	  at	  the	  peaks	  of	  Myc	  on	  promoters	  corresponding	  
to	  not	  regulated	  genes	  (noDEGs).	  
The	   presence	   of	   canonical	   and	   non	  canonical	   Eboxes	   (Perna	   et	   al.,2012)	   was	   also	  
identified	  at	  genes	  with	  a	  Myc	  peaks	  on	  promoters	  in	  the	  region	  +-­‐75	  bp	  around	  the	  peak	  
summit.	  
	  
3.15	  Gene	  ontology	  and	  gene	  set	  enrichment	  analysis	  (GSEA)	  	  
	  
Functional	   annotation	   analysis	   to	   determine	   enriched	   Gene	   Ontology	   was	   performed	  
using	  Molecular	  signature	  database	  (MsigDB)	  of	  GSEA	  Broad	  Institute	  or	  DAVID	  	  (Huang	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et	  al.,	  2008)	  .	  Pre-­‐ranked	  Gene	  set	  enrichment	  analysis	  was	  also	  performed	  	  (Subramanian	  
et	  al.,	  2005).	  	  
	  
3.16	  Other	  bioinformatic	  	  and	  statistical	  analysis	  
Differentially	  expressed	  genes	  were	  also	  analyzed	  by	  Ingenuity	  Pathway	  Analysis	  (IPA)	  
version	  9.0	  (Redwood	  City,	  CA,	  http://www.ingenuity.com)	  software.	  Briefly,	  a	  list	  of	  
genes	  with	  corresponding	  expression	  level	  were	  uploaded	  and	  core	  analysis	  was	  
performed	  in	  IPA.	  Canonical	  pathways	  obtained	  in	  this	  study	  were	  identified	  from	  the	  IPA	  
library	  based	  on	  Fisher’s	  Exact	  Test	  P-­‐value.	  
Bioinformatic	  and	  statistical	  analysis,	   including	  heatmaps	  of	  ChIP-­‐seq	  data	  and	  plots	   for	  
DEGs	   analysis	   of	   RNA-­‐seq	   and	   other	   visual	   representation	   of	   the	   data	  were	   performed	  
using	  R	  with	  Bioconductor	  	  (J	  Zhang	  et	  al	  2004)	  and	  compEpiTool	  packages.	  
All	  the	  experiments,	  except	  for	  ChIP	  and	  RNAseq,	  were	  performed	  in	  biological	  duplicates	  
or	   triplicates.	  Two	  tailed-­‐Student	   t	   test	  was	  used	  to	  calculate	  P	  value.	  Significant	  values	  
are	  reported	  in	  the	  figure	  legends.	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4	  Results	  	  
	  
4.1	  An	  in	  vitro	  model	  for	  conditional	  deletion	  of	  c-­‐Myc	  in	  B	  cells	  	  
	  
In	  order	  to	  map	  Myc-­‐dependent	  transcriptional	  and	  genomic	  responses	  in	  a	  physiological	  
context,	   we	   took	   advantage	   of	   primary	   mouse	   B	   cells	   homozygous	   for	   a	   conditional	  
knockout	  allele	  bearing	   loxP	  sites	   in	   the	   first	   intron	  and	   in	   the	  3’-­‐untranslated	  region	  of	  
the	   c-­‐myc	   gene	   (Trumpp	   et	   al.,	   2001)	   (Figure	   13a	   henceforth	   c-­‐myc	   f/f	   cells).	   	   Using	   a	  
strategy	  analogous	  to	  that	  followed	  in	  our	  laboratory	  for	  the	  screening	  of	  Myc	  dependent	  
serum	  response	  (MDSR)	  genes	  in	  fibroblast	  (Perna	  et	  al.2012),	  conditional	  deletion	  of	  c-­‐
myc	   was	   induced	   before	   cell	   activation	   by	   lipopolysaccharide	   (LPS)	   stimulation	   (Figure	  
13b).	  
	  
	  
Figure	  13	  Schematic	  representation	  of	  the	  experimental	  approach.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
a)	  Design	  of	  the	  genomic	  position	  of	  the	  primers	  designed	  to	  detect	  the	  presence	  of	  deleted	  (myc	  -­‐/-­‐)	  and	  
non-­‐deleted	  (myc	  fl/fl)	  c-­‐myc	  allele.	  b)	  Splenic	  wt	  and	  c-­‐myc	  f/f	  B	  cells	  isolated	  from	  mice	  are	  treated	  with	  
TAT-­‐cre	  for	  1	  h	  in	  optimem	  with	  1%	  of	  serum.	  After	  12h,	  the	  cells	  are	  stimulated	  with	  LPS	  and	  gDNA,	  RNA	  
and	  chromatin	  are	  collected	  at	  various	  time	  points	  for	  profiling.	  
a 
b
	   60	  
	  
Cells	   were	   isolated	   from	   8-­‐10	   weeks	   old	   wt	   and	   homozygous	   c-­‐myc	   f/f	   mice.	   Mature	  
splenic	  B	  cells	  were	  purified	  through	  depletion	  of	  all	  other	  white	  blood	  cells,	  dendritic	  and	  
erithroid	  cells	  	  (“non	  B	  cells”)	  present	  in	  the	  spleen.	  As	  assessed	  by	  flow	  cytometry	  (FACS),	  
the	  B	  cell	   fractions	  were	   in	   large	  part	   (85%)	  B220	  and	   IgM	  positive,	  while	  the	  discarded	  
cells	   were	   negative	   for	   both	   markers	   (Figure	   14).	   B	   cells	   were	   treated	   in	   vitro	   with	   a	  
recombinant	   TAT-­‐cre	   protein	   to	   induce	   deletion	   of	   c-­‐myc	   allele	   and	   then	   plated	   in	  
mitogen	  free	  medium.	  After	  12h,	  the	  quiescent	  cells	  were	  stimulated	  with	  LPS	  to	  induce	  
cellular	  activation	  and	  re-­‐entry	  into	  the	  cell	  cycle	  	  (Kelly	  et	  al.,	  1983):	  different	  time	  points	  
of	   stimulation	   were	   then	   considered	   to	   compare	   their	   transcriptional	   and	   epigenetic	  
profiles.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  14	  Isolation	  of	  mature	  B	  cells.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
FACS	  profile	  of	  purified	  splenic	  mature	  B	  cells	  used	  in	  this	  study	  (on	  the	  left)	  respect	  to	  the	  other	  lymphoid	  
cells	  discarded	  (on	  the	  right).	  
	  
	  
	  
	  
	  
B cells Non B cells 
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TAT-­‐cre	   is	   a	   fusion	   protein	   in	   which	   an	   11–residue	   domain	   of	   HIV	   TAT	   protein	   is	  
juxtaposed	   to	   the	   cre	   recombinase	   in	   order	   to	   make	   it	   able	   to	   pass	   the	   plasma	  
membrane,	   reach	   the	  nucleus	  and	  mediate	  deletion	  of	   loxp-­‐flanked	   targets	   (Capasso	  et	  
al.,	  2009;	  Joshi	  et	  al.,	  2002).	  Since	  its	  effectiveness	  depends	  on	  its	  uptake	  by	  target	  cells,	  
we	  optimized	  the	  conditions	  of	  TAT-­‐cre	  delivery	  in	  our	  system.	  	  	  	  
We	  treated	  c-­‐myc	   fl/fl	  B	  cells	  with	  different	  TAT-­‐cre	  concentration	  and	  for	  different	  times	  
of	  exposure	  (Figure	  15).	  Since	  we	  also	  tested	  in	  the	  same	  experiment	  the	  toxicity	  of	  the	  
fusion	   protein	   through	   Trypan	   blue	   direct	   counting,	   we	   observed	   that	   more	   than	   one	  
hour	   of	   treatment	   originated	   an	   increase	   in	   cell	   death	   compared	   to	   untreated	   cells	  
explaining	   the	   inadequate	   efficiency	   of	   deletion	   in	   the	   remaining	   alive	   cell	   population.	  	  
Approximately	  80%	  of	  deletion	  was	  instead	  achieved	  after	  one	  hour	  of	  treatment	  already	  
at	  the	  lowest	  concentration	  without	  a	  toxicity	  effect	  compared	  to	  untreated	  cells.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  15	  Setting	  up	  of	  the	  TAT-­‐cre	  treatment	  conditions	  in	  terms	  of	  time	  exposure.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
qPCR	  of	  gDNA	  showing	  the	  levels	  of	  	  myc	  -­‐/-­‐	  and	  myc	  fl/fl	  alleles	  relative	  to	  the	  nucleolin	  amplicon,	  in	  c-­‐myc	  
fl/fl	  B	  cells	  treated	  with	  100	  or	  50	  μg	  of	  TAT-­‐cre	  for	  1h,	  4h	  or	  a	  double	  shot	  of	  2h	  of	  incubation	  in	  optimem	  
plus	  1%	  of	  serum.	  Negative	  control	  (cells	  not	  exposed	  to	  the	  TAT-­‐cre	  protein,	  No	  TAT-­‐cre)	  is	  also	  shown.	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Since	  it	  was	  shown	  that	  fetal	  calf	  serum	  (FCS)	  and	  bovine	  serum	  albumin	  (BSA)	  inhibited	  
the	  efficiency	  of	  TAT-­‐cre	  deletion	  in	  erythroblastic	   leukemia	  cells	  (Joshi	  et	  al.,	  2002),	  we	  
also	   tested	   different	   concentration	   of	   these	   reagents	   in	   optimem	   during	   TAT-­‐cre	  
incubation	   with	   our	   cells.	   Coating	   with	   BSA	   or	   serum	   before	   protein	   treatment	   and	  
addition	  of	  1%	  of	  serum	  during	   incubation	  were	  equivalent	  strategy	   in	   term	  of	  deletion	  
efficiency.	   For	   practical	   reasons	   we	   decided	   to	   use	   as	   standard	   condition	   TAT-­‐cre	  
incubation	   with	   1%	   of	   serum	   in	   optimem,	   a	   good	   compromise	   in	   terms	   of	   deletion	  
efficiency	  and	  lack	  of	  cell	  attachment	  to	  the	  plastic	  (Figure	  16).	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  16	  Setting	  up	  of	  the	  TAT-­‐cre	  treatment	  in	  terms	  of	  conditions	  of	  incubation.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
qPCR	  of	  gDNA	  showing	  the	  levels	  of	  	  myc	  -­‐/-­‐	  and	  myc	  fl/fl	  alleles	  relative	  to	  the	  nucleolin	  amplicon,	  in	  c-­‐myc	  
fl/fl	  B	  cells	  treated	  with	  50	  μg	  of	  TAT-­‐cre	  for	  1h	  	  in	  optimem,	  in	  optimem	  plus	  1%	  of	  serum,	  optimem	  plus	  5%	  
of	  serum	  and	  in	  optimem	  after	  coating	  of	  the	  falcons	  with	  1%	  of	  BSA	  or	  1%	  of	  serum.	  Negative	  control	  (cells	  
not	  exposed	  to	  the	  TAT-­‐cre	  protein	  No	  TAT-­‐cre)	  is	  also	  shown.	  	  
	  
	  
Considering	  also	  that	  the	  TAT-­‐cre	  protein	  is	  purified	  from	  bacteria	  (Capasso	  et	  al.,	  2009)	  
and	  may	  thus	  be	  contaminated	  with	  bacterial	  lipopolysaccharides,	  we	  checked	  whether	  it	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could	  induce	  an	  inflammatory	  response	  in	  B	  cells.	  We	  verified	  that	  immediately	  after	  TAT-­‐
cre	   treatment,	   some	   LPS	   responsive	   genes	   were	   induced	   (ccl5,	   ikβα,	   junb)	   in	   a	   similar	  
extent	  as	  after	  LPS	  stimulation	  (the	  positive	  control)	  but	  in	  a	  transient	  manner	  (Figure	  17).	  
12h	   after	   TAT-­‐cre	   treatment,	   when	   we	   started	   the	   LPS	   treatment,	   these	   genes	   have	  
returned	  at	  a	  basal	  level	  and	  were	  still	  LPS	  responsive	  (Figure	  17;	  Figure	  18).	  	  
	  
	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  17	  LPS	  target	  genes	  transcriptional	  response	  after	  TAT-­‐cre	  treatment.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
RT-­‐qPCR	  of	  junb	  and	  Ikβα	  is	  reported.	  mRNA	  expression	  levels	  normalized	  to	  TBP	  are	  shown	  for	  control	  cells	  
taken	  immediately	  after	  purification	  (AP)	  ,	  cell	  taken	  immediately	  after	  and	  whashout	  (0h),	  or	  1	  or12	  h	  after	  
washout	  (the	  later	  corresponding	  to	  the	  time	  at	  which	  we	  wanted	  to	  activate	  cells	  with	  LPS).	  Treatments	  
were:	  TAT-­‐cre,	  No	  TAT-­‐cre	  (50%	  glycerol)	  or	  LPS	  (50	  μg/ml	  LPS)	  for	  1	  hour	  incubation.	  
	  
	  
Figure	  18	  Active	  transcriptional	  response	  of	  LPS	  target	  genes.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
RT-­‐qPCR	  of	  junb	  and	  Ikβα	  is	  reported.	  mRNA	  expression	  levels	  normalized	  to	  TBP	  are	  shown	  for	  in	  c-­‐myc	  fl/fl	  
cells	  	  treated	  or	  not	  with	  TAT-­‐cre	  and	  wt	  cells	  TAT-­‐cre	  treated.	  RNA	  was	  collected	  12h	  after	  treatment	  (0h	  
LPS)	  and	  1,2	  and	  4h	  after	  LPS	  stimulation.	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On	  the	  basis	  of	  these	  observations	  we	  decided	  to	  always	  use	  as	  control	  wt	  B	  cells	  treated	  
with	  TAT-­‐cre,	  instead	  of	  untreated	  c-­‐mycf/f	  cells,	  to	  take	  into	  account	  possible	  unspecific	  
effects	  of	  TAT-­‐cre.	  Therefore,	  we	  decided	  to	  treat	  c-­‐myc	  f/f	  and	  wt	  cells	  with	  50	  μg/ml	  of	  
TAT-­‐cre	  in	  agitation	  at	  37°	  C	  for	  one	  hour	  in	  optimem	  plus	  1%	  serum.	  
qPCR	  analysis	  of	  genomic	  DNA	  indicated	  that	  the	  c-­‐myc	  f/f	  allele	  was	  deleted	  in	  ca,	  80%	  of	  
the	   cells	   12h	   after	   TAT-­‐cre	   treatment	   (c-­‐myc∆/∆	   cells:	   t0	   of	   LPS	   treatment)	   (Figure	   19).	  
Over	  the	  time	  (at	  48	  and	  72h)	  we	  observed	  a	  gradual	  loss	  of	  the	  c-­‐myc∆/∆	  alleles	  in	  favour	  
of	   the	   undeleted	   one	   similarly	   to	   what	   already	   reported	   in	   previous	   studies	   on	   c-­‐myc	  
deletion	   in	  B	  cells	   in	  vivo	   	   (de	  Alborán	  et	  al.,	  2001).	  This	  was	  most	  probably	  due	   to	   the	  
counterselection	  of	   	  myc	  deleted	   cells	   in	   the	  overall	   population	   that	   continue	   to	  divide	  
overcoming	  the	  myc	  deleted	  cells.	  	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  19	  Efficiency	  of	  c-­‐myc	  deletion	  at	  genomic	  DNA	  level.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
q-­‐PCR	  analysis	  of	  gDNA	  to	  assess	  c-­‐myc	  copy	  number	  in	  wt	  and	  c-­‐myc	  ∆/∆	  cells.	  The	  data	  are	  normalized	  to	  
nucleolin	  amplicon	  and	  represent	  the	  average	  ±	  s.d.	  of	  3	  independent	  experiments.	  
	  
	  
Consistent	   with	   the	   efficiency	   of	   deletion	   measured	   on	   the	   gDNA,	   we	   also	   observed	  
reduced	  c-­‐myc	  mRNA	  and	  protein	  accumulation	  upon	  LPS	  stimulation	  in	  the	  floxed	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population	  (Figure	  20;	  Figure	  21).	  In	  control	  cells,	  we	  observed	  a	  peak	  of	  c-­‐myc	  mRNA	  and	  
protein	  induction	  at	  2h	  of	  LPS	  stimulation,	  followed	  by	  a	  progressive	  decrease	  over.	  It	  ‘s	  
well	   established,	   indeed,	   that	   a	  mitogenic	   stimulus	   rapidly	   induces	   the	  expression	  of	  c-­‐
myc	   favoring	   B	   cells	   to	   re-­‐enter	   in	   G1-­‐S	   phase	   of	   the	   cell	   cycle	   (Kelly	   et	   al.,	   1983).	  
Afterwards,	   with	   the	   consequent	   transition	   from	   B	   cells	   to	   plasma	   cells,	   others	  
transcription	  factors	  start	  to	  play	  important	  roles	  in	  controlling	  each	  phase	  of	  plasma	  cells	  
development.	  Not	  surprisingly,	  one	  way	  by	  which	  the	  master	  transcription	  factor	  Blimp-­‐1	  
promotes	  generation	  of	  plasma	  cells	   is	   the	   repression	  of	   c-­‐Myc,	   thereby	  allowing	   the	  B	  
cell	  to	  exit	  the	  cell	  cycle	  and	  undergo	  terminal	  differentiation	  (Lin	  Y	  et	  al.1997,	  Yu	  J	  et	  al.,	  
2000).	  
	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  20	  Myc	  expression	  in	  wt	  and	  c-­‐myc	  ∆/∆	  cells.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  c-­‐
myc	  mRNA	  level	  were	  measured	  by	  RT-­‐qPCR	  in	  control	  and	  deleted	  cells	  followed	  by	  LPS	  stimulation	  as	  
indicated.	  The	  data	  were	  normalized	  to	  TBP	  expression.	  The	  average	  ±	  s.d.	  of	  3	  independent	  experiments	  is	  
shown,	  *P<0.05,	  **P<0.001.	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Figure	  21	  Myc	  protein	  levels	  in	  wt	  	  and	  c-­‐myc	  	  deleted	  B	  cells.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Immunoblot	  of	  cell	  extracts	  from	  wt	  and	  c-­‐myc	  ∆/∆	  B	  cells	  at	  0,	  1,	  2,	  4h	  post	  LPS-­‐activation	  and	  
corresponding	  quantification	  are	  shown.	  
	  
	  
In	  conclusion,	  we	  set	  up	  a	  clean	  model	  system	  to	  perform	  loss	  of	  function	  experiments	  to	  
investigate	  the	  role	  of	  c-­‐Myc	  in	  activated	  B	  cells	  at	  short	  time	  points	  (up	  to	  48h).	  Besides,	  
since	  RT-­‐qPCR	  analysis	  showed	  that	  N-­‐myc	  and	  L-­‐myc	  are	  not	  expressed	  in	  B	  cells	  in	  that	  
condition	   (Figure	  22)	  we	  can	  attribute	  any	  phenotypic	  effects	  observable	  only	   to	  c-­‐myc	  
deletion.	  	  
	  
	  
Figure	  22	  N-­‐myc	  and	  L-­‐myc	  expression	  in	  B	  activated	  cells.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
n-­‐myc	  and	  l-­‐myc	  mRNA	  level	  were	  measured	  by	  RT-­‐qPCR	  in	  control	  and	  deleted	  cells	  followed	  by	  LPS	  
stimulation	  as	  indicated.	  The	  data	  were	  normalized	  to	  TBP	  expression.	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4.2 	  Impaired	  mitogenic	  response	  of	  c-­‐myc∆/∆	  cells	  
	  
A	  vast	  amount	  of	  published	  data	  points	  to	  Myc	  as	  a	  master	  regulator	  of	  cell	  proliferation.	  
Deletion	  of	   the	  c-­‐myc	  gene	   in	  RAT1a	   fibroblasts	  produced	  a	  significant	  delay	   in	  S	  phase	  
entry	  resulting	  in	  a	  prolonged	  cellular	  doubling	  time	  while,	  on	  the	  contrary,	  ectopic	  Myc	  
expression	   in	   non-­‐proliferating	   fibroblasts	   induced	   S	   phase	   entry	   and	   shorter	   doubling	  
time	  (Mateyak	  et	  al.,	  1997;	  Palmieri	  et	  al.,	  1983).	   In	  B	  cells	  specifically,	  de	  Alborán’s	   lab	  
showed	   that	   activation	   and	  proliferation	  upon	  CD40+IL4	   treatment	   is	   c-­‐myc	   dependent	  	  
(de	  Alborán	  et	   al.,	   2001).	  We	   thus	  decided	   to	   check	   if	   there	  was	   an	   impairment	  of	   the	  
proliferative	  response	  in	  c-­‐myc∆/∆	  B	  cells	  stimulated	  with	  LPS.	  Direct	  cell	  counting	  showed	  
a	   clear	   reduction	   in	   proliferation	   of	   c-­‐myc∆/∆	   cells	   compared	   to	   wt	   cells	   (Figure	   23).	  
Proliferation	   in	   c-­‐myc∆/∆	   cultures	   can	   be	   mainly	   explained	   by	   the	   outgrowth	   of	   non-­‐
deleted	  cells,	  as	  shown	  by	  the	  increased	  frequency	  of	  the	  undeleted	  c-­‐mycf/f	  allele	  at	  48h	  
and	  72h	  post	  LPS	  stimulation	  (Figure	  19).	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Figure	  23	  Proliferation	  of	  Myc-­‐deficient	  B	  cells	  is	  impaired	  compared	  to	  wt	  B	  cells.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Growth	  curves	  of	  wt	  and	  fl/fl	  cells	  upon	  different	  treatments.	  In	  the	  upper	  part	  3	  control	  curves	  are	  shown:	  	  
wt	  and	  c-­‐myc	  fl/fl	  cells	  without	  any	  treatment,	  wt	  and	  c-­‐myc	  fl/fl	  cells	  after	  TAT-­‐cre	  only	  or	  LPS	  only.	  Below,	  
growth	  curves	  of	  wt	  and	  fl/fl	  cells	  treated	  with	  TAT-­‐cre	  stimulated	  in	  culture	  with	  LPS	  are	  shown.	  The	  
average	  ±	  s.d.	  of	  3	  independent	  experiments	  is	  reported.	  	  
	  
	  
We	  further	  addressed	   if	   the	  reduced	  growth	  rate	  of	  c-­‐myc∆/∆	  cells	  was	  due	  to	   increased	  
apoptosis,	   decreased	   proliferation	   or	   both.	   Caspase	   activity	   measurement	   and	   Trypan	  
blue	  exclusion	  assay	  showed,	  even	  if	  in	  different	  extent,	  that	  wt	  cells	  start	  to	  die	  at	  72h	  of	  
activation	  and	  then	  undergo	  a	  massive	  cell	  death.	  On	  the	  contrary,	  c-­‐myc∆/∆	  cells	  do	  not	  
display	  the	  same	  behavior	  as	  previously	  published	  	  (de	  Alborán	  et	  al.,	  2004;	  Murn	  et	  al.,	  
2009)	   (Figure	   24).	   de	   Alboran	   and	   colleagues	   propose	   a	   possible	   explanation	   for	   this	  
phenotype,	  which	   remains	   to	  be	  confirmed	   in	   the	  current	   system.	  Since	  CD95/CD95L	   is	  
induced	   in	  mitogenic	   activated	  B	   cells	   and	   leads	   to	   susceptibility	   to	   apoptosis	   via	  CD95	  
pathway,	  it	  was	  shown	  that	  c-­‐myc∆/∆	  cells	  express	  low	  surface	  CD95	  and	  CD95L	  levels	  and	  
when	  treated	  with	  anti-­‐CD95	  antibody	  or	  staurisporine	  show	  resistance	  to	  CD95-­‐induced	  
apoptosis	  than	  control	  cells.	  In	  addition,	  non-­‐activated	  c-­‐Myc-­‐deficient	  B-­‐lymphocytes	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were	  observed	  to	  be	  more	  resistant	  to	  cell	  death	  that	  an	  activated	  wt	  cells	  (de	  Alborán	  et	  
al.,	  2004)	  arguing	  for	  an	  important	  Myc	  role	  on	  this	  process.	  
	  
	  
Figure	  24	  Myc-­‐deficient	  B	  cells	  are	  less	  prone	  to	  apoptosis.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Left:	  Caspase	  3/7	  activity	  as	  a	  measure	  of	  apoptotic	  cell	  death	  in	  normal	  and	  c-­‐myc	  ∆/∆	  cells;	  Right:	  
percentage	  of	  dead	  cells	  counted	  by	  Trypan	  blue.	  The	  average	  ±	  s.d.	  of	  3	  independent	  experiments	  is	  
reported.	  
	  
	  
We	  then	  checked	  if	  Myc-­‐deleted	  cells	  might	  have	  a	  proliferative	  defect	  through	  cell	  cycle	  
analysis.	   Following	   a	   pulse	   of	   BrDU	   labelling	   in	   wt	   and	   c-­‐myc∆/∆	   cells	   at	   different	   time	  
points	  of	  LPS	  stimulation	  we	  observed	  by	  FACS	  analysis	  an	  accumulation	  of	  c-­‐myc∆/∆	  cells	  
in	  G0-­‐G1	  phases	  	  (Figure	  25	  b)	  with	  a	  concomitant	  delay	  in	  S	  phase	  entry	  resulting	  in	  the	  
decrease	  rate	  of	  proliferation	  (Figure	  23;	  Figure	  25).	   In	  fact	  wt	  B	  cells	  start	  to	  enter	  in	  S	  
phase	  after	  12h	  of	  LPS	  stimulation,	  while	  c-­‐myc∆/∆	  cells	  accumulate	  more	  in	  G1	  phase	  and	  
incorporate	  less	  BrDU	  indicating	  that	  are	  not	  prone	  to	  duplicate	  and	  progress	  into	  the	  cell	  
cycle	  as	  wt	  cells	  (Figure	  25	  a).	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Figure	  25	  Conditional	  deletion	  of	  c-­‐myc	  in	  quiescent	  B	  cells	  impairs	  cell-­‐cycle	  re-­‐entry.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  a)	  
Percentages	  of	  cells	  in	  S-­‐phase	  at	  0,	  12,	  24	  and	  48h	  of	  LPS	  stimulation	  in	  wt	  and	  c-­‐myc	  ∆/∆	  cells	  is	  shown.	  
BrdU	  was	  added	  to	  the	  culture	  medium	  for	  30	  min	  at	  each	  time	  points	  and	  incorporation	  was	  assessed	  by	  
flow	  cytometry.	  The	  average	  ±	  s.d.	  of	  two	  independent	  experiments	  is	  reported.	  b)	  FACS	  profile	  of	  wt	  and	  c-­‐
myc	  ∆/∆	  cells	  at	  24h	  after	  LPS	  stimulation	  is	  reported	  as	  example.	  Cells	  after	  BrdU	  incorporation	  and	  ethanol	  
fixation	  were	  stained	  with	  anti-­‐BrdU	  detected	  via	  FITC	  labeled	  antibody	  and	  also	  with	  Propidium	  iodide	  (PI)	  
for	  visualization	  of	  total	  DNA	  content.	  Percentages	  of	  cells	  in	  each	  phase	  of	  cycle	  (Go-­‐G1,	  S,	  M)	  were	  
reported.	  	  
	  
	  
4.3	  Impact	  of	  Myc	  on	  cell	  size,	  RNA	  content	  and	  plasma	  cell	  differentiation	  
	  
In	   normal	   cells	   such	   as	   fibroblasts	   and	   naïve	   T	   cells,	  mitogenic	   growth	   factor	   signaling	  
promotes	  cell	  activation	  through	  the	  induction	  of	  Myc	  expression,	  which	  in	  turn	  enhances	  
the	   transcription	  of	  metabolic	  and	  proliferation-­‐associated	  genes	   	   (Eilers	  and	  Eisenman,	  
2008;	  Wang	  R	  et	  al.,	  2011).	  Upon	  stimulation	  of	  antigen	  receptors,	  quiescent	  naïve	  B	  cells,	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similarly	   to	   T	   cells,	   undergo	   metabolic	   activation	   with	   a	   dramatic	   increase	   in	   RNA	  
production	  and	  protein	  synthesis.	  This	  active	  metabolic	  state	  sustains	  cell	  division,	  clonal	  
expansion	  and	  differentiation	  in	  plasma	  cells	  or	  long-­‐lived	  memory	  cells	  (Rajewsky,	  1996).	  
c-­‐Myc	   has	   a	   fundamental	   role	   in	   this	   mitogen-­‐induced	   growth	   of	   mammalian	   cells	  
(Grumont	   et	   al.,	   2002;	   Eisenman,	   2001;	   Schuhmacher	   et	   al.,	   1999).	   Since	   it	   has	   been	  
proposed	   that	   the	   increase	   in	   cellular	   RNA	   content	   that	   can	   be	   observed	   during	   B	   cell	  
activation	  (Kouzine	  et	  al.,	  2013)	  could	  be	  due	  to	  the	  positive	  effect	  that	  Myc	  exerts	  on	  the	  
transcription	  of	  all	  expressed	  genes	  (the	  so-­‐called	  “transcriptional	  amplification”)	  (Nie	  et	  
al.,	   2012),	  we	   decided	   to	  measure	   the	   RNA	   content	   per	   cell	   in	  wild	   type	   and	   c-­‐myc	   ∆/∆	  
cells.	  	  We	  did	  find	  a	  massive	  increase	  in	  total	  RNA	  after	  24	  and	  48h	  of	  LPS	  stimulation	  in	  
wild	   type	   cells	   that	   was	   less	   pronounced	   in	   c-­‐myc	   ∆/∆	   cells	   but	   we	   could	   not	   score	   a	  
significant	  difference	  in	  the	  first	  12h	  as	  previously	  reported	  	  (Nie	  et	  al.,	  2012)	  (Figure	  26).	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  26	  Increase	  in	  RNA	  levels	  during	  B	  cells	  activation.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Levels	  of	  total	  RNA	  in	  wt	  and	  c-­‐myc	  ∆/∆	  B	  cells	  at	  different	  time	  points	  upon	  LPS	  stimulation.	  The	  average	  ±	  
s.d.,	  of	  3	  independent	  experiments	  is	  shown,	  *P<0.05,	  **P<0.001.	  Adapted	  from	  Sabò	  et	  al.	  2014.	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At	  the	  same	  time,	  we	  also	  observed	  an	  increase	  in	  cell	  size	  during	  LPS	  treatment	  in	  a	  Myc-­‐
dependent	  manner.	  RNA	  content	  does	  not	  show	  a	  significant	  increase	  within	  the	  first	  12	  
hours	  of	  LPS	  stimulation,	  whereas	  the	  enhancement	  in	  forward	  scatter	  (as	  measure	  of	  cell	  
size)	  resembles	  a	  more	  gradual	  process	  starting	  soon	  after	  Myc	  induction	  (Figure	  27).	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  27	  Increase	  in	  cell	  size	  during	  B	  cells	  activation.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Left:	  Distribution	  of	  FSC	  values	  of	  wt	  and	  c-­‐myc	  ∆/∆	  B	  cells	  as	  measured	  by	  FACS.	  Right:	  Percentage	  of	  cells	  
with	  forward	  scatter	  bigger	  than	  600	  was	  reported.	  The	  average	  ±	  s.d.,	  of	  3	  independent	  experiments	  is	  
shown,	  *P<0.05,	  **P<0.001.	  Adapted	  from	  Sabò	  et	  al.	  2014.	  Below	  the	  quantification	  graph,	  images	  of	  wild	  
type	  B	  cells	  resting	  or	  activated	  for	  48h	  are	  shown	  under	  40X	  magnification	  of	  canonical	  optical	  microscope.	  	  
	  
	  
At	   48h,	   the	  differences	   in	  RNA	   content	   and	   cell	   size	  between	  wt	   and	  c-­‐myc∆/∆	   cells	   are	  
reduced	  compared	  to	  24h,	  due	  to	  recovery	  of	  the	  c-­‐myc∆/∆	  cells.	  Since	  we	  know	  that	  there	  
is	  counter-­‐selection	  of	  deleted	  cells	  at	  later	  time	  points,	  we	  decided	  to	  sort	  myc	  deleted	  
and	  wt	  cells	  according	  to	  their	  size	  and	  then	  check	  the	  genotype	  on	  the	  sorted	  cells.	  At	  24	  
and	  48h	  of	  LPS	  stimulation,	  the	  activated	  cells	  are	  bigger	  compared	  to	  resting	  condition	  
and	  are	  mainly	  c-­‐myc	  wt	  even	  when	  sorted	  from	  the	  c-­‐myc	  ∆/∆	  population	  suggesting	  that	  
they	  are	  most	  probably	  escapers.	  On	  the	  other	  hand,	  we	  found	  that	  resting	  cells	  are	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smaller	  and	  mainly	  c-­‐myc	  deleted;	  only	  a	  minor	  part	  (ca.	  24%	  at	  48h	  LPS)	  of	  activated,	  big	  
cells,	  are	  actually	  myc	  knockout.	  (Figure	  28;	  Figure	  29).	  
	  
	  	  	  	  	  	  	  	  	  	  	  
	  
	  
Figure	  28	  Activation	  of	  wt	  and	  c-­‐myc	  ∆/∆	  cells.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
FACS	  analysis	  of	  sorted	  mature	  B	  cells	  from	  wt	  (on	  the	  left)	  and	  c-­‐myc	  ∆/∆	  (on	  the	  right)	  mice	  based	  on	  cell	  
size	  (forward	  scatter)	  and	  internal	  complexity	  (side	  scatter).	  Cells	  were	  sorted	  before	  or	  after	  LPS	  
stimulation	  (0,	  24	  and	  48h	  LPS).	  Gate	  of	  activated	  cells	  (in	  blue)	  is	  reported	  as	  att;	  while	  rest	  stands	  for	  
resting	  cells	  (in	  pink).	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Figure	  29	  Genomic	  analysis	  of	  	  myc	  level	  in	  different	  sorted	  cells	  populations.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Relative	  amount	  of	  amplicon	  c-­‐myc	  fl/fl	  and	  myc	  -­‐/-­‐	  genomic	  DNA	  measured	  by	  quantitative	  RT–PCR	  in	  wt	  
and,	  c-­‐myc	  ∆/∆	  cells	  before	  sorting	  (labels	  in	  black)	  and	  after	  sorting	  (labels	  in	  grey)	  after	  0,24	  and	  48h	  of	  LPS	  
stimulation:	  wt	  	  and	  c-­‐myc	  ∆/∆	  	  A	  (activated),	  wt	  and	  c-­‐myc	  ∆/∆	  	  R	  (resting)	  sorted	  cells	  are	  shown.	  Values	  were	  
normalized	  to	  a	  PCR	  amplicon	  in	  the	  Nucleolin	  locus.	  
	  
In	  conclusion,	  upon	  LPS-­‐mediated	  activation,	  B	  cells	  increase	  in	  size	  and	  RNA	  content	  in	  a	  
Myc-­‐dependent	  manner.	  What	  we	  cannot	  conclude	  from	  this	  data	  is	  whether	  the	  role	  of	  
Myc	   here	   is	   to	   amplify	   the	   expression	   of	   all	   active	   genes	   and	   thus	   make	   the	   cells	   to	  
produce	  more	  RNA	  and	  get	  bigger,	  or	  whether	  it	  regulates	  key	  genes	  involved	  in	  cell	  cycle	  
entry,	  cell	  growth,	  metabolism	  and	  other	  cellular	  features	  that	  may	  then	  feed	  back	  on	  the	  
global	  RNA	  production	  (Sabò	  et	  al.,	  2014).	   In	  the	  latter	  scenario,	  the	  reduced	  amount	  in	  
RNA	   content	   and	   cell	   size	   in	   Myc-­‐deleted	   cells	   would	   actually	   follow	   from	   defects	   in	  
cellular	   activation.	  Although	  Myc	   induction	  has	  a	   fundamental	   role	   in	  proliferation	  of	  B	  
cells,	  Myc	   repression	  was	  also	   reported	   to	  be	  a	  necessary	   step	   for	   terminal	  plasma	  cell	  
differentiation	   	   (Lin	   K.	   et	   al.,	   2000;	   Lin	   Y	   et	   al.,	   1997).	  We	   thus	   analyzed	   by	   qPCR	   the	  
expression	  of	  3	  genes	  associated	  to	  plasma	  cells	  differentiation	  (Blimp1,	  Xbp1,	  Bcl6)	  in	  wt	  
and	  c-­‐myc	  ∆/∆	  cells.	  We	  found	  that	  while	  Blimp1	  was	  more	  induced	  in	  deleted	  cells,	  Xbp1	  
was	  not	  affected	  by	  Myc	  and	  Bcl6	  was	  less	  repressed	  in	  deleted	  cells	  (Figure	  30).	  In	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conclusion,	   we	   could	   at	   least	   exclude	   any	   important	   role	   of	   Myc	   on	   plasma	   cell	  
differentation.	  
	  
	  
Figure	  30	  Gene	  expression	  quantification	  of	  markers	  of	  plasma	  cell	  in	  wt	  and	  c-­‐myc	  ∆/∆cells.	  
Quantitative	  qPCR	  of	  3	  genes	  regulated	  during	  plasma	  cells	  differentiation	  (Blimp1,	  Xbp1,	  Bcl6)	  in	  wt	  and	  c-­‐
myc	  ∆/∆	  cells	  at	  different	  time	  points	  after	  LPS	  stimulation.	  The	  data	  were	  normalized	  to	  TBP.	  The	  average	  ±	  
s.d.,	  of	  3	  independent	  experiments	  is	  shown,	  *P<0.05,	  **P<0.001.	  Adapted	  from	  Sabò	  et	  al.	  2014.	  
	  
	  
In	  addition,	  FACS	  analysis	  of	  surface	  markers	  of	  plasma	  cell	  differentiation	  (CD44,	  CD138	  
and	  CD38)	  revealed	  changes	  in	  the	  level	  of	  CD38	  and	  no	  differences	  in	  the	  distribution	  of	  
the	  other	  markers	  between	  the	  two	  genotypes	  (Figure	  31).	  We	  then	  concluded	  that	  c-­‐myc	  
∆/∆	  cells	  are	  still	  undergoing	  plasma	  cell	  differentiation.	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Figure	  31	  Expression	  of	  plasma	  cells	  differentiation	  surface	  markers	  in	  wt	  	  and	  	  c-­‐myc	  ∆/∆	  cells	  	  by	  
FACS.	  Upper	  part	  (from	  left	  to	  right):	  mock	  staining,	  single	  staining	  for	  CD44	  and	  CD38	  with	  indicated	  gates	  
for	  low	  and	  high	  intensity.	  Bottom	  part:	  Double	  staining	  of	  CD44	  and	  CD38	  in	  wt	  and	  c-­‐myc	  ∆/∆	  B	  cells	  at	  48	  
and	  72h	  after	  LPS	  stimulation.	  
	  
	  
4.4	  Characterization	  of	  the	  Myc-­‐dependent	  transcriptional	  response	  to	  LPS	  
stimulation	  
	  
To	   determine	   whether	   Myc	   binding	   at	   promoters	   implicates	   direct	   transcriptional	  
regulation	  of	  the	  corresponding	  genes,	  we	  decided	  to	  profile	  total	  RNA	  by	  RNA-­‐seq	  in	  wt	  
and	  c-­‐myc∆/∆	  cells	  at	  0,	  2,	  4,	  8	  hr	  after	  LPS	  stimulation.	  As	  a	  preliminary	  control,	  we	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monitored	   the	   expression	   of	   three	   Myc-­‐dependent	   serum	   response	   (MDSR)	   genes	  
previously	  identified	  in	  fibroblasts,	  Gart,	  Smyd2	  and	  Ncl	  	  (Perna	  et	  al.,	  2012).	  	  We	  used	  RT-­‐
qPCR	   to	   profile	   mRNA	   expression	   in	   control	   and	   c-­‐myc	   deleted	   B	   cells	   following	   LPS	  
stimulation	   (Figure	   32).	   We	   observed	   impairment	   in	   the	   LPS-­‐dependent	   induction	   of	  
these	   genes	   in	   c-­‐myc	   ∆/∆	   relative	   to	   control.	   This	   suggests	   that,	   as	   in	   fibroblasts,	   the	  
activation	  of	  these	  genes	  by	  mitogenic	  is	  Myc-­‐dependent	  in	  B-­‐cells.	  	  We	  thus	  proceeded	  
with	  the	  full	  transcriptional	  profiling	  of	  the	  Myc-­‐dependent	  response.	  	  	  	  	  	  	  
	  
	  
Figure	  32	  c-­‐myc	  deletion	  impaired	  the	  transcriptional	  activation	  of	  known	  Myc	  target	  genes	  in	  
response	  to	  LPS.	  RT-­‐qPCR	  of	  the	  3	  genes	  previously	  shown	  to	  be	  dependent	  on	  Myc	  for	  their	  induction	  by	  
serum	  (Perna	  et	  al.	  2012)	  in	  wt	  and	  c-­‐myc	  ∆/∆	  cells.	  The	  data	  were	  normalized	  to	  TBP	  expression.	  The	  
average	  ±	  s.d.	  of	  3	  independent	  experiments	  is	  shown,	  *P<0.05,	  **P<0.001.	  
	  
	  
We	   profiled	   total	   RNA	   and	   considering	   the	   importance	   of	   data	   normalization	   highlight	  
from	  authors	  of	  the	  amplifier	  model,	  we	  extracted	  RNA	  form	  the	  same	  amount	  of	  cells.	  
Within	   8h	   of	   LPS	   stimulation	   we	   didn’t	   observe	   any	   RNA	   transcriptional	   amplification	  
reasoning	  that	  a	  normalization	  of	  the	  data	  per	  cell	  equivalent	  (Lovén	  et	  al.,	  2012;	  Lin	  C	  et	  
al.,	  2012;	  Nie	  et	  al.,	  2012)	  was	  not	  required.	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We	  identified	  differentially	  expressed	  genes	  (DEGs)	  	  (q-­‐value	  lower	  then	  005)	  at	  each	  time	  
point	   of	   LPS	   stimulation	   (for	   details	   see	  Materials	   and	  Methods)	   (Figure	   33).	   The	   total	  
numbers	   of	   DEGs	   increased	   during	   the	   time	   course	   as	   an	   expected	   effect	   of	   B	   cells	  
activation.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  33	  Number	  of	  differentially	  expressed	  genes	  relative	  to	  untreated	  cells	  wt	  and	  c-­‐myc	  ∆/∆	  	  B	  
cells.	  Total	  number	  of	  differentially	  expressed	  genes	  (DEGs)	  on	  the	  basis	  of	  q-­‐value	  <0.05	  at	  2,	  4,	  8,	  after	  
LPS	  stimulation	  respect	  to	  t0	  in	  wt	  and	  c-­‐myc	  cells.	  	  
	  
	  
Quiescent	   and	   transcriptionally	   poised	   B	   cells	   undergo	   a	   global	   transcription	  
reprogramming	  soon	  after	  mitogenic	  activation	  occurs	  (Chen	  &	  Allfrey	  1987;	  Fowler	  et	  al.,	  
2013).	   Thus,	   we	   first	   checked	   wheter	   B	   cells	   transcriptionally	   responded	   to	   LPS	  
irrespective	  to	  their	  genotype:	  both	  in	  wt	  and	  c-­‐myc	  ∆/∆	  2h	  of	  mitogenic	  stimulation	  was	  
enough	   to	   generate	   a	   similar	   transcriptional	   response	   that	   included	   genes	   involved	   in	  
signal	  transduction	  processes	  such	  as	  the	  expected	  TLR	  signaling	  pathways	  with	  robust	  P	  
values	  (Figure	  34).	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Figure	  34	  Common	  differentially	  expressed	  genes	  	  in	  wt	  and	  c-­‐myc	  ∆/∆	  at	  2h	  LPS.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Total	  numbers	  of	  DEGs	  at	  2h	  in	  wt	  and	  c-­‐myc	  ∆/∆	  respect	  to	  the	  own	  time	  0	  are	  compared	  via	  Venn	  Diagram	  
and	  the	  gene	  ontology	  of	  common	  genes	  is	  reported	  below.	  GO	  terms	  in	  biological	  process	  ontology	  	  and	  
immunological	  signature	  are	  considered	  .GO	  terms	  significantly	  enriched	  (FDR	  value	  <	  0.05)	  were	  reported.	  	  
Genes	  set	  with	  activated	  genes	  at	  40,60,	  80	  and	  120	  minutes	  respect	  to	  unstimulated	  bone	  marrow	  derived	  
macrophages	  (e.g	  UNSTIM_VS_60MIN_LPS_BMDM_DN)	  are	  enriched.	  
	  
	  
To	  investigate	  the	  transcriptional	  signature	  that	  distinguishes	  wt	  from	  c-­‐myc	  ∆/∆	  cells,	  we	  
came	  along	  a	  further	  analysis	  of	  DEGs.	  We	  defined	  4	  LPS-­‐associated	  regulatory	  patterns	  
influenced	  by	  the	  loss	  of	  Myc	  (Myc-­‐dependent	  LPS	  response	  genes)	  (Perna	  et	  al.,	  2012),	  
where	  the	  vast	  majority	   is	  Myc-­‐dependent	  LPS	   induced	  genes	   	   (regulatory	  group	  1)	  and	  
Myc-­‐dependent	   LPS	   repressed	   (regulatory	   group	   3).	   In	   a	   minor	   number	   of	   cases,	   Myc	  
deletion	   has	   the	   opposite	   effect,	   augmenting	   either	   activation	   (regulatory	   class	   2)	   or	  
repression	  (regulatory	  class	  4)	  by	  LPS.	  Other	  mRNAs	  showed	  a	  Myc-­‐independent	  response	  
to	  LPS,	  either	  induced	  (regulatory	  class	  5)	  or	  repressed	  (regulatory	  class	  6)	  (Figure	  35)	  (for	  
details,	  see	  Materials	  and	  Methods).	  
Gene$Set$Name$ #$Genes$in$Gene$Set$(K)$ #$Genes$in$Overlap$(k)$ k/K$ p7value$ FDR$q7value$
BIOPOLYMER_METABOLIC_PROCESS/ 1684/ 305/ 0.1811/ 3.66E888/ 1,00E884/
SIGNAL_TRANSDUCTION/ 1634/ 280/ 0.1714/ 4.57E875/ 6.25E872/
NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS/ 1244/ 227/ 0.1825/ 1.04E865/ 9.51E863/
GSE14769_UNSTIM_VS_60MIN_LPS_BMDM_DN/ 200/ 90/ 0.4500/ 4.29E862/ 2.93E859/
GSE14769_UNSTIM_VS_40MIN_LPS_BMDM_DN/ 200/ 84/ 0.4200/ 5.06E855/ 2.77E852/
GSE14769_UNSTIM_VS_80MIN_LPS_BMDM_DN/ 200/ 83/ 0.4150/ 7.1E854/ 3.23E851/
PROTEIN_METABOLIC_PROCESS/ 1231/ 195/ 0.1584/ 1.26E846/ 4.91E844/
TRANSCRIPTION/ 753/ 147/ 0.1952/ 3.28E846/ 1.12E843/
GSE2706_UNSTIM_VS_2H_LPS_DC_DN/ 200/ 76/ 0.3800/ 4.21E846/ 1.28E843/
2h LPS wt 
∆/∆  2h LPS c-myc
2583
462
1282
Total DEGs Total DEGs 
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Figure	  35	  Identification	  of	  categories	  of	  differentially	  expressed	  genes	  at	  4h	  after	  LPS	  
stimulation.	  Different	  categories	  of	  Myc-­‐dependent	  and	  Myc-­‐independent	  LPS	  response	  genes	  were	  
identified	  at	  each	  time	  point.	  This	  scatter	  plot	  is	  relative	  to	  4h	  of	  LPS	  stimulation	  (as	  an	  example	  of	  the	  
analysis	  we	  performed	  at	  each	  time	  point)	  with	  the	  different	  categories	  of	  genes	  represented	  in	  different	  
colors.	  Log2	  of	  the	  ration	  between	  gene	  expression	  at	  4h	  and	  gene	  expression	  at	  0h	  in	  wt	  (x-­‐axis)	  or	  c-­‐myc	  
∆/∆	  (the	  y-­‐axis)	  B	  cells	  is	  plotted.	  
	  
	  
In	   order	   to	   identify	   a	   core	   of	   Myc	   dependent	   genes	   we	   compared	   the	   lists	   of	   Myc	  
dependent	  induced	  and	  repressed	  during	  LPS	  stimulation.	  Venn	  diagrams	  showed	  only	  a	  
mild	   overlap	   among	   the	   genes	   identified	   at	   the	   different	   time	   points	   (Figure	   36).	   That	  
could	  be	  due	  to	   the	  dynamic	  changes	  of	   the	  transcriptional	   response:	  genes	   induced	  or	  
repressed	  at	  a	  certain	  time	  points	  are	  no	  more	  regulated	  at	  the	  subsequent	  one	  because	  
they	  return	  to	  the	  original	  baseline	  level,	  as	  classically	  occurring	  during	  the	  inflammation	  
response	   (Fowler	   et	   al.,	   2003).	   Another	   possibility,	   not	   mutually	   exclusive	   with	   the	  
previous	   one,	   would	   be	   that	   even	   if	   the	   trend	   is	   present	   at	   all	   time	   points	   it	   reaches	  
statistical	  significance	  only	  at	  one.	  
	  
Regulatory groups: 
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Figure	  36	  Overlap	  among	  genes	  Myc	  dependent	  induced	  and	  represssed	  during	  LPS	  stimulation.	  
Genes	  Myc	  dependent	  induced	  	  (on	  the	  left)	  and	  repressed	  (on	  the	  right)	  	  at	  each	  time	  point	  (2h,4h,8h	  LPS)	  
were	  compared	  via	  Venn	  Diagrams.	  	  
	  
	  
In	   order	   to	   verify	   this	   hypothesis	   we	   built	   heatmaps	   that	   show	   the	   changes	   in	   gene	  
expression	  relative	  to	  untreated	  cells	  for	  the	  two	  main	  categories	  of	  DEGs	  Myc	  dependent	  
induced	  and	  repressed	  reported	  in	  the	  Figure	  36	  and	  also	  for	  Myc	  independent	  induced	  
or	   repressed	   genes	   (Figure	   37;	   Figure	   38).	   The	   heatmaps	   pointed	   out	   indeed	   that	   the	  
transcriptional	   response	  of	   genes	   changes	  dynamically	  during	   the	   time	  course	   in	  a	  Myc	  
dependent	   or	   independent	   manner	   (Figure	   37;	   Figure	   38).	   	   We	   observed	   genes	   more	  
induced	  or	  repressed	  in	  a	  transient	  way	  and	  groups	  of	  genes	  with	  a	  progressive	  trend	  of	  
positive	  or	  negative	  regulation.	  On	  the	  other	  hand,	  we	  cannot	  exclude	  that	  some	  of	  these	  	  
2h LPS
4h LPS
8h LPS
4
21
295 207 538
Myc dependent repressed
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genes	  were	  not	  differentially	  expressed	   in	  other	   replicative	  experiments.	   In	   this	   regard,	  
validation	   of	   these	   regulatory	   groups	   of	   genes	   trough	   qPCR	   or	   Nanostring	   would	   be	   a	  
fundamental	  step.	  	  
	  
	  
Figure	  37	  Heatmaps	  of	  the	  Myc	  dependent	  genes	  identified	  in	  LPS	  stimulated	  B	  cells.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Heatmap	  of	  the	  log2(FC)	  (log2	  of	  fold-­‐change)	  values	  of	  all	  Myc	  dependent	  LPS	  induced	  (left)	  and	  repressed	  
(right)	  genes	  in	  at	  least	  one	  time	  point	  between	  2,	  4	  and	  8h	  of	  LPS	  treatment.	  The	  genes	  are	  clustered	  
hierarchically	  on	  the	  basis	  of	  similarities	  in	  the	  relative	  expression	  level.	  
	  
	  
Figure	  38	  Heatmaps	  of	  Myc	  independent	  genes	  identified	  in	  LPS	  stimulated	  B	  cells.	  	  	  	  	  	  	  	  	  	  	  	  
Heatmap	  of	  the	  log2(FC)	  (log2	  of	  fold-­‐change)	  values	  of	  all	  Myc	  independent	  LPS	  induced	  (left)	  	  and	  
repressed	  (right)	  genes	  in	  at	  least	  one	  time	  point	  between	  2,	  4	  and	  8h	  of	  LPS	  treatment.	  The	  genes	  are	  
clustered	  hierarchically	  on	  the	  basis	  of	  similarities	  in	  the	  relative	  expression	  level.	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4.5	  Genome-­‐wide	  analysis	  of	  Myc	  binding	  following	  LPS	  stimulation	  
	  
We	  decided	  to	  map	  the	  Myc-­‐dependent	  transcriptional	  response	  underlying	  the	  different	  
behavior	   of	   Myc	   wt	   and	   deleted	   cells	   in	   response	   to	   LPS.	   First,	   we	   investigated	   the	  
relationship	  between	  Myc	   levels,	  which	   in	  this	  physiological	  setting	  rise	  from	  a	  very	   low	  
baseline	  to	  very	  high	  (Kelly	  et	  al.,	  1983),	  and	  its	  genomic	  occupancy.	  A	  careful	  analysis	  of	  
ChIP-­‐seq	   experiments	   on	   different	   cells	   types	   have	   shown	   that	   Myc	   binding	   to	   the	  
genome	   is	   proportional	   to	   its	   expression	   level:	   when	   highly	   induced	   or	   overexpressed,	  
Myc	  binding	  to	  promoters	  and	  distal	  sites	  increase	  in	  terms	  of	  numbers	  and	  intensity	  and	  
at	   the	   highest	   level,	   Myc	   can	   be	   cross-­‐linked	   at	   virtually	   all	   active	   promoters	   and	  
enhancers	  in	  the	  genome,	  the	  already	  mentioned	  phenomenon	  called	  ‘invasion’	  (Sabò	  et	  
al.,	   2014;	   Sabò	   &	   Amati	   2014;	   Kress	   et	   al.,	   2015).	   To	   investigate	   Myc	   binding	   on	   the	  
genome	  of	  B	  cells,	  we	  then	  performed	  chromatin	   immunoprecipitation	  coupled	  to	  high-­‐
throughput	  sequencing	  (ChIP-­‐Seq)	  with	  a	  specific	  c-­‐Myc	  antibody	  at	  0,	  2,	  4,	  8	  hours	  after	  
LPS-­‐mediated	   induction.	   Initial	   analysis	   by	   ChIP-­‐qPCR	   showed	   that	  Myc	   binding	   to	   the	  
promoters	   of	   previously	   identified	   target	   genes	   reached	   a	   maximum	   at	   2h	   after	   LPS	  
stimulation	   and	  was	  not	  present	  on	   a	  negative	   control	   region	   (AchR)	   (Figure	  39).	   	   As	   a	  
control,	  we	  also	  performed	  ChIP	  with	  the	  c-­‐Myc	  antibody	  in	  c-­‐myc∆/∆	  cells	  and	  with	  a	  non-­‐
specific	  IgG	  in	  wild	  type	  cells:	  in	  both	  cases,	  we	  did	  not	  retrieve	  any	  significant	  enrichment	  
on	  the	  target	  amplicons	  (Figure	  39).	  	  
The	  genome-­‐wide	  analysis	  of	  the	  recovered	  DNA	  after	  Myc	  ChIP	  yielded	  ca.	  2000	  binding	  
sites	  in	  resting	  wild-­‐type	  B	  cells	  rising	  up	  to	  around	  22000	  after	  2h	  of	  LPS	  stimulation	  and	  
remaining	  similar	  in	  number	  at	  4	  and	  8	  h.	  Almost	  all	  Myc	  peaks,	  in	  resting	  condition,	  were	  
proximal	  (-­‐2	  to	  +1	  Kb)	  to	  an	  annotated	  transcription	  start	  site	  (TSS),	  which	  is	  the	  interval	  
we	  hereby	  annotate	  as	  	  ‘promoter’.	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In	  stimulated	  cells,	  the	  new	  binding	  sites	  were	  not	  only	  on	  promoters,	  but	  also	  on	  distal	  
sites,	  with	  an	  equal	  proportion	  of	   intra-­‐	  and	  extragenic	   locations	   (Figure	  40).	  Almost	  all	  
Myc	   peaks	   identified	   in	   control	   samples	   (0h	   LPS)	   were	   retrieved	   in	   the	   LPS-­‐stimulated	  
samples	   and	   almost	   all	   the	   peaks	   identified	   at	   each	   time	   point	   of	   stimulation	   are	  
contained	  in	  the	  previous	  one	  (Figure	  41).	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  39	  Myc	  binding	  to	  the	  promoters	  of	  target	  genes	  increases	  upon	  LPS	  stimulation.	  	  	  	  	  	  	  	  	  	  
ChIP-­‐qPCR	  of	  Myc	  binding	  to	  promoters	  of	  selected	  bound	  (pus7,	  smyd2,	  ncl)	  and	  unbound	  (AchR)	  genes.	  
The	  average	  ±	  s.d.,	  of	  3	  independent	  experiments	  is	  shown.	  As	  controls,	  ChIP-­‐qPCR	  with	  the	  anti-­‐Myc	  
antibody	  in	  c-­‐myc	  ∆/∆	  cells	  and	  with	  the	  normal	  rabbit	  IgGs	  in	  wt	  cells	  at	  0	  and	  2h	  after	  LPS	  stimulation	  is	  
shown.	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Figure	  40	  Myc	  binding	  sites	  increase	  in	  number	  after	  2h	  of	  LPS	  stimulation	  and	  are	  not	  restricted	  
to	  gene	  promoters.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Pie	  charts	  showing	  genomic	  distribution	  of	  Myc	  binding	  sites.	  The	  total	  number	  of	  peaks	  is	  reported	  in	  
brackets	  and	  divided	  in	  subgroups	  on	  the	  basis	  of	  annotation:	  peaks	  on	  promoters,	  in	  intergenic	  region	  and	  
gene	  body	  or	  intragenic	  regions.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
Figure	  41	  Overlap	  between	  Myc	  ChIP-­‐seq	  peaks.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Percentages	  of	  peaks	  overlapping	  (at	  least	  1bp)	  with	  the	  reference	  samples	  are	  reported	  in	  each	  column.	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In	  order	  to	  better	  characterize	  distal	  sites,	  we	  took	  advantage	  of	  chromatin	  profiles	  
generated	  in	  our	  lab	  on	  splenic	  B	  cells	  of	  either	  wild	  type	  (C)	  or	  young	  Eμ-­‐myc	  mice	  (P)	  
along	  with	  those	  obtained	  in	  Eμ-­‐myc	  lymphomas	  (T)	  (Sabò	  et	  al.,	  2014).	  We	  reasoned	  that	  
the	  wild-­‐type	  B	  cells	  in	  vivo	  should	  be	  very	  similar	  to	  our	  untreated	  B-­‐cells	  in	  vitro	  (t0	  of	  
LPS)	  in	  terms	  of	  Myc	  levels	  and	  active	  promoter/enhancers	  profiles.	  Indeed,	  by	  western	  
blot	  we	  verified	  that	  Myc	  protein	  levels	  are	  low	  in	  Eμ-­‐myc	  control	  cells	  (C)	  and	  LPS-­‐
untreated	  wild	  type	  cells	  and	  increase	  to	  a	  similar	  extent	  either	  in	  Eμ-­‐myc	  transgenic	  pre-­‐
tumoral	  cells	  (P)	  or	  upon	  LPS	  treatment	  (Figure	  42).	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  42	  Levels	  of	  Myc	  protein	  in	  normal	  B	  cells	  and	  Eµ-­‐myc	  transgenic	  B	  cells.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Immunoblot	  of	  cell	  extracts	  to	  monitor	  Myc	  protein	  levels	  in	  LPS	  stimulated	  B	  cells	  and	  Eµ-­‐myc	  control	  (C),	  
pre-­‐tumoral	  (P)	  and	  tumor	  (T)	  samples.	  
	  
	  
As	   shown	   in	   the	   qualitative	   heatmaps	   (Figures	   43,	   Figure	   44),	   the	   distribution	   of	  Myc	  
binding	  sites	  in	  resting	  B	  cells	  (0h)	  is	  comparable	  with	  the	  Eμ-­‐myc	  C	  sample	  and	  following	  
2h	   LPS	   is	   very	   similar	   to	   the	   Eμ-­‐myc	  P	   sample,	   reflecting	   the	  Myc	   protein	   levels	   in	   the	  
different	   conditions	   (Figure	  42).	   	   According	   to	   the	  distribution	  of	   the	  epigenetic	  marks,	  
Myc,	  when	  induced,	  binds	  already	  active	  promoters	  marked	  by	  the	  presence	  of	  H3K4me3	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and	  H3K27ac	   (Figure	   43).	   Consistently	  most	   of	   the	  unbound	  promoters	   show	  no	   active	  
marks	   (Figure	   44).	   Considering	   the	   distal	   Myc	   peaks,	   most	   of	   them	   are	   found	   in	  
H3K4me1/H3K27ac	   positive	   regions	   that,	   when	   placed	   outside	   promoters	   and/or	   CpG	  
islands,	  can	  be	  classified	  as	  active	  enhancers	  (Heintzman	  et	  al.,	  2009).	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Figure	  43	  Myc	  binds	  open	  and	  active	  chromatin.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Heatmaps	  showing	  the	  distribution	  of	  Myc	  peaks	  at	  annotated	  promoters	  (top	  panel)	  and	  enhancers	  sites	  
(bottom	  panel)	  in	  LPS-­‐stimulated	  wt	  B	  cells	  (0,	  2,	  4,	  8h)	  and	  Eμ-­‐myc	  (C,	  P,	  T1,	  T2,	  T3)	  samples.	  The	  
distribution	  of	  histone	  marks	  (H3K4me1,	  H3K4me3,	  H3K27ac)	  in	  Eμ-­‐myc	  control	  sample	  is	  also	  shown.	  Each	  
row	  represents	  a	  different	  genomic	  interval	  (6	  kb	  width	  centered	  on	  Myc	  peaks).	  The	  panels	  include	  every	  
annotated	  promoter	  and	  every	  enhancers	  at	  chromosome	  1	  identified	  as	  Myc-­‐associated	  by	  ChIP-­‐seq	  in	  at	  
least	  one	  of	  the	  experimental	  samples.	  Annotated	  genes	  (exons	  in	  red,	  introns	  in	  pink;	  +	  sense,	  -­‐	  antisense	  
strand)	  are	  also	  shown.	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Figure	  44	  Promoters	  and	  enhancers	  not	  bound	  by	  Myc	  are	  mainly	  inactive.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Regions	  not	  bound	  by	  Myc	  at	  annotated	  promoters	  (top	  panel)	  and	  at	  enhancers	  (bottom	  panel)	  in	  LPS-­‐
stimulated	  wt	  B	  cells	  (0,	  2,	  4,	  8h)	  and	  Eμ-­‐myc	  samples	  are	  shown.	  The	  distribution	  of	  histone	  marks	  
(H3K4me1,	  H3K4me3,	  H3K27ac)	  in	  Eμ-­‐myc	  control	  sample	  is	  also	  shown.	  Each	  row	  represents	  a	  different	  
genomic	  interval	  (6	  kb	  width	  centered	  on	  trascriptional	  start	  site	  for	  the	  promoters	  and	  6	  kb	  width	  centered	  
on	  H3K4me1	  peaks	  for	  the	  enhancers).	  Annotated	  genes	  (exons	  in	  red,	  introns	  in	  pink;	  +	  sense,	  -­‐	  antisense	  
strand)	  are	  also	  shown.	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In	   addition,	   the	   hierarchy	   of	   Myc	   binding	   at	   promoters	   is	   conserved	   at	   different	   Myc	  
levels	  after	  LPS	  treatment,	  as	  previously	  shown	  (Sabò	  et	  al.,	  2014),	  and	  is	  very	  similar	  to	  
what	  we	  already	  observed	  in	  the	  Eμ-­‐myc	  C-­‐>P-­‐>T	  progression	  (Figure	  45).	  	  
	  
	  	  	  	  	   	  
Figure	  45	  Myc-­‐binding	  hierarchy	  on	  promoters	  is	  conserved	  at	  different	  Myc	  expression	  levels	  
after	  LPS	  stimulation	  and	  shows	  a	  similar	  pattern	  of	  distribution	  in	  Eµ-­‐myc	  samples.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Quantitative	  heatmap	  showing	  library	  size-­‐normalized	  ChIP-­‐seq	  read	  counts	  at	  Myc	  bound	  promoters	  in	  B	  
cells	  after	  LPS	  stimulation	  (0,	  2,	  4,	  8h)	  or	  in	  Eµ-­‐myc	  samples	  (Control,	  Pre-­‐tumoral	  and	  three	  Tumors)	  as	  
indicated.	  
	  
	  
	  Moreover,	  as	  reported	  above,	  Myc	  peaks	  at	  t0	  are	  mostly	  positioned	  at	  promoters	  and	  
we	  found	  that	  Myc	  binding	  sites	  at	  promoters	  are	  generally	  stronger	  (higher	  enrichment)	  
compared	  to	  the	  ones	  at	  enhancers	  (Figure	  46)	  representing	  higher	  affinity	  binding	  sites.	  
The	  fact	  that	  the	  few	  distal	  peaks	  at	  t0	  have	  a	  high	  enrichment	  suggest	  that	  they	  could	  
actually	  be	  not	  yet	  annotated	  promoters.	  	  
B cells                                         Eµ-myc  
LPS stimulation 
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Figure	  46	  Myc	  binding	  intensity	  at	  promoters	  and	  enhancers	  peaks.	  	  
Peak	  enrichment	  of	  Myc	  binding	  sites	  in	  wt	  B	  cells	  without	  LPS	  (0h)	  and	  after	  2h,	  4h,	  8h	  of	  LPS	  stimulation.	  
The	  boxes	  are	  drawn	  with	  widths	  proportional	   to	   the	   square	   roots	  of	   the	  number	  of	  observations	   in	   the	  
groups.	  	  
	  
	  
Myc	   is	   known	   to	   preferentially	   bind	   a	   DNA	   target	   sequence,	   the	   “E-­‐box”	   consensus	  
CACGTGA and	   few	   variant	  motifs	   (Blackwell	   and	  Weintraub	   1990).	  We	   thus	   performed	  
motif	  analysis	  on	  Myc	  binding	  sites	  and	  checked	  for	  the	  occurrence	  of	  canonical	  (CACGTG)	  
and	   non-­‐canonical	   E-­‐boxes	   (CACGCG,	   CATGCG,	   CACGAG,	   CATGTG)	   as	   defined	   in	   the	  
papers	  of	  Grandori	  et	  al.,	  1996	  and	  Perna	  et	  al.	  2012.	  	  In	  stimulated	  cells,	  around	  60%	  of	  
Myc	   binding	   sites	   (both	   at	   promoters	   and	   enhancers)	   were	   devoid	   of	   any	   E-­‐box;	   the	  
remaining	  40%	  of	   sites	   contained	  either	   the	  canonical	  E-­‐box	   (around	  8%)	  or	  one	  of	   the	  
non-­‐canonical	  E-­‐boxes	  (around	  30%).	  	  In	  resting	  conditions,	  when	  Myc	  is	  lowly	  expressed,	  
and	  bound	  only	  to	  its	  highest	  affinity	  targets,	  the	  fraction	  of	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bound	   promoters	   that	   contains	   an	   E-­‐box	  was	   higher	   reaching	   around	   60%	   (Figure	   47).	  
Indeed	   canonical	   E-­‐box	   containing	   sites	   have	   the	   highest	   peak	   enrichment	   followed	   by	  
those	   containing	   non-­‐canonical	   E-­‐boxes	   and	   those	  without	   any	   E-­‐box	   	   (Figure	   48).	   This	  
hierarchy	  between	  Eboxes	  and	  enrichment	  was	  detected	  also	  for	  enhancers	  even	  if	  in	  this	  
case	   the	   fractions	   of	   bound	   enhancers	   that	   contain	   Eboxes	   at	   time	   0h	   and	   during	  
stimulation	  were	  similar	   (Figures	  47;	  Figure	  48)	  arguing	  that	  Myc,	  once	   it’s	   induced	  and	  
invades	   chromatin,	   does	   not	   discriminate	   enhancers	   based	   on	   presence	   or	   absence	   of	  
Eboxes	  containing	  sites.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  
Figure	  47	  Percentages	  of	  Myc	  binding	  sites	  containing	  canonical	  or	  not	  canonical	  E-­‐boxes	  in	  
promoters	  and	  distal	  sites	  of	  resting	  and	  stimulated	  wt	  B	  cells.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Percentages	  of	  Myc	  binding	  sites	  containing	  canonical	  and	  not	  canonical	  E-­‐boxes	  in	  the	  region	  surrounding	  
the	  peak	  summit	  (+/-­‐75bp)	  for	  Myc	  binding	  site	  at	  promoters	  and	  enhancers	  in	  wt	  B	  cells	  during	  LPS	  
stimulation.	  
	  
	  
0h
 2h 4h 8h 0h 2h 4h 8h
0
50
100
150
         % Eboxes  
%
 o
f p
ea
ks
No Eboxes
Eboxes 
No canonical Eboxes 
promoter distal sites
9 
15 
43 
31 32 31 31 24 32 33 
7 8 8 9 8 8.5 
42 
61 60 60 60 67 58 58 
No Eboxes 
 
 
0h
 2h 4h 8h 0h 2h 4h 8h
0
50
100
150
         % Eboxes  
%
 o
f p
ea
ks
o Eboxes
Eboxes 
No canonical Eboxes 
promoter distal sites
9 
15 
43 
31 32 31 31 24 32 33 
7 8 8 9 8 8.5 
42 
61 60 60 60 67 58 58 
Canonical Eboxes 
ot C i l Eboxes 
Eboxes and variants distribution  
promoters  enhancers 
	   93	  
	  
	   	  
Figure	  48	  Myc	  binding	  intensity	  correlates	  with	  presence	  of	  canonical	  and	  non-­‐canonical	  Eboxes.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Myc	  enrichment	  as	  log2	  (ChIP-­‐input)	  reads	  is	  reported	  for	  promoters	  and	  distal	  sites	  at	  different	  time	  points	  
divided	  on	  the	  basis	  of	  the	  presence	  of	  canonical	  and	  not	  canonical	  E-­‐boxes	  in	  the	  region	  of	  peak	  summit	  	  
+/-­‐75	  bp.	  	  The	  boxes	  are	  drawn	  with	  widths	  proportional	  to	  the	  square	  roots	  of	  the	  number	  of	  observations	  
in	  the	  groups.	  
	  
	  
We	  can	  hypothesize	  that	  when	  Myc	  is	  highly	  expressed	  such	  as	  post	  LPS-­‐mediated	  B	  cell	  
activation,	   it	   can	   bind	   to	   the	   open	   chromatin	   not	   only	   through	   specific	   interaction	  
(canonical	   E-­‐box	   recognition)	  but	   also	   through	   less	   specific	   binding	   to	   the	  DNA	   (variant	  
sites,	  such	  as	  non	  canonical	  E-­‐boxes)	  and/or	  protein-­‐protein	  interactions	  (Sabò	  A.	  &	  Amati	  
B.	   2014;	  Afek	   et	   al.2014;	   Siggers	   and	  Gordan	  2014).	   This	   observation	   fits	  with	   a	  model	  
proposed	  in	  our	  lab	  for	  which	  there	  is	  a	  temporal	  order	  of	  Myc	  binding	  to	  the	  DNA	  and	  a	  
hierarchy	  of	  binding	  from	  high	  to	  low	  affinity	  binding	  sites.	  In	  particular,	  Myc/Max	  dimers	  
are	  first	  recruited	  to	  active	  promoters	  and	  enhancers	  via	  protein-­‐protein	  interactions,	  and	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then	  they	  may	  scan	  locally	  DNA	  sequence	  and	  stabilize	  on	  medium/high	  affinity	  sites	  (E-­‐
boxes	   and	   variants).	   	   Once	   Myc	   is	   high	   or	   overexpressed,	   the	   selectivity	   of	   binding	  
decrease	  and	  it	  can	  occupy	  also	  variant	  sites	  with	  lower	  affinity	  for	  Myc/Max	  binding	  (Lin	  
C	  et	  al.2012;	  Sabò	  &	  Amati	  2014;	  Guo	  et	  al.,2014).	  	  In	  summary,	  in	  resting	  cells,	  Myc	  binds	  
higher	   fraction	  of	   high	   affinity	   Ebox	   containing	   sites	   compared	   to	   activated	   cells	  where	  
high	  Myc	  levels	  increase	  the	  probability	  of	  a	  less	  sequence	  specific	  binding	  to	  the	  DNA.	  	  
	  
	  4.6	  Correlation	  between	  Myc	  genomic	  occupancy	  and	  Myc	  driven	  
transcription	  
	  
In	  order	  to	  determine	  which	  of	  the	  Myc-­‐dependent	  LPS	  regulated	  genes	  were	  direct	  Myc	  
targets,	   we	   combined	   Myc	   binding	   and	   gene	   expression	   profiles.	   Consistent	   with	   the	  
phenomenon	  of	  ’invasion’,	  from	  2h	  of	  LPS	  onward	  a	  large	  majority	  of	  all	  expressed	  genes	  
were	  bound	  by	  Myc	  at	  their	  promoters,	  whether	  regulated	  by	  LPS,	  Myc,	  or	  none	  (Table	  
1).	   Thus	  Myc	   binding	   to	   promoters	  was	   not	   predictive	   of	  Myc-­‐dependent	   regulation	   as	  
also	  reported	  for	  serum-­‐responsive	  genes	  in	  fibroblasts	  (Perna	  et	  al.,	  2012).	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Table	  1	  Summary	  of	  Myc	  binding	  and	  gene	  regulation	  in	  LPS-­‐stimulated	  B-­‐cells.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
The	  table	  gives	  the	  total	  numbers	  of	  genes	  in	  each	  regulatory	  category	  and	  the	  percentages	  of	  promoters	  
bound	  by	  Myc	  at	  different	  time	  points	  	  after	  LPS	  stimulation.	  The	  regulatory	  categories,	  as	  defined	  in	  Figure	  
37,	  as	  the	  following:	  1.	  Myc-­‐dependent	  LPS	  induced	  (LPS+/Myc+);	  2.	  Myc-­‐dependent	  repressed	  LPS	  induced	  
(LPS+/Myc-­‐)	  3.	  Myc-­‐dependent	  LPS	  repressed	  (LPS-­‐/Myc-­‐);	  4.	  Myc-­‐dependent	  induced	  LPS	  repressed	  (LPS-­‐
/Myc+)	  ;	  5.	  Myc-­‐independent	  LPS	  induced;	  6.	  	  Myc-­‐	  independent	  LPS	  repressed.	  	  
	  
	  
The	   above	   notwithstanding,	   Myc-­‐dependent	   LPS	   induced	   genes	   (regulatory	   group	   1)	  
enriched	   while	  Myc-­‐dependent	   LPS	   repressed	   genes	   (regulatory	   group	   3)	   depleted	   for	  
Myc	   bound	   genes	   compared	   to	   the	   whole	   population,	   suggesting	   that	   Myc	   mediated	  
repression	  could	  occur	  either	  via	  other	  proteins	  (regulated	  by	  Myc)	  or	  via	  indirect	  binding	  
of	  Myc	  to	  chromatin	  (justifying	  a	  lower	  or	  even	  lost	  	  ChIP-­‐seq	  signal).	  We	  thus	  restricted	  
our	  lists	  of	  Myc-­‐dependent	  genes	  to	  the	  genes	  that	  are	  also	  bound.	  
Since	   the	   mere	   presence	   of	   a	   Myc	   peak	   at	   promoters	   was	   not	   predictive	   of	   gene	  
regulation,	  we	  wondered	  whether	   the	   intensity	  of	   the	  peak	  could	  be	  more	   informative.	  
Compared	  to	  non-­‐regulated	  genes,	  Myc	  dependent	  LPS	   induced	  genes	  have	  higher	  Myc	  
binding	   intensity	  whereas	  Myc	  dependent	   LPS	   repressed	   genes	   have	   lower	   one	   (Figure	  
49).	  In	  particular,	  among	  the	  LPS	  induced	  genes,	  those	  that	  were	  Myc	  dependent	  were	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more	  highly	  bound	  compared	  to	   the	  Myc	   independent	  genes.	  The	  same	  distinction	  was	  
not	  apparent	  for	  repressed	  genes.	  	  
Consistent	   with	   these	   findings,	   a	   quantile	   stratification	   of	   Myc	   binding	   strength	   (low,	  
medium	  and	  high	  intensity)	  confirmed	  that	  Myc	  dependent	  LPS	  Induced	  genes	  (regulatory	  
group	  1)	  contained	  the	  highest	  percentage	  of	  high	  affinity	  Myc	  binding	  sites	  (Figure	  50).	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	   49	   Myc	   dependent	   Induced	   genes	   have	   the	   highest	   Myc	   enrichment	   at	   promoters.	  	  	  	  	  	  	  	  	  	  
Box	  plots	  showing	  the	  maximum	  Myc	  enrichment	  during	  the	  time	  course	  of	  LPS	  stimulation	  for	  the	  different	  
gene	   categories:	   No	   DEGs,	   Myc-­‐dependent	   LPS	   induced	   (regulatory	   group	   1)	   or	   Myc-­‐dependent	   LPS	  
repressed	   (regulatory	  group	  3),	  Myc-­‐independent	  LPS	   induced	   (regulatory	  group	  5)	  and	  Myc-­‐independent	  
LPS	  repressed.	  Width	  of	  boxplots	  are	  proportional	  to	  the	  square-­‐roots	  of	  the	  number	  of	  observations	  in	  the	  
groups.	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Figure	  50	  Percentages	  of	  peaks	  belonging	  to	  different	  levels	  of	  Myc	  enrichment	  in	  the	  different	  
categories	  of	  DEGs.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Percentages	  of	  genes	  bound	  by	  Myc	  with	  high,	  medium	  and	  low	  affinity	  intensity	  in	  each	  gene	  category	  	  
defined	  by	  gene	  expression	  (NoDEGs,	  Myc-­‐dependent	  LPS	  induced	  (regulatory	  group	  1),	  Myc-­‐dependent	  
LPS	  repressed	  (regulatory	  group	  3),	  Myc	  independent	  LPS	  induced	  (regulatory	  group	  5)	  and	  Myc	  
independent	  LPS	  repressed	  (regulatory	  group	  6)	  at	  4	  and	  8h	  after	  LPS	  stimulation.	  At	  each	  time	  point	  the	  
distribution	  of	  Myc	  enrichment	  	  was	  divided	  in	  quantile	  to	  define	  3	  different	  levels	  of	  affinity:	  low,	  medium	  
and	  high	  (see	  Materials	  &	  Methods	  for	  details).	  	  
	  
	  
Since	  Myc	   preferentially	   binds	   the	   E-­‐box	   motif	   CACGTG	   and	   a	   series	   of	   variant	   motifs	  
(Blackwell	   T.K	   et	   al	   1993;	   Perna	   et	   al.,	   2012;	   Grandori	   et	   el.,	   1996),	   we	   calculated	   the	  
frequency	  of	  canonical	  and	  non	  canonical	  E-­‐boxes	  under	  the	  peak	  summit	  of	  Myc-­‐bound	  
promoters	   corresponding	   to	   the	   different	   regulatory	   categories	   (Figure	   51).	   Myc-­‐
dependent	  induced	  genes	  had	  the	  highest	  fraction	  and	  Myc-­‐dependent	  repressed	  genes	  
the	   lowest	   fraction	  of	   sites	  containing	  an	  E-­‐box,	  with	   the	  Myc-­‐independent	  genes	   in	  an	  
intermediate	  situation	  (Figure	  51).	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Figure	  51	  Distribution	  of	  Myc	  binding	  sites	  containing	  canonical	  and	  non-­‐canonical	  E-­‐boxes	  in	  
differentially	  regulated	  promoters.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Percentages	  of	  genes	  in	  each	  category	  (No	  DEGs,	  Myc-­‐dependent	  LPS	  induced	  (regulatory	  group	  1),	  Myc-­‐
dependent	  LPS	  repressed	  (regulatory	  group	  3)	  and	  Myc-­‐independent	  LPS	  induced	  (regulatory	  group	  5)	  and	  
Myc-­‐independent	  LPS	  repressed	  (regulatory	  group	  6)	  in	  at	  least	  one	  time	  point	  of	  stimulation)	  having	  a	  Myc	  
peak	  at	  their	  promoter	  without	  any	  E-­‐box,	  or	  with	  a	  canonical	  or	  not	  canonical	  E-­‐box	  (identified	  on	  the	  
summit	  of	  the	  peaks	  +/-­‐75	  bp).	  	  
	  
	  
In	   conclusion,	   the	   analysis	   of	   DNA	   sequence	   and	   binding	   intensity	   of	   Myc	   gave	   us	   a	  
coherent	  picture:	  Myc	  dependent	  LPS	  induced	  genes	  are	  the	  highest	  affinity	  (presence	  of	  
E-­‐box	   and	   highest	   Myc	   enrichment)	   while	   Myc	   dependent	   repressed	   are	   the	   lowest	  
(absence	  of	  E-­‐box	  and	  lowest	  Myc	  enrichment)	  suggesting	  that	  on	  repressed	  genes	  Myc	  
could	  be	  less	  frequently	  directly	  bound	  to	  DNA	  and	  possibly	  interact	  with	  other	  TFs,	  such	  
as	  Miz1,	  Sp1	  or	  NF-­‐kb,	  antagonizing	  or	   reversing	   their	  activation	   function	   	   (Crescenzi	  et	  
al.,	  1994;	  Tanaka	  et	  al.2001;	  Herkert	  and	  Eilers,	  2010).	  Distinct	  transcription	  factors	  may	  
contribute	   to	   the	   Myc	   transcriptional	   response	   and	   may	   raise	   the	   possibility	   to	  
discriminate	   between	   Myc	   dependent	   induced	   and	   repressed	   genes	   and	   perhaps	  
between	   Myc	   dependent	   and	   Myc	   independent	   regulation.	   To	   address	   this	   issue,	   we	  
performed	  a	  position	  weight	  matrix	  (PWM)	  enrichment	  analysis	  on	  the	  set	  of	  sequences	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around	  the	  summit	  of	  Myc	  peaks	  in	  the	  promoters	  of	  each	  different	  category	  of	  DEGs.	  We	  
identified	  motifs	  with	  a	  significant	  z	  score	  (>3)	  for	  each	  time	  point	  (Table	  2)	  respect	  to	  a	  
genomic	  background	  constituted	  by	  sequences	  at	  the	  summit	  of	  Myc	  promoter	  peaks	  of	  
NoDEGs.	  Among	  the	  motifs	  enriched	  in	  the	  Myc	  dependent	  LPS	  Induced	  genes	  there	  were	  
the	  ones	  for	  Myc	  itself,	  another	  validation	  of	  the	  higher	  Myc	  binding	  affinity	  to	  the	  DNA	  
of	   these	   gene	   category.	   	   Since	   many	   motifs	   are	   in	   common	   among	   the	   different	  
categories,	   we	   decided	   to	   manually	   curate	   our	   table	   keeping	   only	   the	   motifs	   that	  
specifically	   belong	   to	   a	   single	   category	   of	   gene	   regulation	   (in	   at	   least	   one	   time	   point),	  
discarding	  the	  ones	  that	  belong	  to	  classes	  found	  in	  more	  than	  one	  category	  and	  also	  the	  
ones	  that	  are	  not	  expressed	  in	  our	  system.	  The	  resulting	  lists	  of	  motifs	  are	  summarized	  in	  	  
Table	  2.	  Among	  the	  motifs	  identified	  univocally	  in	  the	  Myc	  dependent	  LPS	  Induced	  gene	  
promoters	  were	   for	  example	   the	  binding	   sites	   for	  NFX2,	   a	   thyroid	   specific	   transcription	  
factor	  which	  plays	  a	  role	  in	  ribosomal	  gene	  transcription	  (Diermeier	  et	  al.,	  2013)	  or	  p53.	  	  
Among	   Myc	   dependent	   repressed	   genes,	   we	   could	   score	   binding	   sites	   for	   the	   SMAD	  
transcription	  factor	  family,	  known	  to	  be	  inhibited	  by	  direct	  interaction	  with	  Myc	  (Xin-­‐Hua	  
Feng	  et	  al	  2002).	  The	  lists	  of	  motifs	  enriched	  into	  the	  Myc	  independent	  genes	  categories	  
could	  also	  be	  useful	  for	  identification	  of	  different	  mechanisms	  of	  regulation	  compared	  to	  
the	  dependent	  genes.	  For	  example	  among	   the	  Myc	   independent	   induced	  genes	  we	  can	  
identify	  motifs	   for	   CREBB,	   NFKb1	   and	   2,	   transcription	   factors	   that	   have	   role	   in	   growth	  
control	  and	  cell	  signaling	  activation	  response	  respectively.	  The	  role	  of	  any	  of	  these	  TFs	  in	  
Myc	  activity	  will	  require	  further	  investigation.	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!Myc$dependent*genes*bound*by*Myc*
zscore>3*
2h*LPS* 4h*LPS* 8h*LPS*
Induced*(12/76)* Repressed*(1/5)* Induced*(24/248)! Repressed*(22/200)* Induced*(34/300)! Repressed*(44/292)*
TFs!!!!!!!!zscore!!!!!!!Class! TFs!!!!!!!zscore!!!!!Class! TFs!!!!!!!!!zscore!!!!!Class! !TFs!!!!!!!zscore!!!!!!Class! TFs!!!!!!!!!zscore!!!!!!Class! TFs!!!!!!!zscore!!!!!!Class!
FOXD2!!!!!Inf!!!!!!!!!!!241!
HEY2!*!!!!!5.37!!!!!!!!!429!
NF2L2!!!!!4.87!!!!!!!!!!15!
NFE2L2!!!4.87!!!!!!!!!!45!
MYC::MAX!!!4.79!!!429!
KAISO!!!!!4.34!!!!!!!!270!
NFE2!!!!!!4.34!!!!!!!!!!112!
NRF2!!!!!!4.34!!!!!!!!!!45!
NR2F6!!!!3.97!!!!!!!!!!9!
NR1H3!!!!3.63!!!!!!!!!371!
SRBP2!!!!!3.62!!!!!!!!!437!
TF3C2!!!!!3.21!!!!!!!!!313!
KAISO!!!Inf!!!!!!!!!!270! APEX1!!!!!!!!!inf!!!!!!!!!!!352!
ATF4!!!!!!!!!!!!Inf!!!!!!!!!!404!!!!!!!!
FOXD1!!!!!!!!!Inf!!!!!!!!!!241!
FOXD2!!!!!!!!!Inf!!!!!!!!!!241!
FOXG1!!!!!!!!!Inf!!!!!!!!!!241!
FOXO4!!!!!!!!!Inf!!!!!!!!!!241!
HAND1!!!!!!!!Inf!!!!!!!!!!40!
HNF4G!!!!!!!!Inf!!!!!!!!!!251!
MAFK!!!!!!!!!!Inf!!!!!!!!!!15!
MYF5!!!!!!!!!!!Inf!!!!!!!!!!369!
NF2L2!!!!!!!!!!Inf!!!!!!!!!!15!
NFAC1!!!!!!!!!Inf!!!!!!!!!!93!
NFATC1!!!!!!!Inf!!!!!!!!!!91!
NFE2L2!!!!!!!!Inf!!!!!!!!!!45!
NFIA+NFIB+!
NFIC+NFIX!!!Inf!!!!!!!!!!41!
NKXX2!!!!!!!!!!Inf!!!!!!!!!!!7!
NRF2!!!!!!!!!!!!Inf!!!!!!!!!!45!
TCF21!!!!!!!!!!!Inf!!!!!!!!!129!
ZNF282!!!!!!!!Inf!!!!!!!!!!83!
BHE41!!!!!!!!!5.36!!!!!!!!429!
MYC!!!!!!!!!!!!5.05!!!!!!!!429!
TBX2!!!!!!!!!!!!3.8!!!!!!!!!!82!
ENOA!!!!!!!!!!3.71!!!!!!!!429!
MAX!!!!!!!!!!!!3.02!!!!!!!!429!
APEX1!!!!!!!!Inf!!!!!!!!!!352!
ARID5A!!!!!Inf!!!!!!!!!!!107!
BPTF!!!!!!!!!!Inf!!!!!!!!!!!227!
FOXC2!!!!!!!Inf!!!!!!!!!!!99!
GFI1B!!!!!!!!Inf!!!!!!!!!!!247!
HLTF!!!!!!!!!!Inf!!!!!!!!!!!59!
MYF5!!!!!!!!!Inf!!!!!!!!!369!
NFATC1!!!!!Inf!!!!!!!!!91!
NR4A2!!!!!!!Inf!!!!!!!!!!!!2!
PO6F1!!!!!!!Inf!!!!!!!!!!!406!
POU3F3!!!!!Inf!!!!!!!!!!406!
ZFP652!!!!!!Inf!!!!!!!!!!!393!
ZNF713!!!!!!Inf!!!!!!!!!!418!
SPI1!!!!!!!!!!!5.8!!!!!!!!!!211!
SPIB!!!!!!!!!!!4.37!!!!!!!!211!
RUNX2!!!!!!3.84!!!!!!!!207!
SMAD1!!!!!3.79!!!!!!!!314!
TF65!!!!!!!!!!3.37!!!!!!!!442!!!
THA!!!!!!!!!!!3.37!!!!!!!!331!
AR!!!!!!!!!!!!!3.16!!!!!!!!!66!
GCM1!!!!!!!3.16!!!!!!!!!114!
SPIC!!!!!!!!!!3.07!!!!!!!!!211!
!
!
ARI3A!!!!!!!!Inf!!!!!!!!!!!406!
CEBPG!!!!!!!Inf!!!!!!!!!!!403!
GMEB1!!!!!!!Inf!!!!!!!!!!197!
HOXA11!!!!!!Inf!!!!!!!!!172!
HXB1!!!!!!!!!!!Inf!!!!!!!!!265!
HXC6!!!!!!!!!!!Inf!!!!!!!!!267!
IRF7!!!!!!!!!!!!!Inf!!!!!!!!!424!
IRF9!!!!!!!!!!!!!Inf!!!!!!!!!427!
NKX2!!!!!!!!!!!Inf!!!!!!!!!!!3!
NR1H4!!!!!!!!Inf!!!!!!!!!290!
NR1I2!!!!!!!!!!Inf!!!!!!!!!106!
NRI13!!!!!!!!!!!Inf!!!!!!!!106!
NR2E3!!!!!!!!!Inf!!!!!!!!!104!
RORG!!!!!!!!!!!Inf!!!!!!!!!!18!
TBX21!!!!!!!!!!Inf!!!!!!!!!!82!!
THA!!!!!!!!!!!!!!Inf!!!!!!!!331!
TP73!!!!!!!!!!!!!Inf!!!!!!!!297!
IRF1!!!!!!!!!!!!!9.91!!!!!!424!
MYC!!!!!!!!!!!!!8.53!!!!!429!
MYCN!!!!!!!!!!8.39!!!!!429!
IRF2!!!!!!!!!!!!!7.82!!!!!!424!
SPI1!!!!!!!!!!!!!5.93!!!!!!211!
STAT2!!!!!!!!!!5.63!!!!!!425!
SPZ1!!!!!!!!!!!!4.51!!!!!!!60!
P53!!!!!!!!!!!!!!4.13!!!!!!295!
MLXPL!!!!!!!!3.75!!!!!!!25!
TATA_BOX!!3.59!!!!!58!
RARG!!!!!!!!!!!3.56!!!!!!!2!
STAT3!!!!!!!!!!3.28!!!!!!!42!
NHLH1!!!!!!!!!3.17!!!!!423!
MAX!!!!!!!!!!!!!3.14!!!!!429!
EPAS1!!!!!!!!!!3.02!!!!!!!50!
AR!!!!!!!!!!!!!!Inf!!!!!!!!!66!
ARID5A!!!!!!Inf!!!!!!!!!66!
ATF4!!!!!!!!!!!Inf!!!!!!!!404!
FOXB1!!!!!!!!Inf!!!!!!!!!99!
GATA5!!!!!!!!Inf!!!!!!!!237!
GFI1B!!!!!!!!!Inf!!!!!!!!!247!
HNF6!!!!!!!!!!Inf!!!!!!!!!252!
IRF9!!!!!!!!!!!!!Inf!!!!!!!427!
LMX1B!!!!!!!Inf!!!!!!!!!406!
MEF2A!!!!!!!Inf!!!!!!!!!430!
NKX1Q2!!!!!!!Inf!!!!!!!!406!
NKX2Q3!!!!!!!Inf!!!!!!!!!!72!
NRI13!!!!!!!!!inf!!!!!!!!!106!
NR3C2!!!!!!!!Inf!!!!!!!!409!
OG2X!!!!!!!!!!Inf!!!!!!!!406!
PAX6!!!!!!!!!!!Inf!!!!!!!!!56!
PO4F2!!!!!!!!!Inf!!!!!!!!308!
PO5F1!!!!!!!!!Inf!!!!!!!!26!
PO6F1!!!!!!!!!Inf!!!!!!!!406!
POU3F4!!!!!!Inf!!!!!!!!406!
POU5F1!!!!!!Inf!!!!!!!!26!
RAX!!!!!!!!!!!!!Inf!!!!!!!!406!
SCRT2!!!!!!!!!Inf!!!!!!!!128!
SOX11!!!!!!!!!Inf!!!!!!!!23!
TAL1!!!!!!!!!!!!Inf!!!!!!!!326!
TAL1:TCF3!!Inf!!!!!!!!36!
TFE2!!!!!!!!!!!!!Inf!!!!!!!326!
THA!!!!!!!!!!!!!!Inf!!!!!!!331!
ZFP410!!!!!!!!Inf!!!!!!!302!
ZNF238!!!!!!!!Inf!!!!!!!388!
KLF1!!!!!!!!!!!5.61!!!!!!335!
IRF8!!!!!!!!!!!!5.36!!!!!!426!
STAT4!!!!!!!!!5.36!!!!!!323!
ESRRA!!!!!!!!!5.31!!!!!!!12!
KLF3!!!!!!!!!!!!5.1!!!!!!!!!335!
ATF6A!!!!!!!!!4.64!!!!!!!225!
MAFA!!!!!!!!!!4.27!!!!!!!273!
ZNF75A!!!!!!!4.09!!!!!!!94!
ZEP2!!!!!!!!!!!!4.04!!!!!!!345!
ESR2!!!!!!!!!!!!3.85!!!!!!!!!!2!
TATA_BOX!!3.85!!!!!!!58!
POU2F1!!!!!!!3.59!!!!!!406!
POU2F2!!!!!!!3.27!!!!!406!
SMAD2!!!!!!!!!3.18!!!!315!
!
	   101	  
	  
	  
Table	  2	  Enriched	  transcription	  factor	  binding	  sites	  at	  promoters	  of	  Myc-­‐	  bound	  transcriptional	  
dependent	  and	  independent	  	  genes.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Significant	  enriched	  motifs	  respect	  to	  the	  backgroud	  (zscore>3)	  are	  reported	  for	  each	  time	  point	  and	  each	  
category	  of	  genes.‘Inf’	  comes	  from	  the	  total	  absence	  of	  the	  motif	  in	  the	  background.	  Since	  many	  TFs	  can	  be	  
classified	  inside	  the	  same	  categories	  of	  regulation,	  a	  column	  of	  the	  corrisponding	  class	  of	  the	  transcription	  
factor	  is	  also	  shown	  for	  each	  gene	  category.	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Table	  3	  Summary	  of	  TFs	  identified	  at	  promoters	  of	  Myc-­‐bound	  transcriptional	  dependent	  and	  
independent	  genes.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Lists	  of	  TF	  PWMs	  enriched	  in	  at	  least	  one	  time	  point	  with	  associated	  class	  and	  highest	  zscore	  presented	  
during	  the	  time	  course	  are	  shown.	  Common	  PWMs	  among	  categories	  and	  PWMs	  of	  the	  same	  class	  were	  
excluded.	  
	  
	  
4.7	  Mechanism	  of	  transcriptional	  regulation:	  RNAPol2	  recruitment	  versus	  
elongation	  	  
	  
Even	   though	   Myc	   has	   been	   reported	   to	   enhance	   the	   loading	   of	   RNA	   polymerase	   II	  
(RNAPol2)	  on	   target	  promoters	   	   (Martinato	  et	  al.	  2008),	   it	  was	  suggested	   that	   it	  mainly	  
modulates	  transcriptional	  pause	  release	  and	  elongation,	  in	  particular	  by	  recruiting	  the	  P-­‐	  
!Myc$dependent*genes*bound*by*Myc*
Induced_at*least*1*5me*point* Repressed_at*least*1*5me*point*
TFs! Class! Max_zscore! !!!TFs! Class! Max_zscore!
GMEB1! Class197! Inf!
NKX2! Class3! Inf!
NRF2! Class45! Inf!
P53! Class295! 4.13!
NR2F6! Class9! 3.97!
SRBP2! Class437! 3.62!
TF3C2! Class313! 3.21!
BPTF! Class227! Inf!
GFI1B! Class247! Inf!
HLTF! Class59! Inf!
NR3C2! Class409! Inf!
ZFP410! Class302! Inf!
STAT4! Class323! 5.36!
ESRRA! Class12! 5.31!
ATF6A! Class225! 4.64!
ZNF75A! Class94! 4.09!
ZEP2! Class345! 4.04!
RUNX2! Class207! 3.84!
SMAD1! Class314! 3.79!
SMAD2! Class315! 3.18!
GCM1! Class114! 3.16!
!Myc$independent+genes+bound+by+Myc+
Induced_at+least+1+6me+point+ Repressed_at+least+1+6me+point+
TFs! Class! Max_zscore! !!!TFs! Class! Max_zscore!
CBP! Class355! Inf!
NR4A3! Class13! Inf!
PEBB! Class300! Inf!
ZBTB12! Class151! Inf!
ZIC2! Class161! Inf!
ZN589! Class319! Inf!
ZNF306! Class389! Inf!
NFKB1! Class438! 6.63!
TBP! Class258! 6.01!
NFKB2! Class443! 4.97!
HSF2! Class152! 4.32!
HSF1! Class254! 4.28!
E2F4! Class157! 3.85!
ZN238! Class347! 3.3!
E2F1! Class157! 3.04!
GRHL1! Class395! Inf!
HOMEZ! Class182! Inf!
MAFF! Class48! Inf!
MEF2B! Class401! Inf!
MEF2C! Class212! Inf!
MYBB! Class280! Inf!
SP100! Class144! Inf!
STA5A! Class320! Inf!
TCF2! Class205! Inf!
ZBT7B! Class339! Inf!
ZNF410! Class390! Inf!
MBD1! Class125! 4.37!
IRF4! Class428! 4.35!
HNRPK! Class365! 3.39!
PURA! Class311! 3.37!
	   103	  
	  
TEFb	  complex	  (cyclin	  T1	  and	  Cdk9),	  which	  phosphorylates	  the	  carboxy-­‐terminal	  domain	  of	  
RNAPol2	  on	  Ser2	   favouring	   transcriptional	  elongation	   (Rahl	  et	  al.	  2010;	  Bouchard	  et	  al.,	  
2004;	  Eberhardy	  et	  al.,	  2001).	  	  
ChIP-­‐qPCR	  data	  on	  the	  promoters	  of	  selected	  Myc-­‐dependent	  LPS	  induced	  gene	  indicate	  
that	  RNAPol2	  is	  already	  present	  before	  LPS	  treatment	  and	  increases	  after	  stimulation	  in	  a	  
Myc-­‐dependent	  manner	  (Figure	  52).	  These	  data	  would	  be	  consistent	  with	  a	  role	  for	  Myc	  
in	  RNAPol2	  recruitment	  at	  its	  target	  genes,	  without	  excluding	  a	  role	  for	  elongation.	  
	  
	  
Figure	  52	  RNAPol2	  binding	  to	  the	  promoters	  of	  Myc	  target	  genes	  increases	  upon	  LPS	  
stimulation.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
ChIP-­‐qPCR	  for	  RNAPol2	  on	  the	  TSS	  of	  Myc-­‐regulated	  genes	  in	  wt	  and	  c-­‐myc∆/∆	  cells,	  at	  0,	  2,	  or	  4h	  after	  LPS	  
stimulation.	  The	  average	  ±	  s.d.	  of	  3	  independent	  experiments	  is	  shown.	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In	  order	   to	   clarify	   the	   role	  of	  Myc	   in	  RNA	  polymerase	   recruitment,	   promoter	   clearance	  
and/or	  elongation	  we	  performed	  RNAPol2	  ChIP-­‐seq	  experiments	  in	  wt	  and	  c-­‐myc∆/∆	  cells	  
upon	   LPS	   treatment.	   In	   wt	   cells,	   the	   numbers	   of	   RNApol2	   peaks	   increased	   during	   LPS	  
stimulation,	  which	   did	   not	   occur	   in	   the	   absence	   of	  Myc,	   albeit	  we	   could	   identify	  more	  
peaks	   in	   c-­‐myc∆/∆	   than	   in	   wt	   cells	   at	   the	   earliest	   time-­‐points	   (0	   and	   2h,	   Figure	   53a).	  	  	  
Almost	  all	   the	  peaks	   identified	  at	  0h	  LPS	  were	   retrieved	  also	   in	   LPS	   stimulated	   samples	  
(Figure	   53b)	   both	   in	   wt	   and	   c-­‐myc∆/∆	   cells.	   In	   addition,	   we	   observed	   a	   large	   overlap	  
between	  wt	  and	  c-­‐myc∆/∆	  cells,	  with	  68	  to	  97%	  of	  the	  peaks	  in	  wt	  cells	  also	  contained	  in	  c-­‐
myc∆/∆	  cells	  and,	  reciprocally,	  60	  to	  97%	  of	  peaks	  in	  c-­‐myc∆/∆	  cells	  included	  in	  wt	  cells.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	   53	  RNAPol2	   peaks	   numbers	   and	  overlap	   between	  RNAPol2	  peaks	   in	   different	   samples.	  	  	  	  	  	  	  
a)	   Number	   of	   peaks	   in	   wt	   and	   c-­‐myc∆/∆	   cells	   upon	   LPS	   treatment.	   b)	   Percentages	   of	   RNAPol2	   peaks	  
overlapping	  (by	  least	  1bp)	  with	  the	  reference	  samples	  are	  reported	  in	  each	  column.	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As	  already	  discussed,	  we	  considered	  the	  epigenetic	  profiles	  of	  control	  B	  cells	  in	  vivo	  (the	  C	  
sample	  of	  our	  Eμ-­‐myc	   study,	  Sabò	  et	  al.	  2014)	  as	   surrogates	   for	  unstimulated	  B-­‐cells	   in	  
our	   experiments:	   based	   on	   this	   analysis,	   we	   deduced	   that	   almost	   all	   the	   Myc	   bound	  
promoters	  are	  already	  pre-­‐loaded	  with	  RNAPol2	  and	  marked	  by	  H3K4me3	  and	  H3K27ac	  in	  
resting	   conditions	   (Figure	   54a).	   RNAPol2	   is	   pre-­‐engaged	  not	   only	   on	  promoters	   of	  Myc	  
binding	  sites	  but	  also	  on	  enhancers.	  Indeed,	  distal	  RNAPol2	  binding	  sites	  show	  H3K4me1,	  
H3K27ac	  marks	  and	   to	  a	   lesser	  extent	  also	  a	  Myc	  peak,	  arguing	   that	  most	  of	   the	  active	  
enhancers	  are	  Pol2	  and	  Myc	  loaded	  (Figure	  54b).	  Unlike	  Myc-­‐bound	  elements,	  those	  that	  
were	   not	   bound	   showed	   no	   RNAPol2,	   as	   observed	   at	   either	   promoters	   (Figure	   55a)	   or	  
enhancers	  (Figure	  55b),	  the	  latter	  selected	  as	  distal	  H3K4me1	  sites	  with	  no	  Myc.	  In	  most	  
cases,	   lack	   of	   Myc	   and	   Pol2	   also	   correlated	   with	   lack	   of	   the	   corresponding	   activation	  
marks	  (H3K4me3	  in	  promoters,	  and	  H3K27ac	  in	  either	  promoters	  or	  enhancers).	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Figure	  54	  RNAPol2	  is	  pre-­‐loaded	  on	  active	  promoters	  and	  distal	  sites.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Heatmaps	  showing	  the	  distribution	  of	  RNAPol2	  and	  Myc	  peaks	  at	  annotated	  promoters	  (top	  panel)	  and	  at	  
distal	  H3K4me1	  positive	  binding	  sites	  (botton	  panel)	  upon	  LPS	  stimulation	  of	  wt	  and	  	  c-­‐myc∆/∆	  B	  cells	  (0,	  2,	  
4h)	  at	  chromosome	  1.	  The	  distribution	  of	  histone	  marks	  (H3K4me1,	  H3K4me3,	  H3K27ac)	  in	  Eμ-­‐myc	  control	  
sample	  is	  also	  shown.	  Each	  row	  represents	  a	  different	  genomic	  interval	  (6	  kb	  width	  centered	  on	  the	  
midpoint	  of	  the	  RNAPol2	  peaks).	  Annotated	  genes	  (exons	  in	  red,	  introns	  in	  pink;	  +	  sense,	  -­‐	  antisense	  strand)	  
are	  also	  shown.	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Figure	  55	  RNAPol2	  unbound	  regions	  are	  mainly	  inactive.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Regions	  not	  bound	  by	  RNAPol2	  and	  Myc	  at	  annotated	  promoters	  (top	  panel)	  and	  at	  enahncers	  (distal	  
H3K4me1	  positive	  sites)	  (botton	  panel)	  upon	  LPS	  stimulation	  of	  wt	  and	  c-­‐myc∆/∆	  	  B	  cells	  (0,	  2,	  4,	  8h)	  at	  
chromosome	  1.	  The	  distribution	  of	  histone	  marks	  (H3K4me1,	  H3K4me3,	  H3K27ac)	  in	  Eμ-­‐myc	  control	  sample	  
is	  also	  shown.	  Each	  row	  represents	  a	  different	  genomic	  interval.	  In	  the	  top	  heatmap	  no	  Myc	  and	  RNApol2	  
bound	  promoters	  (6	  kb	  width	  centered	  on	  the	  transcription	  start	  site);	  in	  the	  bottom	  heatmap	  no	  Myc	  and	  
RNAPol2	  bound	  enhancers	  (6	  kb	  width	  centered	  on	  H3K4me1	  peaks)	  are	  shown.	  Annotated	  genes	  (exons	  in	  
red,	  introns	  in	  pink;	  +	  sense,	  -­‐	  antisense	  strand)	  are	  also	  shown.	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It	   is	   noteworthy	   here	   that	   the	   above	   heatmaps,	   which	   represent	   a	   qualitative	   yes/no	  
score,	  did	  not	   reveal	  any	  obvious	  differences	  between	  wt	  and	  c-­‐myc∆/∆	   cells	   in	   terms	  of	  
RNAPol2	   distribution	   at	   promoters	   and	   distal	   sites	   (Figure	   54;	   Figure	   55).	   A	   more	  
quantitative	  analysis	  was	  thus	  needed	  to	  evaluate	  if	  and	  to	  which	  extent	  Myc	  could	  affect	  
RNAPol2recruitment	   and/or	   elongation.	   To	   this	   aim,	   we	   plotted	   the	   distribution	   of	  
RNAPol2	   reads	   in	   the	   TSS	   region	   and	   the	   gene	   body	   of	   the	   different	   regulatory	   groups	  
identified	   by	   RNA-­‐seq	   and	   we	   also	   examined	   the	   stalling	   index,	   based	   on	   the	   ratio	   of	  
RNAPol2	   reads	   in	   the	   promoter	   and	   gene	   body	   (Rahl	   et	   al.2010;	   Zeitlinger	   et	   al.	   2007)	  	  
(Figure	  56;	   for	  the	  sake	  of	  simplicity,	  only	  the	  results	  of	  the	  4h	  LPS	  time	  point	   is	  shown	  
here).	  Different	  effects	  of	  RNApol2	  occupancy	  were	  observed	  in	  the	  groups	  of	  DEGs.	  Most	  
remarkably,	  Myc-­‐dependent	  induced	  genes	  showed	  higher	  level	  of	  RNAPol2	  both	  on	  the	  
TSS	  and	  gene	  body	   in	  wt	   cells,	  which	  were	  essentially	   lost	   in	  c-­‐myc∆/∆cells	   (Figure	  56a).	  
Unexpectedly,	  Myc-­‐independent	  induced	  genes	  still	  showed	  some	  dependency	  upon	  Myc	  
in	  RNAPol2	  recruitment	  at	  either	  promoters	  or	  gene	  bodies	  (Figure	  56b),	  a	  feature	  shared	  
also	   with	   non-­‐regulated	   genes	   and,	   on	   promoters,	   with	   repressed	   genes	   (Figure	   56a;	  
Figure	  56b).	  While	  these	  observations	  remain	  to	  be	  validated,	  they	  point	  to	  possible	  non-­‐
specific	  and/or	  indirect	  effects	  of	  Myc	  on	  Pol2	  loading.	  	  
The	  above	  considerations	  limit	  the	  significance	  of	  the	  stalling	  index	  (see	  also	  Sabò	  et	  al.,	  
2014).	  We	  note,	  however,	   that	   in	  no	   instance	  did	  activated	  genes	  show	  the	  decrease	   in	  
stalling	   index	   that	  would	   be	   expected	   from	   a	   selective	   augmentation	   of	   elongation,	   as	  
was	  proposed	  to	  occur	  upon	  activation	  of	  all	  expressed	  genes	  by	  Myc	  (Rahl	  et	  al.,	  2009;	  
Lin	   C.	   et	   al.,	   2012).	   These	   data	   do	   not	   allow	   us	   to	   assign	   any	   exclusive	   role	   to	   either	  
loading	  or	  elongation	  in	  Myc-­‐regulated	  transcription.	  Tentatively,	  we	  speculate	  that	  both	  
steps	  may	  be	  involved.	  
	   109	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  56	  Stalling	  index	  analysis	  on	  the	  different	  regulatory	  groups	  of	  genes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Stalling	  index	  and	  Log10	  reads	  at	  4h	  LPS	  in	  wt	  and	  c-­‐myc∆/∆	  cells	  on	  TSS	  and	  gene	  body	  are	  reported	  on	  No-­‐
DEGs,	  Myc-­‐dependent	  induced	  and	  repressed	  genes	  (a)	  and	  on	  Myc-­‐independent	  induced	  and	  repressed	  
genes	  (b).	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4.8	  Investigating	  biological	  functions	  of	  Myc	  dependent	  genes	  	  
	  
To	   investigate	   the	   biological	   processes	   regulated	   by	   Myc	   in	   B-­‐cells,	   we	   applied	   gene	  
ontology	   (GO)	   and	   Gene	   set	   enrichment	   analysis	   (GSEA)	   to	   our	   RNA-­‐seq	   data.	   Myc-­‐
dependent	   LPS	   induced	   and	   repressed	   genes	   affect	   biological	   processes	   consistently	  
regulated	  by	  Myc	  in	  many	  other	  systems	  (Kress	  et	  al.,	  2015).	  In	  particular,	  we	  concentrate	  
on	   Myc-­‐dependent	   induced	   and	   Myc	   bound	   genes	   (called	   “Myc-­‐dependent	   induced	  
bound	   genes”)	   and	   Myc-­‐dependent	   repressed	   and	   Myc	   bound	   genes	   (called	   “Myc-­‐
dependent	   repressed	  bound	  genes”).	  The	   few	  Myc–dependent	   induced	  bound	  genes	  at	  
2h	   of	   LPS	   were	   manually	   checked	   and,	   as	   expected,	   they	   were	   involved	   in	  
mitogenic/signal	   response.	  At	   4h	   and	  8h	  after	   LPS	  Myc-­‐dependent	   induced	  genes	  were	  
mainly	   involved,	   among	   others,	   in	   RNA	   metabolic	   processes,	   energy	   metabolism,	  
translation	   and	   ribosome	   assembly	   (Table	   4).	   Given	   specificity	   to	   this	   finding,	   we	  
performed	   a	   pre-­‐ranked	   analysis	   with	   GSEA	   for	   the	   Myc-­‐dependent	   induced	   and	  
repressed	  genes	  and	  we	  observed	  at	  8h	  after	   LPS	  a	   significant	  enrichment	  of	  gene	  sets	  
involved	  in	  ribosome	  biogenesis,	  translation	  and	  mitochondrial	  biosynthesis	  (Table	  5),	  as	  
confirmed	   by	   GO.	   In	   addition,	   ingenuity	   pathway	   analysis	   (IPA)	   also	   underlines	   a	  
significant	  enrichment	  of	  signaling	  pathways	  involved	  in	  initial	  translation	  (eIF2	  and	  eIF4),	  
mTOR	   and	   mitochondrial	   metabolic	   pathways	   (Table	   6).	   	   It	   has	   already	   been	  
demonstrated	   that	   Myc	   promotes	   the	   RNAPolII	   mediated	   transcription	   of	   many	  
translation	  initiation	  factors	  for	  example	  through	  E-­‐box’s	  binding	  at	  the	  promoter	  of	  eIF4	  	  
(Jones	  et	  al.,	  1996).	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We	   thus	   confirmed	   that	   Myc	   induction	   causes	   a	   re-­‐organization	   of	   cell’s	   physiology,	  
activating	  genes	  involved	  in	  the	  whole	  protein	  biosynthetic	  apparatus,	  growth	  and	  energy	  
metabolism.	  	  
Among	  the	  Myc-­‐dependent	  repressed	  genes,	  the	  overall	  picture	  is	  less	  clear	  (Table	  4).	  At	  
4h	  and	  8h	  post	  LPS,	  this	  category	  enriched	  for	  genes	  implicated	  in	  negative	  regulation	  of	  
cellular	  growth,	  cell	  cycle	  and	  in	  signal	  transduction.	  Other	  down-­‐regulated	  genes	  belong	  
to	  GADD45	  signaling	  and	  it	  was	  already	  shown	  that	  Gadd45a	  (mainly	  involved	  in	  growth	  
arrest	  and	  DNA-­‐damage	  response)	  is	  a	  dowregulated	  Myc	  target	  gene	  (Yap	  et	  al.,	  2011).	  
In	   conclusion,	  RNA-­‐seq	  profiling	   indicates	   that	  Myc	   can	   selective	  up	  and	  down	   regulate	  
genes	   in	   response	   to	   LPS.	   These	   genes	   control	   processes	   such	   as	   translation,	   energy	  
metabolism,	   nucleotide	   biosynthesis	   consistent	   with	   the	   role	   of	  Myc	   in	   driving	   cellular	  
activation	  in	  response	  to	  extracellular	  cues	  (de	  Alboran	  et	  al.,	  2001).	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4h#LPS#
Myc*dependent#induced#bound#genes#
#
Gene#Set#Name# ##Genes#in#Gene#Set#(K)# ##Genes#in#Overlap#(k)# k/K# p*value# FDR#q*value#
BIOPOLYMER_METABOLIC_PROCESS/ 1684/ 84/ 0.0499/ 1.87E829/ 1.54E826/
NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS/ 1244/ 70/ 0.0563/ 1.3E827/ 5.36E825/
RNA_METABOLIC_PROCESS/ 841/ 52/ 0.0618/ 1.72E822/ 4.73E820/
TRANSCRIPTION_DNA_DEPENDENT/ 636/ 33/ 0.0519/ 1.42E812/ 2.12E810/
TRANSCRIPTION/ 753/ 36/ 0.0478/ 1.44E812/ 2.12E810/
RNA_BIOSYNTHETIC_PROCESS/ 638/ 33/ 0.0517/ 1.55E812/ 2.12E810/
RNA_PROCESSING/ 173/ 17/ 0.0983/ 2.69E811/ 3.17E89/
RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_ASSEMBLY/ 86/ 12/ 0.1395/ 3.84E810/ 3.96E88/
REGULATION_OF_RNA_METABOLIC_PROCESS/ 471/ 25/ 0.0531/ 4.77E810/ 4.37E88/
RIBOSOME_BIOGENESIS_AND_ASSEMBLY/ 18/ 7/ 0.3889/ 7.94E810/ 6.55E88/
REGULATION_OF_NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METAB
OLIC_PROCESS/ 618/ 27/ 0.0437/ 6.44E89/ 4.43E87/
TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER/ 457/ 23/ 0.0503/ 6.45E89/ 4.43E87/
REGULATION_OF_TRANSCRIPTIONDNA_DEPENDENT/ 461/ 23/ 0.0499/ 7.59E89/ 4.81E87/
RRNA_PROCESSING/ 15/ 6/ 0.4000/ 1.11E88/ 6.53E87/
ORGANELLE_ORGANIZATION_AND_BIOGENESIS/ 473/ 23/ 0.0486/ 1.22E88/ 6.72E87/
RRNA_METABOLIC_PROCESS/ 16/ 6/ 0.3750/ 1.76E88/ 9.05E87/
REGULATION_OF_TRANSCRIPTION/ 566/ 25/ 0.0442/ 1.9E88/ 9.21E87/
PROTEIN_METABOLIC_PROCESS/ 1231/ 39/ 0.0317/ 2.44E88/ 1.12E86/
REGULATION_OF_GENE_EXPRESSION/ 673/ 27/ 0.0401/ 3.74E88/ 1.62E86/
REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER/ 289/ 17/ 0.0588/ 6.7E88/ 2.76E86/
REGULATION_OF_CELLULAR_METABOLIC_PROCESS/ 787/ 29/ 0.0368/ 7.23E88/ 2.84E86/
REGULATION_OF_METABOLIC_PROCESS/ 799/ 29/ 0.0363/ 9.93E88/ 3.72E86/
CELLULAR_PROTEIN_METABOLIC_PROCESS/ 1117/ 35/ 0.0313/ 1.68E87/ 6.04E86/
CELLULAR_MACROMOLECULE_METABOLIC_PROCESS/ 1131/ 35/ 0.0309/ 2.26E87/ 7.75E86/
BIOPOLYMER_MODIFICATION/ 650/ 24/ 0.0369/ 9.35E87/ 3.09E85/
PROTEIN_MODIFICATION_PROCESS/ 631/ 23/ 0.0365/ 1.95E86/ 6.19E85/
CELL_CYCLE_GO_0007049/ 315/ 15/ 0.0476/ 5.4E86/ 1.65E84/
BIOPOLYMER_CATABOLIC_PROCESS/ 117/ 9/ 0.0769/ 9.97E86/ 2.94E84/
RNA_SPLICING/ 91/ 8/ 0.0879/ 1.17E85/ 3.32E84/
CELLULAR_MACROMOLECULE_CATABOLIC_PROCESS/ 104/ 8/ 0.0769/ 3.1E85/ 8.53E84/
MACROMOLECULE_CATABOLIC_PROCESS/ 137/ 9/ 0.0657/ 3.52E85/ 9.38E84/
POSITIVE_REGULATION_OF_BIOLOGICAL_PROCESS/ 709/ 21/ 0.0296/ 1.1E84/ 2.83E83/
MACROMOLECULAR_COMPLEX_ASSEMBLY/ 280/ 12/ 0.0429/ 1.26E84/ 3.14E83/
RNA_CATABOLIC_PROCESS/ 23/ 4/ 0.1739/ 1.35E84/ 3.25E83/
POSITIVE_REGULATION_OF_CELLULAR_PROCESS/ 668/ 20/ 0.0299/ 1.38E84/ 3.25E83/
CHROMATIN_REMODELING/ 25/ 4/ 0.1600/ 1.89E84/ 4.34E83/
CELLULAR_CATABOLIC_PROCESS/ 212/ 10/ 0.0472/ 2.11E84/ 4.71E83/
CELLULAR_COMPONENT_ASSEMBLY/ 298/ 12/ 0.0403/ 2.24E84/ 4.85E83/
DNA_METABOLIC_PROCESS/ 257/ 11/ 0.0428/ 2.41E84/ 5.09E83/
ESTABLISHMENT_AND_OR_MAINTENANCE_OF_CHROMATIN_ARCHITECTURE/ 77/ 6/ 0.0779/ 2.85E84/ 5.88E83/
AMINO_ACID_METABOLIC_PROCESS/ 78/ 6/ 0.0769/ 3.06E84/ 6.03E83/
REGULATION_OF_CELL_CYCLE/ 182/ 9/ 0.0495/ 3.07E84/ 6.03E83/
CATABOLIC_PROCESS/ 225/ 10/ 0.0444/ 3.4E84/ 6.52E83/
CHROMATIN_MODIFICATION/ 55/ 5/ 0.0909/ 4.52E84/ 8.47E83/
POSITIVE_REGULATION_OF_RNA_METABOLIC_PROCESS/ 120/ 7/ 0.0583/ 5.34E84/ 9.75E83/
POST_TRANSLATIONAL_PROTEIN_MODIFICATION/ 476/ 15/ 0.0315/ 5.44E84/ 9.75E83/
CHROMOSOME_ORGANIZATION_AND_BIOGENESIS/ 124/ 7/ 0.0565/ 6.5E84/ 1.14E82/
AMINO_ACID_AND_DERIVATIVE_METABOLIC_PROCESS/ 101/ 6/ 0.0594/ 1.21E83/ 2.05E82/
TRANSPORT/ 795/ 20/ 0.0252/ 1.22E83/ 2.05E82/
TRANSCRIPTION_FROM_RNA_POLYMERASE_III_PROMOTER/ 19/ 3/ 0.1579/ 1.32E83/ 2.18E82/
Gene ontology of Myc dependent bound genes 
4h#LPS##
Myc*dependent#repressed#bound#genes#
#
Gene#Set#Name# ##Genes#in#Gene#Set#(K)# ##Genes#in#Overlap#(k)# k/K# p*value# FDR#q*value#
BIOPOLYMER_MODIFICATION1 6501 241 0.03691 1.45E;121 1.19E;91
PROTEIN_MODIFICATION_PROCESS1 6311 231 0.03651 5.59E;121 2.3E;91
PROTEIN_METABOLIC_PROCESS1 12311 301 0.02441 7.06E;111 1.94E;81
CELLULAR_PROTEIN_METABOLIC_PROCESS1 11171 281 0.02511 1.68E;101 3.47E;81
CELLULAR_MACROMOLECULE_METABOLIC_PROCESS1 11311 281 0.02481 2.23E;101 3.67E;81
BIOPOLYMER_METABOLIC_PROCESS1 16841 341 0.02021 4.98E;101 6.85E;81
POST_TRANSLATIONAL_PROTEIN_MODIFICATION1 4761 161 0.03361 3.15E;81 3.72E;61
SIGNAL_TRANSDUCTION1 16341 271 0.01651 1.71E;61 1.77E;41
RESPONSE_TO_STRESS1 5081 131 0.02561 1.22E;51 1.12E;31
NEGATIVE_REGULATION_OF_GROWTH1 401 41 0.10001 9.15E;51 7.2E;31
GROWTH1 771 51 0.06491 9.6E;51 7.2E;31
REGULATION_OF_CELL_CYCLE1 1821 71 0.03851 1.11E;41 7.5E;31
NEGATIVE_REGULATION_OF_CELLULAR_PROCESS1 6461 131 0.02011 1.4E;41 8.24E;31
REGULATION_OF_CELL_GROWTH1 461 41 0.08701 1.59E;41 8.74E;31
GLYCOPROTEIN_METABOLIC_PROCESS1 901 51 0.05561 2.01E;41 1.01E;21
REGULATION_OF_BIOLOGICAL_QUALITY1 4191 101 0.02391 2.16E;41 1.01E;21
NEGATIVE_REGULATION_OF_BIOLOGICAL_PROCESS1 6771 131 0.01921 2.2E;41 1.01E;21
REGULATION_OF_CELLULAR_METABOLIC_PROCESS1 7871 141 0.01781 2.77E;41 1.2E;21
REGULATION_OF_METABOLIC_PROCESS1 7991 141 0.01751 3.22E;41 1.33E;21
CELL_CYCLE_ARREST_GO_00070501 571 41 0.07021 3.65E;41 1.44E;21
REGULATION_OF_GROWTH1 581 41 0.06901 3.91E;41 1.47E;21
ONE_CARBON_COMPOUND_METABOLIC_PROCESS1 261 31 0.11541 4.77E;41 1.65E;21
CELL_SURFACE_RECEPTOR_LINKED_SIGNAL_TRANSDUCTION_GO_00071661 6411 121 0.01871 4.79E;41 1.65E;21
BIOSYNTHETIC_PROCESS1 4701 101 0.02131 5.32E;41 1.7E;21
PROTEIN_AMINO_ACID_DEPHOSPHORYLATION1 631 41 0.06351 5.36E;41 1.7E;21
PHOSPHORYLATION1 3131 81 0.02561 5.88E;41 1.8E;21
REGULATION_OF_GENE_EXPRESSION1 6731 121 0.01781 7.32E;41 2.16E;21
DEPHOSPHORYLATION1 701 41 0.05711 7.99E;41 2.27E;21
CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT1 1231 51 0.04071 8.43E;41 2.32E;21
NEGATIVE_REGULATION_OF_CELLULAR_METABOLIC_PROCESS1 2591 71 0.02701 9.31E;41 2.48E;21
GLYCOPROTEIN_BIOSYNTHETIC_PROCESS1 741 41 0.05411 9.84E;41 2.49E;21
NEGATIVE_REGULATION_OF_METABOLIC_PROCESS1 2621 71 0.02671 9.95E;41 2.49E;21
G_PROTEIN_COUPLED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY1 3421 81 0.02341 1.04E;31 2.53E;21
NEGATIVE_REGULATION_OF_CELL_CYCLE1 791 41 0.05061 1.26E;31 2.91E;21
NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS1 12441 171 0.01371 1.27E;31 2.91E;21
HEART_DEVELOPMENT1 371 31 0.08111 1.36E;31 3.03E;21
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8h#LPS##
Myc*dependent#induced#bound#genes#
#
Gene#Set#Name# ##Genes#in#Gene#Set#(K)# ##Genes#in#Overlap#(k)# k/K# p*value# FDR#q*value#
CELLULAR_BIOSYNTHETIC_PROCESS1 3211 671 0.20871 9.47E<581 6.58E<551
TRANSLATION1 1801 551 0.30561 1.6E<571 6.58E<551
BIOSYNTHETIC_PROCESS1 4701 731 0.15531 3.12E<531 8.57E<511
MACROMOLECULE_BIOSYNTHETIC_PROCESS1 3211 611 0.19001 5.25E<501 1.08E<471
NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS1 12441 1021 0.08201 1.34E<471 2.21E<451
PROTEIN_METABOLIC_PROCESS1 12311 981 0.07961 1.41E<441 1.94E<421
CELLULAR_PROTEIN_METABOLIC_PROCESS1 11171 921 0.08241 5.07E<431 5.97E<411
CELLULAR_MACROMOLECULE_METABOLIC_PROCESS1 11311 921 0.08131 1.41E<421 1.46E<401
RNA_METABOLIC_PROCESS1 8411 681 0.08091 2.42E<311 2.22E<291
BIOPOLYMER_METABOLIC_PROCESS1 16841 951 0.05641 4.38E<311 3.62E<291
RNA_PROCESSING1 1731 271 0.15611 2.08E<201 1.56E<181
TRANSCRIPTION1 7531 491 0.06511 7.55E<191 5.19E<171
REGULATION_OF_METABOLIC_PROCESS1 7991 491 0.06131 8.38E<181 5.32E<161
RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_ASSEMBLY1 861 191 0.22091 1.01E<171 5.94E<161
REGULATION_OF_CELLULAR_METABOLIC_PROCESS1 7871 481 0.06101 2.28E<171 1.25E<151
REGULATION_OF_GENE_EXPRESSION1 6731 411 0.06091 5.42E<151 2.79E<131
TRANSCRIPTION_DNA_DEPENDENT1 6361 391 0.06131 2.06E<141 9.88E<131
PROTEIN_RNA_COMPLEX_ASSEMBLY1 671 151 0.22391 2.27E<141 9.88E<131
RNA_BIOSYNTHETIC_PROCESS1 6381 391 0.06111 2.28E<141 9.88E<131
MACROMOLECULAR_COMPLEX_ASSEMBLY1 2801 261 0.09291 4.18E<141 1.73E<121
RNA_SPLICING1 911 161 0.17581 1.73E<131 6.76E<121
CELLULAR_COMPONENT_ASSEMBLY1 2981 261 0.08721 1.8E<131 6.76E<121
POSITIVE_REGULATION_OF_CELLULAR_PROCESS1 6681 371 0.05541 2.02E<121 7.25E<111
POSITIVE_REGULATION_OF_BIOLOGICAL_PROCESS1 7091 381 0.05361 2.71E<121 9.32E<111
REGULATION_OF_NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS1 6181 341 0.05501 1.93E<111 6.37E<101
ORGANELLE_ORGANIZATION_AND_BIOGENESIS1 4731 291 0.06131 4.71E<111 1.49E<91
CELL_PROLIFERATION_GO_00082831 5131 291 0.05651 3.16E<101 9.66E<91
PROTEIN_FOLDING1 581 111 0.18971 4.56E<101 1.34E<81
REGULATION_OF_TRANSCRIPTION1 5661 301 0.05301 7.19E<101 2.04E<81
TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER1 4571 261 0.05691 2.29E<91 6.29E<81
NUCLEOBASENUCLEOSIDE_AND_NUCLEOTIDE_METABOLIC_PROCESS1 521 101 0.19231 2.47E<91 6.56E<81
TRANSLATIONAL_INITIATION1 391 91 0.23081 2.8E<91 7.21E<81
REGULATION_OF_RNA_METABOLIC_PROCESS1 4711 261 0.05521 4.27E<91 1.07E<71
REGULATION_OF_TRANSLATIONAL_INITIATION1 311 81 0.25811 8.25E<91 2,00E<071
MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS1 481 91 0.18751 1.98E<81 4.66E<71
REGULATION_OF_TRANSCRIPTIONDNA_DEPENDENT1 4611 241 0.05211 5.06E<81 1.16E<61
MRNA_PROCESSING_GO_00063971 731 101 0.13701 7.44E<81 1.66E<61
RIBOSOME_BIOGENESIS_AND_ASSEMBLY1 181 61 0.33331 1.17E<71 2.54E<61
MRNA_METABOLIC_PROCESS1 841 101 0.11901 2.88E<71 6.1E<61
REGULATION_OF_APOPTOSIS1 3411 191 0.05571 4.47E<71 9.22E<61
REGULATION_OF_PROGRAMMED_CELL_DEATH1 3421 191 0.05561 4.67E<71 9.4E<61
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RRNA_PROCESSING, 15, 5, 0.3333, 1.4E66, 2.46E65,
POSITIVE_REGULATION_OF_METABOLIC_PROCESS, 236, 15, 0.0636, 1.43E66, 2.46E65,
REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION_AND_BIOGENESIS, 125, 11, 0.0880, 1.6E66, 2.69E65,
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REGULATION_OF_I_KAPPAB_KINASE_NF_KAPPAB_CASCADE, 93, 7, 0.0753, 3.37E64, 3.31E63,
CATABOLIC_PROCESS, 225, 11, 0.0489, 3.61E64, 3.51E63,
POSITIVE_REGULATION_OF_SIGNAL_TRANSDUCTION, 126, 8, 0.0635, 4.12E64, 3.95E63,
NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, 197, 10, 0.0508, 4.94E64, 4.68E63,
CELLULAR_RESPONSE_TO_EXTRACELLULAR_STIMULUS, 12, 3, 0.2500, 5.43E64, 5.04E63,
PURINE_NUCLEOTIDE_METABOLIC_PROCESS, 12, 3, 0.2500, 5.43E64, 5.04E63,
GLUCOSE_METABOLIC_PROCESS, 28, 4, 0.1429, 5.92E64, 5.42E63,
INTRACELLULAR_TRANSPORT, 280, 12, 0.0429, 6.47E64, 5.84E63,
ESTABLISHMENT_OF_LOCALIZATION, 870, 25, 0.0287, 6.52E64, 5.84E63,
MACROMOLECULE_CATABOLIC_PROCESS, 137, 8, 0.0584, 7.18E64, 6.37E63,
ESTABLISHMENT_AND_OR_MAINTENANCE_OF_CHROMATIN_ARCHITECTURE, 77, 6, 0.0779, 7.43E64, 6.52E63,
AMINO_ACID_METABOLIC_PROCESS, 78, 6, 0.0769, 7.96E64, 6.91E63,
REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER, 289, 12, 0.0415, 8.52E64, 7.32E63,
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AEROBIC_RESPIRATION, 15, 3, 0.2000, 1.09E63, 9.14E63,
CELLULAR_COMPONENT_DISASSEMBLY, 33, 4, 0.1212, 1.12E63, 9.14E63,
NUCLEAR_EXPORT, 33, 4, 0.1212, 1.12E63, 9.14E63,
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Table	  4.	  Gene	  Ontology	  for	  Myc-­‐dependent	  induced	  and	  repressed	  bound	  genes.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
GO	  functional	  analysis	  was	  performed	  for	  Myc-­‐dependent	  induced	  bound	  genes	  and	  Myc-­‐dependent	  
repressed	  bound	  genes	  at	  4	  and	  8h	  LPS.	  All	  genes	  set	  with	  significant	  FDR	  (<0.05)	  are	  shown	  for	  all	  the	  
regulatory	  groups	  of	  genes.	  Numbers	  of	  genes	  overlapping	  with	  the	  indicated	  dataset	  (k),	  total	  genes	  in	  the	  
dataset	  (K),	  ratio	  (k/K),	  pvalue	  and	  FDR	  are	  repo	  
	  
8h#LPS#
Myc*dependent#repressed#bound#genes#
#
Gene#Set#Name# ##Genes#in#Gene#Set#(K)# ##Genes#in#Overlap#(k)# k/K# p*value# FDR#q*value#
SIGNAL_TRANSDUCTION. 1634. 67. 0.0410. 1.57E819. 1.3E816.
BIOPOLYMER_METABOLIC_PROCESS. 1684. 60. 0.0356. 8.25E815. 3.41E812.
REGULATION_OF_TRANSCRIPTION. 566. 30. 0.0530. 5.07E812. 9.54E810.
NEGATIVE_REGULATION_OF_CELLULAR_PROCESS. 646. 32. 0.0495. 5.78E812. 9.54E810.
NEGATIVE_REGULATION_OF_BIOLOGICAL_PROCESS. 677. 32. 0.0473. 1.94E811. 2.67E89.
REGULATION_OF_TRANSCRIPTIONDNA_DEPENDENT. 461. 26. 0.0564. 3.52E811. 4.15E89.
REGULATION_OF_NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS. 618. 30. 0.0485. 4.39E811. 4.53E89.
REGULATION_OF_RNA_METABOLIC_PROCESS. 471. 26. 0.0552. 5.62E811. 5.16E89.
TRANSCRIPTION. 753. 33. 0.0438. 6.75E811. 5.25E89.
REGULATION_OF_METABOLIC_PROCESS. 799. 34. 0.0426. 7.52E811. 5.25E89.
REGULATION_OF_GENE_EXPRESSION. 673. 31. 0.0461. 7.63E811. 5.25E89.
REGULATION_OF_CELLULAR_METABOLIC_PROCESS. 787. 33. 0.0419. 2.09E810. 1.33E88.
ESTABLISHMENT_OF_LOCALIZATION. 870. 33. 0.0379. 2.56E89. 1.51E87.
INTRACELLULAR_SIGNALING_CASCADE. 667. 28. 0.0420. 4.89E89. 2.69E87.
TRANSCRIPTION_DNA_DEPENDENT. 636. 27. 0.0425. 7.3E89. 3.76E87.
RNA_BIOSYNTHETIC_PROCESS. 638. 27. 0.0423. 7.79E89. 3.78E87.
NEGATIVE_REGULATION_OF_CELLULAR_METABOLIC_PROCESS. 259. 17. 0.0656. 9.7E89. 4.45E87.
NEGATIVE_REGULATION_OF_METABOLIC_PROCESS. 262. 17. 0.0649. 1.15E88. 5,00E807.
TRANSPORT. 795. 30. 0.0377. 1.54E88. 6.35E87.
RESPONSE_TO_STRESS. 508. 23. 0.0453. 2.99E88. 1.17E86.
NEGATIVE_REGULATION_OF_TRANSCRIPTION. 188. 14. 0.0745. 4.07E88. 1.53E86.
BIOPOLYMER_MODIFICATION. 650. 26. 0.0400. 4.54E88. 1.63E86.
RNA_METABOLIC_PROCESS. 841. 30. 0.0357. 5.3E88. 1.82E86.
PROTEIN_MODIFICATION_PROCESS. 631. 25. 0.0396. 9.87E88. 3.26E86.
PROTEIN_METABOLIC_PROCESS. 1231. 37. 0.0301. 1.18E87. 3.74E86.
NEGATIVE_REGULATION_OF_NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLI
C_PROCESS. 211. 14. 0.0664. 1.71E87. 5.22E86.
POST_TRANSLATIONAL_PROTEIN_MODIFICATION. 476. 21. 0.0441. 1.83E87. 5.38E86.
ANATOMICAL_STRUCTURE_DEVELOPMENT. 1013. 32. 0.0316. 2.92E87. 8.32E86.
CELLULAR_PROTEIN_METABOLIC_PROCESS. 1117. 33. 0.0295. 8.4E87. 2.31E85.
CELLULAR_MACROMOLECULE_METABOLIC_PROCESS. 1131. 33. 0.0292. 1.1E86. 2.93E85.
NEGATIVE_REGULATION_OF_TRANSCRIPTION_DNA_DEPENDENT. 130. 10. 0.0769. 2.63E86. 6.79E85.
ORGANELLE_ORGANIZATION_AND_BIOGENESIS. 473. 19. 0.0402. 2.77E86. 6.92E85.
NEGATIVE_REGULATION_OF_RNA_METABOLIC_PROCESS. 132. 10. 0.0758. 3.02E86. 7.34E85.
TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER. 457. 18. 0.0394. 6.59E86. 1.55E84.
REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER. 289. 14. 0.0484. 7.05E86. 1.62E84.
SYSTEM_DEVELOPMENT. 861. 26. 0.0302. 8.42E86. 1.88E84.
MULTICELLULAR_ORGANISMAL_DEVELOPMENT. 1049. 29. 0.0276. 1.35E85. 2.94E84.
REGULATION_OF_CATALYTIC_ACTIVITY. 276. 13. 0.0471. 2,00E805. 4.23E84.
CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS. 208. 11. 0.0529. 3.02E85. 6.22E84.
CATION_TRANSPORT. 147. 9. 0.0612. 5.14E85. 1.03E83.
ION_TRANSPORT. 185. 10. 0.0541. 5.73E85. 1.13E83.
METAL_ION_TRANSPORT. 117. 8. 0.0684. 6.15E85. 1.18E83.
PROTEIN_AMINO_ACID_DEPHOSPHORYLATION1 631 61 0.09521 8.28E:51 1.55E:31
NEGATIVE_REGULATION_OF_GROWTH1 401 51 0.12501 8.87E:51 1.63E:31
REGULATION_OF_MOLECULAR_FUNCTION1 3241 131 0.04011 1.03E:41 1.78E:31
MESODERM_DEVELOPMENT1 221 41 0.18181 1.03E:41 1.78E:31
REGULATION_OF_TRANSFERASE_ACTIVITY1 1611 91 0.05591 1.04E:41 1.78E:31
LIPID_METABOLIC_PROCESS1 3251 131 0.04001 1.06E:41 1.78E:31
CELLULAR_LOCALIZATION1 3711 141 0.03771 1.08E:41 1.78E:31
ORGAN_DEVELOPMENT1 5711 181 0.03151 1.19E:41 1.93E:31
INFLAMMATORY_RESPONSE1 1291 81 0.06201 1.22E:41 1.93E:31
ANATOMICAL_STRUCTURE_MORPHOGENESIS1 3761 141 0.03721 1.24E:41 1.93E:31
DEPHOSPHORYLATION1 701 61 0.08571 1.49E:41 2.28E:31
PROTEIN_KINASE_CASCADE1 2931 121 0.04101 1.56E:41 2.33E:31
NERVOUS_SYSTEM_DEVELOPMENT1 3851 141 0.03641 1.58E:41 2.33E:31
CELL_SURFACE_RECEPTOR_LINKED_SIGNAL_TRANSDUCTION_GO_00071661 6411 191 0.02961 1.71E:41 2.44E:31
CELL_PROJECTION_BIOGENESIS1 251 41 0.16001 1.74E:41 2.44E:31
REGULATION_OF_CELL_GROWTH1 461 51 0.10871 1.75E:41 2.44E:31
ESTABLISHMENT_OF_CELLULAR_LOCALIZATION1 3531 131 0.03681 2.38E:41 3.27E:31
GROWTH1 771 61 0.07791 2.53E:41 3.42E:31
PHOSPHORYLATION1 3131 121 0.03831 2.85E:41 3.79E:31
RESPONSE_TO_WOUNDING1 1901 91 0.04741 3.57E:41 4.67E:31
INTRACELLULAR_TRANSPORT1 2801 111 0.03931 4.11E:41 5.3E:31
REGULATION_OF_PROTEIN_KINASE_ACTIVITY1 1551 81 0.05161 4.26E:41 5.41E:31
REGULATION_OF_KINASE_ACTIVITY1 1571 81 0.05101 4.64E:41 5.8E:31
REGULATION_OF_GROWTH1 581 51 0.08621 5.22E:41 6.43E:31
SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION1 891 61 0.06741 5.53E:41 6.7E:31
TISSUE_DEVELOPMENT1 1381 71 0.05071 1.07E:31 1.26E:21
CELL_DEVELOPMENT1 5771 161 0.02771 1.1E:31 1.26E:21
REGULATION_OF_BIOLOGICAL_QUALITY1 4191 131 0.03101 1.17E:31 1.32E:21
PROTEIN_POLYMERIZATION1 191 31 0.15791 1.24E:31 1.38E:21
PROTEIN_AMINO_ACID_PHOSPHORYLATION1 2791 101 0.03581 1.48E:31 1.63E:21
APOPTOSIS_GO1 4311 131 0.03021 1.5E:31 1.63E:21
PROGRAMMED_CELL_DEATH1 4321 131 0.03011 1.53E:31 1.64E:21
CELL_CYCLE_PROCESS1 1931 81 0.04151 1.76E:31 1.86E:21
REGULATION_OF_DEVELOPMENTAL_PROCESS1 4401 131 0.02951 1.8E:31 1.88E:21
REGULATION_OF_APOPTOSIS1 3411 111 0.03231 2.02E:31 2.06E:21
REGULATION_OF_PROGRAMMED_CELL_DEATH1 3421 111 0.03221 2.06E:31 2.08E:21
NEGATIVE_REGULATION_OF_CELL_CYCLE1 791 51 0.06331 2.11E:31 2.1E:21
NEGATIVE_REGULATION_OF_CELL_PROLIFERATION1 1561 71 0.04491 2.16E:31 2.12E:21
REGULATION_OF_G_PROTEIN_COUPLED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY1 231 31 0.13041 2.19E:31 2.13E:21
MICROTUBULE_BASED_PROCESS1 821 51 0.06101 2.49E:31 2.39E:21
BRAIN_DEVELOPMENT1 511 41 0.07841 2.72E:31 2.57E:21
CELLULAR_LIPID_METABOLIC_PROCESS1 2551 91 0.03531 2.78E:31 2.61E:21
NUCLEOCYTOPLASMIC_TRANSPORT1 871 51 0.05751 3.22E:31 2.98E:21
RESPONSE_TO_EXTERNAL_STIMULUS1 3121 101 0.03211 3.32E:31 3.04E:21
NUCLEAR_TRANSPORT1 881 51 0.05681 3.38E:31 3.07E:21
CALCIUM_ION_TRANSPORT1 271 31 0.11111 3.5E:31 3.1E:21
POSITIVE_REGULATION_OF_BIOLOGICAL_PROCESS1 7091 171 0.02401 3.55E:31 3.11E:21
ANATOMICAL_STRUCTURE_FORMATION1 561 41 0.07141 3.82E:31 3.31E:21
CELL_CYCLE_ARREST_GO_00070501 571 41 0.07021 4.07E:31 3.5E:21
POSITIVE_REGULATION_OF_CELLULAR_PROCESS1 6681 161 0.02401 4.64E:31 3.94E:21
SUPEROXIDE_METABOLIC_PROCESS1 101 21 0.20001 5.48E:31 4.61E:21
DI___TRI_VALENT_INORGANIC_CATION_TRANSPORT1 321 31 0.09381 5.69E:31 4.74E:21
MACROMOLECULE_LOCALIZATION1 2351 81 0.03401 5.8E:31 4.79E:21
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Table	  5.	  Myc–dependent	  bound	  genes	  are	  mainly	  involved	  in	  metabolic,	  RNA	  and	  signal	  
transduction	  processes.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Table	  of	  top	  scoring	  gene	  sets	  through	  GSEA	  pre-­‐ranked	  in	  Myc-­‐dependent	  induced	  bound	  and	  repressed	  
bound	  	  genes	  after	  8h	  of	  LPS	  stimulation.	  The	  number	  of	  genes	  (size)	  in	  each	  set,	  the	  normalized	  
enrichment	  score	  (NES)	  and	  the	  test	  of	  statistical	  significance	  (FDR	  q-­‐value)	  are	  indicated.	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Table	  6	  Ingenuity	  Pathway	  analysis	  of	  Myc	  dependent	  bound	  genes	  at	  8h	  LPS.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Table	  of	  top	  canonical	  pathways	  identified	  for	  Myc	  dependent	  genes	  at	  8h	  LPS	  and	  barplots	  with	  
percentages	  of	  the	  corrisponding	  Myc-­‐dependent	  induced	  bound	  (red)	  and	  Myc-­‐dependent	  repressed	  
bound	  (green)	  genes	  inside	  each	  pathways	  are	  reported	  below.	  
	  
	  
	  
	  
	  
	  
EI2F Signaling 
Regulation of eIF4 and p7056K Signaling 
mTOR Signaling 
 
Oxidative Phosphorilation 
Mitocondrial Dysfunction 
Cell Cyle:G1/S Checkpoint Regulation 
UVA-Induced MAPK Signaling 
GADD45 Signaling 
p53 Signaling  
Choline Biosynthesis III 
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4.9	  Comparison	  of	  Myc	  dependent	  genes	  in	  physiology	  and	  pathology	  
	  
To	   further	   characterize	  Myc	   target	  genes	   in	  a	  physiological	   versus	  pathological	   context,	  
we	   compared	   the	   core	   of	   genes	   identified	   in	  mitogen-­‐activated	   B	   cells	   with	   the	   genes	  
regulated	   by	  Myc	   during	   lymphomagenesis.	   Specifically,	   we	   compared	  Myc-­‐dependent	  
bound	  genes	  in	  primary	  B	  cells	  with	  differentially	  regulated	  and	  Myc-­‐bound	  genes	  at	  the	  
pre-­‐tumoral	  and	  tumoral	  stages	  in	  Eμ-­‐myc	  mouse	  B	  cells	  in	  vivo	  relative	  to	  their	  wild	  type	  
counterpart	  (Sabò	  et	  al.	  2014).	  This	  analysis	  showed	  that	  around	  56%	  (659/1174)	  of	  the	  
Myc-­‐dependent	   induced	  bound	  genes	  at	  either	  2h,	  4h	  or	  8h	  after	  LPS	  treatment	   in	  wild	  
type	   B	   cells	   were	   also	   up	   regulated	   during	   lymphomagenesis	   in	   Eμ-­‐myc	   B	   cells	   (Figure	  
57a).	  Among	   all	   these	   common	   genes,	   half	   of	   them	   (347/659)	  were	   specifically	   shared	  
with	  pretumoral	  and	  tumoral	  lymphomas.	  	  The	  biological	  processes	  in	  which	  these	  genes	  
are	   implicated	   concern	   nucleotide	   biosynthesis	   and	   metabolic	   processes	   necessary	   for	  
normal	  cell	  growth	  (Figure	  57b).	  	  
The	  overlap	  between	  Myc-­‐dependent	   repressed	  genes	   in	   LPS-­‐treated	  B-­‐cells	  and	   tumor	  
progression	   was	   lower	   (Figure	   58a).	   In	   total	   28%	   of	   Myc	   dependent	   bound	   repressed	  
genes	   were	   shared	   with	   Eμ-­‐myc	   B	   cells.	   These	   common	   genes	   enriched	   for	   a	   lower	  
number	  of	  terms	  with	  lower	  statistical	  significances	  and	  less	  precise	  biological	  meanings,	  
such	   as	   signal	   transduction,	   general	   regulation	   of	   transcription	   and	   post-­‐translational	  
events	  (Figure	  58b).	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Myc-dependent induced bound 
(1174) 
PvsC_Up bound  
(1556) 
TvsC_Up bound 
(1357) 
515
347
195 117
497
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376
Myc_d pInduced_LPS_Myc bound  
                      (1174)
PvsC_Up_Myc bound
             (1556)
TvsC_Up_Myc bound
             (1357)
a 
Gene$ontology$of$all$common$Myc$Induced$genes$
Gene$Set$Name$ #$Genes$in$Gene$Set$(K)$#$Genes$in$Overlap$(k)$ k/K$ p@value$ FDR$q@value$
NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS1 12441 1501 0.12061 2.73E;721 2.25E;691
BIOPOLYMER_METABOLIC_PROCESS1 16841 1541 0.09141 9.21E;581 3.8E;551
RNA_METABOLIC_PROCESS1 8411 891 0.10581 4.62E;381 1.27E;351
CELL_CYCLE_GO_00070491 3151 541 0.17141 5.18E;341 1.07E;311
CELL_CYCLE_PROCESS1 1931 411 0.21241 5.69E;301 9.39E;281
ORGANELLE_ORGANIZATION_AND_BIOGENESIS1 4731 541 0.11421 5.02E;251 6.05E;231
RNA_PROCESSING1 1731 351 0.20231 5.13E;251 6.05E;231
MITOTIC_CELL_CYCLE1 1531 331 0.21571 1.32E;241 1.36E;221
CELL_CYCLE_PHASE1 1701 331 0.19411 4.62E;231 4.23E;211
DNA_METABOLIC_PROCESS1 2571 371 0.14401 5.46E;211 4.5E;191
M_PHASE1 1141 261 0.22811 2.45E;201 1.84E;181
PROTEIN_METABOLIC_PROCESS1 12311 781 0.06341 3.05E;191 2.1E;171
CELLULAR_PROTEIN_METABOLIC_PROCESS1 11171 721 0.06451 3.1E;181 1.96E;161
NUCLEOBASENUCLEOSIDE_AND_NUCLEOTIDE_METABOLIC_PROCESS1 521 181 0.34621 4.3E;181 2.53E;161
BIOSYNTHETIC_PROCESS1 4701 451 0.09571 4.76E;181 2.62E;161
CELLULAR_MACROMOLECULE_METABOLIC_PROCESS1 11311 721 0.06371 6.03E;181 3.11E;161
TRANSCRIPTION1 7531 561 0.07441 4.22E;171 2.05E;151
TRANSCRIPTION_DNA_DEPENDENT1 6361 501 0.07861 2.32E;161 1.06E;141
RNA_BIOSYNTHETIC_PROCESS1 6381 501 0.07841 2.63E;161 1.14E;141
REGULATION_OF_CELLULAR_METABOLIC_PROCESS1 7871 561 0.07121 2.91E;161 1.17E;141
M_PHASE_OF_MITOTIC_CELL_CYCLE1 851 201 0.23531 2.99E;161 1.17E;141
RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_ASSEMBLY1 861 201 0.23261 3.82E;161 1.43E;141
REGULATION_OF_METABOLIC_PROCESS1 7991 561 0.07011 5.6E;161 2.01E;141
MITOSIS1 821 191 0.23171 2.25E;151 7.72E;141
CELLULAR_BIOSYNTHETIC_PROCESS1 3211 341 0.10591 2.93E;151 9.68E;141
CELL_PROLIFERATION_GO_00082831 5131 431 0.08381 3.17E;151 1.01E;131
REGULATION_OF_CELL_CYCLE1 1821 261 0.14291 4.43E;151 1.35E;131
REGULATION_OF_NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS1 6181 471 0.07611 6.45E;151 1.9E;131
CHROMOSOME_ORGANIZATION_AND_BIOGENESIS1 1241 211 0.16941 6.05E;141 1.72E;121
RNA_SPLICING1 911 181 0.19781 2.31E;131 6.34E;121
RESPONSE_TO_ENDOGENOUS_STIMULUS1 2001 251 0.12501 3.32E;131 8.84E;121
NUCLEOTIDE_METABOLIC_PROCESS1 421 131 0.30951 1.01E;121 2.6E;111
RESPONSE_TO_DNA_DAMAGE_STIMULUS1 1621 221 0.13581 1.6E;121 4,00E;111
DNA_REPLICATION1 1021 181 0.17651 1.8E;121 4.38E;111
RESPONSE_TO_STRESS1 5081 381 0.07481 4.22E;121 9.94E;111
RIBOSOME_BIOGENESIS_AND_ASSEMBLY1 181 91 0.50001 1.88E;111 4.2E;101
MACROMOLECULAR_COMPLEX_ASSEMBLY1 2801 271 0.09641 1.88E;111 4.2E;101
ESTABLISHMENT_OF_LOCALIZATION1 8701 501 0.05751 3.18E;111 6.9E;101
TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER1 4571 341 0.07441 6.55E;111 1.39E;91
CELLULAR_COMPONENT_ASSEMBLY1 2981 271 0.09061 7.84E;111 1.62E;91
RIBONUCLEOTIDE_METABOLIC_PROCESS1 161 81 0.50001 2.59E;101 5.2E;91
MACROMOLECULE_BIOSYNTHETIC_PROCESS1 3211 271 0.08411 4.15E;101 8.16E;91
TRANSPORT1 7951 451 0.05661 5.01E;101 9.62E;91
DNA_REPAIR1 1251 171 0.13601 5.27E;101 9.87E;91
REGULATION_OF_RNA_METABOLIC_PROCESS1 4711 331 0.07011 5.82E;101 1.07E;81
b
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Figure	  57	  Overlap	  between	  Myc	  dependent	  Induced	  bound	  genes	  in	  LPS	  activated	  B	  cells	  and	  
upregulated	  bound	  genes	  in	  Eμ-­‐myc	  B	  cells.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
a.	  Venn	  diagrams	  representing	  the	  overlap	  between	  Myc	  dependent	  induced	  bound	  genes	  in	  at	  least	  one	  
time	  point	  after	  LPS	  stimulation	  (2	  ,4,	  8h)	  with	  upregulated	  Myc	  bound	  genes	  in	  Eμ-­‐myc	  pretumoral	  (P)	  or	  
tumor	  (T)	  compared	  to	  control	  (C)	  (as	  described	  in	  the	  paper	  Sabo	  et	  al.2014:	  qvalue<0.05	  and	  log2(T/C)	  >	  
or	  <0).	  b.	  Gene	  ontology	  analysis	  for	  all	  the	  common	  genes	  (659	  genes)	  is	  shown.	  All	  gene	  sets	  with	  
significant	  FDR	  (<0.05)	  are	  reported.	  Separate	  analysis	  on	  117,	  347	  and	  195	  genes	  gave	  very	  similar	  results	  
(data	  not	  shown).	  
	  
	   	  
TRANSLATION) 180) 20) 0.1111) 6.38E210) 1.14E28)
INTERPHASE) 68) 13) 0.1912) 7.7E210) 1.35E28)
POSITIVE_REGULATION_OF_CELLULAR_PROCESS) 668) 40) 0.0599) 9.39E210) 1.61E28)
REGULATION_OF_GENE_EXPRESSION) 673) 40) 0.0594) 1.16E29) 1.96E28)
POSITIVE_REGULATION_OF_BIOLOGICAL_PROCESS) 709) 41) 0.0578) 1.6E29) 2.64E28)
CELLULAR_CATABOLIC_PROCESS) 212) 21) 0.0991) 1.98E29) 3.2E28)
INTERPHASE_OF_MITOTIC_CELL_CYCLE) 62) 12) 0.1935) 2.98E29) 4.73E28)
AMINO_ACID_METABOLIC_PROCESS) 78) 13) 0.1667) 4.51E29) 7.02E28)
REGULATION_OF_TRANSCRIPTION) 566) 35) 0.0618) 4.64E29) 7.08E28)
BIOPOLYMER_MODIFICATION) 650) 38) 0.0585) 4.72E29) 7.08E28)
REGULATION_OF_MITOSIS) 41) 10) 0.2439) 5.74E29) 8.35E28)
CATABOLIC_PROCESS) 225) 21) 0.0933) 5.77E29) 8.35E28)
RRNA_PROCESSING) 15) 7) 0.4667) 6.59E29) 9.37E28)
CELLULAR_LOCALIZATION) 371) 27) 0.0728) 9.5E29) 1.33E27)
RRNA_METABOLIC_PROCESS) 16) 7) 0.4375) 1.15E28) 1.58E27)
MITOTIC_SPINDLE_ORGANIZATION_AND_BIOGENESIS) 10) 6) 0.6000) 1.17E28) 1.58E27)
MACROMOLECULE_LOCALIZATION) 235) 21) 0.0894) 1.25E28) 1.66E27)
AMINO_ACID_AND_DERIVATIVE_METABOLIC_PROCESS) 101) 14) 0.1386) 1.36E28) 1.77E27)
ESTABLISHMENT_OF_CELLULAR_LOCALIZATION) 353) 26) 0.0737) 1.39E28) 1.77E27)
NEGATIVE_REGULATION_OF_BIOLOGICAL_PROCESS) 677) 38) 0.0561) 1.4E28) 1.77E27)
NUCLEOCYTOPLASMIC_TRANSPORT) 87) 13) 0.1494) 1.78E28) 2.22E27)
REGULATION_OF_TRANSCRIPTIONDNA_DEPENDENT) 461) 30) 0.0651) 1.87E28) 2.31E27)
NUCLEAR_TRANSPORT) 88) 13) 0.1477) 2.05E28) 2.48E27)
SPINDLE_ORGANIZATION_AND_BIOGENESIS) 11) 6) 0.5455) 2.53E28) 3.03E27)
MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS) 48) 10) 0.2083) 2.95E28) 3.48E27)
PROTEIN_IMPORT) 62) 11) 0.1774) 3.54E28) 4.11E27)
PROTEIN_TARGETING) 109) 14) 0.1284) 3.68E28) 4.22E27)
NEGATIVE_REGULATION_OF_CELLULAR_PROCESS) 646) 36) 0.0557) 4.01E28) 4.53E27)
APOPTOSIS_GO) 431) 28) 0.0650) 5.74E28) 6.33E27)
INTRACELLULAR_TRANSPORT) 280) 22) 0.0786) 5.75E28) 6.33E27)
PROGRAMMED_CELL_DEATH) 432) 28) 0.0648) 6.03E28) 6.54E27)
CELL_DEVELOPMENT) 577) 33) 0.0572) 8.05E28) 8.63E27)
PROTEIN_RNA_COMPLEX_ASSEMBLY) 67) 11) 0.1642) 8.18E28) 8.65E27)
NITROGEN_COMPOUND_METABOLIC_PROCESS) 155) 16) 0.1032) 9.16E28) 9.56E27)
MRNA_METABOLIC_PROCESS) 84) 12) 0.1429) 1.05E27) 1.08E26)
PROTEIN_TRANSPORT) 157) 16) 0.1019) 1.1E27) 1.12E26)
AMINE_METABOLIC_PROCESS) 141) 15) 0.1064) 1.55E27) 1.55E26)
MRNA_PROCESSING_GO_0006397) 73) 11) 0.1507) 2.03E27) 2.02E26)
PROTEIN_MODIFICATION_PROCESS) 631) 34) 0.0539) 2.08E27) 2.05E26)
REGULATION_OF_DNA_METABOLIC_PROCESS) 45) 9) 0.2000) 2.12E27) 2.06E26)
INTRACELLULAR_PROTEIN_TRANSPORT) 145) 15) 0.1034) 2.23E27) 2.14E26)
ESTABLISHMENT_OF_PROTEIN_LOCALIZATION) 190) 17) 0.0895) 2.93E27) 2.78E26)
PROTEIN_LOCALIZATION) 214) 18) 0.0841) 3.33E27) 3.12E26)
MICROTUBULE_CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS) 35) 8) 0.2286) 3.39E27) 3.14E26)
ESTABLISHMENT_AND_OR_MAINTENANCE_OF_CHROMATIN_ARCHITECTURE) 77) 11) 0.1429) 3.55E27) 3.26E26)
CELL_CYCLE_CHECKPOINT_GO_0000075) 48) 9) 0.1875) 3.81E27) 3.46E26)
REGULATION_OF_APOPTOSIS) 341) 23) 0.0674) 4.49E27) 4.02E26)
REGULATION_OF_PROGRAMMED_CELL_DEATH) 342) 23) 0.0673) 4.72E27) 4.19E26)
CARBOXYLIC_ACID_METABOLIC_PROCESS) 178) 16) 0.0899) 6.11E27) 5.37E26)
MICROTUBULE_BASED_PROCESS) 82) 11) 0.1341) 6.81E27) 5.91E26)
PURINE_RIBONUCLEOTIDE_METABOLIC_PROCESS) 10) 5) 0.5000) 7.03E27) 6.04E26)
ORGANIC_ACID_METABOLIC_PROCESS) 180) 16) 0.0889) 7.1E27) 6.04E26)
CHROMATIN_MODIFICATION) 55) 9) 0.1636) 1.28E26) 1.08E25)
TRNA_METABOLIC_PROCESS) 19) 6) 0.3158) 1.3E26) 1.08E25)
DNA_DEPENDENT_DNA_REPLICATION) 56) 9) 0.1607) 1.5E26) 1.23E25)
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Figure	  58	  Overlap	  between	  Myc	  dependent	  repressed	  bound	  genes	  in	  LPS	  activated	  B	  cells	  and	  
downregulated	  bound	  genes	  in	  Eμ-­‐myc	  B	  cells.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
a.	  Venn	  diagrams	  representing	  the	  overlap	  between	  Myc-­‐dependent	  repressed	  bound	  genes	  in	  at	  least	  one	  
time	  point	  after	  LPS	  stimulation	  (2	  ,4,	  8h)	  with	  downregulated	  Myc	  bound	  genes	  in	  Eμ-­‐myc	  tumor	  compared	  
to	  control	  (as	  described	  in	  the	  paper	  Sabo	  et	  al.2014:	  qvalue<0.05	  and	  log2(T/C)	  >	  or	  <0).	  b.	  Gene	  ontology	  
analysis	  for	  all	  the	  common	  genes	  (215	  genes)	  is	  shown.	  All	  gene	  sets	  with	  significant	  FDR	  (<0.05)	  are	  
reported.	  Separate	  analysis	  on	  87,	  67	  and	  61	  genes	  gave	  very	  similar	  results	  (data	  not	  shown).	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Gene$ontology$of$all$common$Myc$repressed$genes$
Gene$Set$Name$ #$Genes$in$Gene$Set$(K)$ #$Genes$in$Overlap$(k)$ k/K$ p>value$ FDR$q>value$
SIGNAL_TRANSDUCTION. 1634. 35. 0.0214. 4.01E815. 3.31E812.
BIOPOLYMER_METABOLIC_PROCESS. 1684. 24. 0.0143. 2.92E87. 1.18E84.
REGULATION_OF_METABOLIC_PROCESS. 799. 16. 0.0200. 4.28E87. 1.18E84.
INTRACELLULAR_SIGNALING_CASCADE. 667. 14. 0.0210. 1.34E86. 2.76E84.
REGULATION_OF_CELLULAR_METABOLIC_PROCESS. 787. 15. 0.0191. 1.82E86. 3.01E84.
TRANSCRIPTION. 753. 14. 0.0186. 5.38E86. 6.54E84.
REGULATION_OF_TRANSCRIPTION. 566. 12. 0.0212. 7,00E806. 6.54E84.
CELLULAR_PROTEIN_METABOLIC_PROCESS. 1117. 17. 0.0152. 7.47E86. 6.54E84.
REGULATION_OF_GENE_EXPRESSION. 673. 13. 0.0193. 7.84E86. 6.54E84.
NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS. 1244. 18. 0.0145. 7.93E86. 6.54E84.
CELLULAR_MACROMOLECULE_METABOLIC_PROCESS. 1131. 17. 0.0150. 8.78E86. 6.58E84.
REGULATION_OF_NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_.
PROCESS. 618. 12. 0.0194. 1.67E85. 1.15E83.
PROTEIN_MODIFICATION_PROCESS. 631. 12. 0.0190. 2.05E85. 1.3E83.
PROTEIN_METABOLIC_PROCESS. 1231. 17. 0.0138. 2.58E85. 1.51E83.
BIOPOLYMER_MODIFICATION. 650. 12. 0.0185. 2.74E85. 1.51E83.
REGULATION_OF_TRANSCRIPTIONDNA_DEPENDENT. 461. 10. 0.0217. 3.4E85. 1.75E83.
BIOSYNTHETIC_PROCESS. 470. 10. 0.0213. 4,00E805. 1.87E83.
REGULATION_OF_RNA_METABOLIC_PROCESS. 471. 10. 0.0212. 4.07E85. 1.87E83.
NEGATIVE_REGULATION_OF_CELLULAR_METABOLIC_PROCESS. 259. 7. 0.0270. 1.38E84. 5.98E83.
NEGATIVE_REGULATION_OF_METABOLIC_PROCESS. 262. 7. 0.0267. 1.48E84. 6.1E83.
REGULATION_OF_CATALYTIC_ACTIVITY. 276. 7. 0.0254. 2.03E84. 7.98E83.
LEUKOCYTE_ACTIVATION. 69. 4. 0.0580. 2.28E84. 8.54E83.
PROTEIN_KINASE_CASCADE. 293. 7. 0.0239. 2.92E84. 1.05E82.
CELL_ACTIVATION. 77. 4. 0.0519. 3.47E84. 1.19E82.
TRANSCRIPTION_DNA_DEPENDENT. 636. 10. 0.0157. 4.59E84. 1.49E82.
RNA_BIOSYNTHETIC_PROCESS. 638. 10. 0.0157. 4.7E84. 1.49E82.
MACROMOLECULE_BIOSYNTHETIC_PROCESS. 321. 7. 0.0218. 5.03E84. 1.51E82.
NEGATIVE_REGULATION_OF_CELLULAR_PROCESS. 646. 10. 0.0155. 5.18E84. 1.51E82.
REGULATION_OF_MOLECULAR_FUNCTION. 324. 7. 0.0216. 5.32E84. 1.51E82.
REGULATION_OF_PROTEIN_KINASE_ACTIVITY. 155. 5. 0.0323. 5.71E84. 1.57E82.
REGULATION_OF_KINASE_ACTIVITY. 157. 5. 0.0318. 6.06E84. 1.61E82.
REGULATION_OF_TRANSFERASE_ACTIVITY. 161. 5. 0.0311. 6.78E84. 1.75E82.
NEGATIVE_REGULATION_OF_BIOLOGICAL_PROCESS. 677. 10. 0.0148. 7.41E84. 1.85E82.
INTERLEUKIN_8_BIOSYNTHETIC_PROCESS. 10. 2. 0.2000. 8.04E84. 1.95E82.
RNA_METABOLIC_PROCESS. 841. 11. 0.0131. 1.09E83. 2.54E82.
POST_TRANSLATIONAL_PROTEIN_MODIFICATION. 476. 8. 0.0168. 1.11E83. 2.54E82.
INTERLEUKIN_8_PRODUCTION. 12. 2. 0.1667. 1.17E83. 2.55E82.
PERIPHERAL_NERVOUS_SYSTEM_DEVELOPMENT. 12. 2. 0.1667. 1.17E83. 2.55E82.
NEGATIVE_REGULATION_OF_TRANSCRIPTION. 188. 5. 0.0266. 1.35E83. 2.87E82.
b
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In	   order	   to	   find	   the	   core	   of	   Myc	   dependent	   genes	   during	   mitogenic	   stimulation	   we	  
compared	   our	   dataset	   with	   Myc	   dependent	   serum-­‐response	   (MDSR)	   genes	   in	   serum-­‐
stimulated	  fibroblasts	   (Perna	  et	  al	  2012).	  Around	  half	  of	  the	  previously	  described	  MDSR	  
genes	  bound	  by	  Myc	  were	  retrieved	  as	  Myc	  dependent	  bound	  also	  upon	  LPS	  stimulation,	  
albeit	  many	  more	  Myc-­‐dependent	  genes	  were	  identified	  in	  the	  B	  cells	  (Figure	  59a).	  Once	  
again,	   the	   common	   group	   included	   genes	   involved	   in	   nucleotide	   biosynthesis	   and	   RNA	  
processing	   (Figure	  59b).	  On	   the	  other	  hand,	  only	  3	  genes	   repressed	  and	  bound	  by	  Myc	  
(Lipa,	  Cryz,	  Didt3)	  were	  shared	  between	  the	  two	  datasets	  (Figure	  59a).	  This	  is	  consistent	  
with	   the	   lesser	   relevance	   of	   Myc-­‐dependent	   repression	   in	   the	   stimulated	   fibroblasts	  
(Perna	   et	   al.	   2012),	   possibly	   due	   to	   the	   lower	   levels	   of	  Myc	   expression	   in	   those	   cells,	  
compared	   to	   LPS-­‐stimulated	   B-­‐cells.	   Lipa	   encodes	   for	   a	   lipase	   involved	   in	   hydrolysis	   of	  
cholesteryl	  esters	  and	  triglycerides	  reinforced	  the	  notion	  that	  the	  lipid	  pathway	  is	  mainly	  
dowregulated	  by	  Myc	  as	  we	  shown	  through	  the	  IPA	  analysis.	  Instead,	  Cryz	  encodes	  for	  a	  
quinone	   reductases	   and	   Didt3	   is	   a	   negative	   regulator	   of	   several	   C/EBP	   transcription	  
factors	  mainly	  involved	  in	  apoptosis	  in	  response	  to	  cell	  stress.	  	  
In	   conclusion,	   the	   multiple	   analyses	   performed	   through	   the	   intersection	   of	   different	  
datasets	  will	  shed	  light	  into	  specific	  genes	  and	  pathways	  regulated	  by	  Myc	  in	  B	  cells	  under	  
physiological	   circumstances.	   These	   Myc	   dependent	   pathways	   are	   mainly	   involved	   in	  
metabolism	  activation,	  growth	  and	  translation.	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Figure	  59	  Overlap	  between	  Myc	  dependent	  bound	  genes	  in	  LPS	  activated	  B	  cells	  and	  serum	  
stimulated	  fibroblasts	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
a.	  Venn	  diagram	  representing	  the	  overlap	  between	  Myc	  dependent	  induced	  bound	  	  genes	  in	  at	  least	  one	  
time	  point	  (2,4,8h	  after	  LPS	  stimulation)	  with	  MDSR,	  Myc	  dependent	  serum	  response	  genes	  bound	  by	  Myc	  
upregulated	  (MDSR_Up	  bound)	  and	  dowregulated	  (MDSR_Down	  bound)	  (as	  described	  in	  material	  and	  
methods	  of	  Perna	  et	  al.2012	  paper).	  b.	  Gene	  ontology	  analysis	  for	  all	  the	  common	  induced	  genes	  (120	  
genes)	  is	  shown.	  All	  gene	  sets	  with	  significant	  FDR	  (<0.05)	  are	  reported.	  	  
	  
	  
	  
Myc-dependent induced bound  
(1174) 
Myc-dependent repressed bound 
(755)  
MDSR_Down bound 
MDSR_Up bound 
Gene$Set$Name$
#$Genes$in$
Gene$Set$(K)$
#$Genes$in$
Overlap$(k)$ k/K$ p7value$ FDR$q7value$
NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PR
OCESS1 12441 261 0.02091 9.42E9171 7.77E9141
RNA_METABOLIC_PROCESS1 8411 201 0.02381 4.56E9141 1.88E9111
BIOPOLYMER_METABOLIC_PROCESS1 16841 261 0.01541 1.12E9131 3.08E9111
ORGANELLE_ORGANIZATION_AND_BIOGENESIS1 4731 131 0.02751 2.9E9101 5.97E981
RNA_PROCESSING1 1731 81 0.04621 1.65E981 2.72E961
GO for common Up genes   
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                         (755)
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Gene$ontology$of$common$Myc$induced$genes$
Gene$Set$Name$ #$Genes$in$Gene$Set$(K)$ #$Genes$in$Overlap$(k)$ k/K$ p?value$ FDR$q?value$
NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS1 12441 261 0.02091 9.42E9171 7.77E9141
RNA_METABOLIC_PROCESS1 8411 201 0.02381 4.56E9141 1.88E9111
BIOPOLYMER_METABOLIC_PROCESS1 16841 261 0.01541 1.12E9131 3.08E9111
ORGANELLE_ORGANIZATION_AND_BIOGENESIS1 4731 131 0.02751 2.9E9101 5.97E981
RNA_PROCESSING1 1731 81 0.04621 1.65E981 2.72E961
RRNA_PROCESSING1 151 41 0.26671 5.33E981 7.33E961
RRNA_METABOLIC_PROCESS1 161 41 0.25001 7.09E981 8.36E961
PROTEIN_METABOLIC_PROCESS1 12311 161 0.01301 1.02E971 1.05E951
RIBOSOME_BIOGENESIS_AND_ASSEMBLY1 181 41 0.22221 1.19E971 1.09E951
TRANSCRIPTION1 7531 121 0.01591 5.48E971 4.28E951
REGULATION_OF_NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC
_PROCESS1 6181 111 0.01781 5.71E971 4.28E951
CELLULAR_PROTEIN_METABOLIC_PROCESS1 11171 141 0.01251 1.04E961 7.18E951
CELLULAR_MACROMOLECULE_METABOLIC_PROCESS1 11311 141 0.01241 1.21E961 7.67E951
RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_ASSEMBLY1 861 51 0.05811 2.9E961 1.71E941
TRANSCRIPTION_DNA_DEPENDENT1 6361 101 0.01571 5.68E961 2.84E941
REGULATION_OF_CELLULAR_METABOLIC_PROCESS1 7871 111 0.01401 5.8E961 2.84E941
RNA_BIOSYNTHETIC_PROCESS1 6381 101 0.01571 5.84E961 2.84E941
REGULATION_OF_METABOLIC_PROCESS1 7991 111 0.01381 6.69E961 2.99E941
MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS1 481 41 0.08331 7.12E961 2.99E941
TRANSLATION1 1801 61 0.03331 7.25E961 2.99E941
CHROMATIN_MODIFICATION1 551 41 0.07271 1.23E951 4.84E941
CHROMOSOME_ORGANIZATION_AND_BIOGENESIS1 1241 51 0.04031 1.74E951 6.51E941
REGULATION_OF_RNA_METABOLIC_PROCESS1 4711 81 0.01701 2.95E951 1.06E931
G1_S_TRANSITION_OF_MITOTIC_CELL_CYCLE1 271 31 0.11111 4.5E951 1.54E931
ESTABLISHMENT_AND_OR_MAINTENANCE_OF_CHROMATIN_ARCHITECTURE1 771 41 0.05191 4.68E951 1.54E931
DNA_METABOLIC_PROCESS1 2571 61 0.02331 5.37E951 1.7E931
REGULATION_OF_GENE_EXPRESSION1 6731 91 0.01341 5.96E951 1.82E931
REGULATION_OF_TRANSCRIPTION1 5661 81 0.01411 1.06E941 3.13E931
CELL_CYCLE_GO_00070491 3151 61 0.01901 1.63E941 4.65E931
CELLULAR_BIOSYNTHETIC_PROCESS1 3211 61 0.01871 1.81E941 4.82E931
MACROMOLECULE_BIOSYNTHETIC_PROCESS1 3211 61 0.01871 1.81E941 4.82E931
BIOSYNTHETIC_PROCESS1 4701 71 0.01491 2.11E941 5.44E931
BIOPOLYMER_MODIFICATION1 6501 81 0.01231 2.71E941 6.78E931
CELL_PROLIFERATION_GO_00082831 5131 71 0.01361 3.58E941 8.68E931
INTERPHASE_OF_MITOTIC_CELL_CYCLE1 621 31 0.04841 5.45E941 1.28E921
MITOTIC_CELL_CYCLE1 1531 41 0.02611 6.54E941 1.5E921
INTERPHASE1 681 31 0.04411 7.14E941 1.59E921
BASE_EXCISION_REPAIR1 171 21 0.11761 8.52E941 1.85E921
CELL_CYCLE_PHASE1 1701 41 0.02351 9.68E941 2.05E921
CELLULAR_RESPONSE_TO_STIMULUS1 191 21 0.10531 1.07E931 2.15E921
TRNA_METABOLIC_PROCESS1 191 21 0.10531 1.07E931 2.15E921
REGULATION_OF_TRANSCRIPTIONDNA_DEPENDENT1 4611 61 0.01301 1.21E931 2.37E921
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5.	  Discussion	  	  	  
Myc	   is	   required	   for	   the	   response	  of	   B-­‐lymphocytes	   upon	  exposure	   to	   activating	   stimuli	  
(Kelly	   et	   al	   1983;	   de	   Alboran	   et	   al.,	   2001),	   but	   a	   clear	   picture	   of	   the	   transcriptional	  
programs	  regulated	  by	  Myc	  in	  this	  setting	  is	  still	  missing.	  In	  the	  present	  study,	  we	  provide	  
integrated	  maps	   of	   genome	   occupancy	   by	  Myc	   and	   gene	   expression	   profiles	   upon	   LPS	  
mediated	  activation	  of	  primary	  B-­‐cells.	  The	  dependency	  of	  transcriptional	  responses	  upon	  
Myc	  was	  determined	  by	  comparing	  wild	  type	  cells	  with	  cells	  in	  which	  conditional	  deletion	  
of	  c-­‐myc	  was	  induced	  prior	  to	  LPS	  stimulation.	  Our	  data	  clearly	  pinpoint	  the	  requirement	  
for	  Myc	   in	   the	  up-­‐	  and	  down-­‐regulation	  of	  specific	  groups	  of	  genes	  at	  early	   time-­‐points	  
following	   stimulation,	   in	   contrast	   with	   the	   concept	   that	   Myc	   acts	   to	   generally	   amplify	  
expression	   of	   all	   active	   genes.	   	   This	   work	   represents	   an	   accurate	   description	   of	  
transcriptional	   regulation	   by	   Myc	   in	   a	   physiological	   setting,	   and	   constitutes	   a	   starting	  
point	  for	  studies	  delineating	  of	  how	  select	  Myc	  target	  genes	  may	  affect	  different	  cellular	  
outcomes.	  
	  
5.1	  Myc	  is	  required	  for	  B	  cell	  activation,	  proliferation	  and	  cell	  growth	  	  	  
For	   decades,	   induction	   of	   c-­‐myc	   expression	   has	   been	   associated	  with	   cell	   activation	   in	  
diverse	  cell	  types,	  including	  normal	  fibroblasts	  and	  lymphocytes	  (Kelly	  et	  al.	  1983;	  Rabitts	  
et	   al.	   1985):	   starting	   from	  a	  very	   low	  baseline	  during	  G0-­‐G1	  phase,	  Myc	   is	   then	   rapidly	  
induced	  by	  mitogenic	   stimulation.	   In	   line	  with	   this	   concept,	  we	  and	  others	   (Lin	  C	  et	  al.,	  
2012;	  de	  Alboran	  et	  al.,	  2001)	  have	  observed	  that,	  Myc	   is	   rapidly	   induced	  at	   the	  mRNA	  
and	  protein	  levels	  upon	  LPS	  stimulation	  in	  B	  cells,	  allowing	  their	  clonal	  expansion	  and	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metabolic	  changes	  such	  as	  increase	  in	  size,	  protein	  synthesis	  and	  global	  RNA	  production,	  
which	  may	  prepare	  their	  differentiation	  in	  plasma	  cells.	  Also	  in	  T	  cells,	  Myc	  expression	  is	  
required	   for	   activation-­‐induced	   cell	   growth,	  proliferation	  and	  metabolic	   reprogramming	  
(Wang	  et	  al.,	  2011).	  In	  addition,	  the	  strength	  of	  TCR	  activation	  signalling	  pathway	  dictates	  
Myc	  mRNA	  expression	   levels	   in	  T	  cells	  while	  other	  external	   stimuli	   such	  as	   IL2	  maintain	  
high	  Myc	  protein	  levels,	  since	  they	  can	  ensure	  a	  high	  rate	  of	  amino	  acid	  uptake	  and	  so	  a	  
high	   rate	  of	  protein	   synthesis	   (Preston	  et	  al.,	  2015).	   	   Thus,	  TCR	  activation	  alone	  cannot	  
sustain	  expression	  of	  Myc	  and	  the	  post-­‐transcriptional	  control	  of	  Myc	  protein	  is	  ensured	  
by	   IL2,	   generating	  possible	  discordances	  between	  Myc	  protein	   and	  mRNA	   levels.	   These	  
observations	   in	   activated	   T	   cells	   seem	   to	   be	   in	   line	  with	   our	   observations	   in	   B	   cells,	   in	  
which	   the	   c-­‐myc	   mRNA	   is	   maximally	   induced	   at	   2h	   of	   LPS	   activation	   and	   declines	  
thereafter,	  whereas	  Myc	  protein	  levels	  reach	  a	  maximum	  at	  the	  same	  point,	  but	  remain	  
elevated	  at	  4h	  and	  8h	  (Figure	  21;	  Figure	  42).	  At	  these	  later	  time	  points,	  we	  also	  started	  to	  
observe	   a	   slight	   increase	   in	   cell	   size	   consistent	   with	   the	   notion	   that	   all	   the	   protein	  
biosynthetic	  apparatus	  of	  the	  cell	  and	  thus	  its	  mass	  expand	  when	  Myc	  is	  highly	  expressed,	  
both	   in	   normal	   and	   tumoral	   lymphocytes	   (Wang	   et	   al.	   2011;	   B.	   Iritani	   &	   R.	   Eisenman	  
1999).	  	  
This	  effect	  of	  Myc	  on	  growth	  is	  preceded	  by	  a	  direct	  and	  well-­‐described	  effect	  of	  Myc	  on	  
cell	  cycle	  progression.	   Indeed	  our	  data	  showed	  that	  deletion	  of	  myc	   in	  quiescent	  B	  cells	  
impaired	  S-­‐phase	  entry,	  as	  also	  observed	  in	  a	  previous	  study	  (de	  Alboran	  et	  al.,	  2001).	  The	  
decreased	  rate	  of	  proliferation	  of	  Myc	  deleted	  cells	  was	  due	  to	  a	  cell	  cycle	  defect,	  and	  not	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to	   an	   increase	   in	   apoptosis.	  On	   the	   contrary,	  Myc	  deleted	   cells	  were	  more	   resistant	   to	  
spontaneous	  cell	  death	  as	  was	  also	  previously	  published	  (de	  Alboran	  et	  al.,	  2003;	  Murn	  et	  
al.,	   2009).	   Myc	   deletion	   has	   also	   been	   shown	   to	   promote	   plasma	   cell	   differentiation	  
(Murn	   et	   al	   2009)	   but	   analysis	   of	   cell	   surface	   markers	   and	   terminal	   differentiation-­‐
associated	  genes	  did	  not	  confirm	  this	  in	  our	  system.	  	  We	  speculate	  that	  Myc	  may	  exert	  its	  
transcriptional	  activity	  principally	  during	  the	  initial	  phases	  of	  B	  cell	  activation	  in	  order	  to	  
modulate	  proliferation	  and	  growth,	  and	  may	  then	  be	  down	  regulated	  by	   transcriptional	  
regulators	  that	  control	  the	  plasma	  cell	  differentation	  factor	  network,	  such	  as	  Blimp1	  (Lin	  
Y.	   et	   al.	   1997).	   Inducing	   c-­‐myc	  deletion	   later,	   after	   24-­‐48h	  of	   LPS	   stimulation,	   could	   be	  
also	  useful	  to	  clarify	  its	  role	  in	  the	  last	  phases	  of	  plasma	  cell	  differentation.	  	  
	  
5.2	  Widespread	  Myc	  binding	  to	  chromatin	  occurs	  soon	  after	  mitogenic	  
stimulation	  	  	  	  
We	  observed	  that	  the	  distribution	  of	  Myc	  binding	  sites	  in	  wild	  type	  splenic	  B	  cells	  in	  vitro	  
without	   stimulation	  with	   LPS	  was	   comparable	   to	   that	   observed	   in	   vivo	   in	   our	   previous	  
study	  (Sabò	  et	  al.	  2014).	  Low	  Myc	  levels	  justify	  the	  lower	  numbers	  of	  Myc	  peaks	  observed	  
in	  those	  conditions,	  and	  their	  predominant	   location	  at	  active/poised	  promoters	  (Sabò	  &	  
Amati	  2014;	  Kress	  et	  al.,	  2015).	  Following	  2h	  of	  LPS	  stimulation	  in	  vitro,	  Myc	  protein	  levels	  
and	  its	  genomic	  distribution	  were	  very	  similar	  to	  those	  seen	  in	  Eμ-­‐myc	  transgenic	  mice	  at	  
the	  pre-­‐tumoral	  stage:	  the	  number	  of	  Myc	  binding	  sites	  increased	  on	  active	  promoters	  as	  
well	  as	  on	  distal	  sites	  with	  pre-­‐existing	  H3K4me1/H3K27ac	  marks	   in	  control	  cells,	  which	  
can	  be	  equated	  to	  active	  enhancers	  (Sabò	  et	  al.,	  2014;	  Nie	  et	  al.,	  2012).	  Thus,	  as	  soon	  as	  
Myc	  levels	  rise	  upon	  LPS	  stimulation,	  the	  protein	  starts	  binding	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open	   and	   active	   chromatin	   at	   promoters	   and	   distal	   sites	   in	   a	  widespread	  manner	   (the	  
“invasion”	  phenomenon),	  in	  very	  similar	  to	  what	  occurs	  in	  Myc	  overexpressing	  B	  cells.	  
As	  outlined	   in	  other	  studies	   (Walz	  et	  al.2014;	  Sabò	  et	  2014)	  a	  sizeable	  portion	  of	  active	  
promoters	   (which	   are	   not	   only	   RNAPol2	   pre-­‐loaded	   but	   also	   H3K4me3	   marked)	   are	  
already	  bound	   at	   low	  Myc	   levels.	   These	   sites	   are	   still	   bound	   in	   LPS	   stimulated	   samples	  
where	   they	   represent	   the	  most	   enriched	   peaks.	   Thus,	   relative	   binding	   affinities	   to	   the	  
different	  genomic	  loci	  are	  maintained	  regardless	  of	  Myc	  expression	  levels	  in	  the	  cell	  (Sabò	  
et	  al	  2014;	  Sabò	  &	  Amati	  2014;	  Kress	  et	  al.,	  2015).	  This	  raise	  the	  possibility	  to	  distinguish	  
Myc	   high	   affinity,	   highly	   enriched,	   E-­‐boxes	   driven	   binding	   sites	   from	   low	   affinity,	   low	  
enriched	  and	  less	  specific	  sites.	  
Altogether,	  our	  ChIP-­‐seq	  data	  in	  activated	  B	  cells	  showed	  that	  Myc	  was	  initially	  bound	  to	  
promoters	   with	   high	   affinity	   sites,	   characterized	   by	   a	   higher	   presence	   of	   E-­‐boxes,	   and	  
then	   concomitant	   with	   its	   increasing	   levels,	   bound	   also	   low	   affinity	   sites,	   both	   at	  
promoters	  and	  distal	  enhancers.	  	  
	  
5.3	  Selective	  transcriptional	  response	  precedes	  RNA	  amplification	  	  
	  
By	  taking	  advantage	  of	  conditional	  c-­‐myc	  deletion,	  we	  produced	  what	  is	  to	  our	  knowledge	  
the	  first	  description	  of	  the	  Myc-­‐dependent	  transcriptional	  program	  in	  normal	  B	  cells.	  We	  
have	  shown	  that	  upon	  activation	  of	  quiescent	  B	  cells	  with	  LPS,	  c-­‐myc	   is	   rapidly	   induced	  
and	  is	  required	  for	  the	  subsequent	  induction	  and	  repression	  distinct	  sets	  of	  ca.	  1280	  and	  
1040	  genes,	  respectively,	  within	  the	  first	  8h	  upon	  LPS	  stimulation.	  This	  occurs	  before	  the	  
global	  increase	  in	  RNA	  content,	  which	  we	  could	  observe	  only	  starting	  from	  12h	  after	  LPS	  	  
	   127	  
	  
stimulation.	  In	  summary,	  as	  shown	  in	  other	  physiological	  or	  pathological	  settings	  (Sabò	  et	  
al.2014;	  Walz	  et	  al	  2014;	  	  Ji	  et	  al.,	  2011)	  we	  observed	  a	  selective	  transcriptional	  regulation	  
by	  Myc	  which	  does	  not	  fit	  with	  the	  general	  transcriptional	  activation	  by	  Myc	  described	  in	  
the	  amplifier	  model	   (Nie	  et	  al.2012;	  Lin	  C	  et	  al.2012).	  These	  results	  are	  also	   in	   line	  with	  
what	  observed	  during	  serum	  stimulation	  of	  fibroblasts,	  in	  which	  selective	  Myc	  dependent	  
gene	  activation	  occurs	  in	  the	  early-­‐mid	  G1	  phase	  of	  the	  cell	  cycle	  (Perna	  et	  al.2011),	  RNA	  
amplification	   occurring	   only	   at	   a	   later	   stage	   (Sabò	   et	   al.2014).	   Altogether,	   these	   data	  
imply	  that	  the	  primary	  action	  of	  Myc	  lies	  in	  the	  transcriptional	  control	  of	  specific	  groups	  
of	  genes,	  RNA	  amplification	  occurring	  as	  a	  secondary	  consequence	  of	  cellular	  activation	  
(Kress	  et	  al.,	  2015).	  
	  
5.4	  Myc	  and	  the	  global	  RNA	  increase	  
	  
	  A	  bit	   in	  contrast	  with	  the	  claim	  that	  Myc	  may	   induce	  concomitant	   increase	   in	  both	  cell	  
size	  and	  global	  RNA	  amplification	  (Nie	  et	  al.	  2012),	  we	  noticed	  a	  more	  gradual	  increase	  in	  
size	  (in	  part	  Myc	  dependent)	  and	  only	  a	   later	  abrupt	   increase	   in	  global	  RNA	  production.	  	  
The	   general	   increase	   in	   the	   transcriptional	   activity	   of	   a	   cell	   undergoing	   metabolic	  
activation	   and	   cell	   size	   expansion,	   as	   happens	   during	   plasma	   cell	   differentiation,	   is	   a	  
highly	   conserved	   process,	   which	   actually	   pre-­‐dates	   Myc	   in	   evolution	   (Marguerat	   and	  
Bähler,	   2012;	   	   das	   Neves	   et	   al.,	   2010).	   Thus	   growth	   in	   cell	   size	   correlates	   with	   RNA	  
amplification	  and	  cell	  cycle	  but	  the	  cause-­‐to	  effect	  relationship	  between	  these	  changes	  is	  
still	   unclear.	   Therefore,	   it	   will	   be	   fundamental	   to	   understand	   how	   Myc	   and	   its	   target	  
genes	  can	  impact	  on	  these	  processes	  considering	  that	  Myc	  is	  one	  of	  the	  regulators	  of	  cell	  
activation	  and	  growth.	  Recently,	  one	  possible	  mechanism	  of	  indirect	  RNA	  amplification	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promoted	  by	  Myc	  was	  highlighted	  by	  the	  finding	  that	  a	  single	  rate	  limiting	  enzyme	  in	  de	  
novo	   Purine	   biosynthesis	   (PRPS2),	   indirectly	   induced	   by	   Myc	   through	   enhanced	  
translation	   of	   its	   mRNA,	   is	   required	   for	   increased	   RNA	   production	   in	   Eμ-­‐myc	   B	   cells	  
(Cunningham	   JT	   et	   al.	   2014).	   In	   conclusion,	   the	   present	   work	   is	   a	   starting	   point	   to	  
delineate	  and	   test	   the	  pathways	   that	  mediate	   the	  effects	  of	  Myc	  on	  cellular	  physiology	  
and	  metabolism.	  
	  
5.5	  Myc	  occupancy	  is	  not	  predictive	  of	  gene	  regulation	  	  
	  
Combining	   Myc	   binding	   with	   gene	   expression	   profiles,	   we	   have	   shown	   here	   and	   in	  
published	   work	   (Sabò	   et	   al	   2014)	   that	   (i.)	   not	   all	   the	   genes	   bound	   by	   Myc	   were	  
differentially	   regulated,	   (ii.)	  around	  80	  %	  of	   induced	  genes	   (whether	  Myc	  dependent	  or	  
not)	  and	  70%	  of	  the	  repressed	  genes	  were	  Myc	  bound.	  For	  this	  reason,	  we	  concluded	  that	  
widespread	   Myc	   binding	   to	   active	   chromatin	   (or	   "invasion")	   couldn’t	   be	   equated	   to	  
productive	   engagement	   of	   Myc	   at	   all	   loci.	   Upon	   closer	   examination	   of	   the	   correlation	  
between	  Myc	   binding	   and	   transcriptional	   response,	  we	   found	   that	  Myc-­‐dependent	   LPS	  
Induced	  genes	  were	  bound	  at	  their	  promoters	  with	  higher	  frequency	  and	  higher	  intensity	  
compared	  to	  Myc-­‐repressed	  genes,	  a	  common	  feature	  observed	  in	  several	  other	  systems	  
in	  our	   lab	   (unpublished	  data).	   Conceptually,	   these	  observations	   are	   consistent	  with	   the	  
notion	  that	  the	  mechanisms	  of	  Myc	  repression	  are	  likely	  to	  be	  more	  indirect	  e.g.	  via	  Miz1,	  
AP-­‐2,	   Sp-­‐1,	   or	   other	   tethering	   factors	   with	   inhibitory	   activities	   (Peukert	   et	   al.,	   1997;	  
Gaubatz	  et	  al.,	  1995;	  Gartel	  et	  al	  2001).	  	  
The	   above	   notwithstanding,	   additional	   TFs	   may	   contribute	   to	   either	   repression	   or	  
activation	  by	  Myc.	  	  Motif	  analysis	  showed	  significant	  enrichment	  of	  many	  TF	  binding	  sites	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within	  the	  Myc	  peaks	  in	  the	  promoters	  of	  induced	  and	  repressed	  genes.	  	  For	  example,	  the	  
binding	  motif	  of	  Nfatc	  (nuclear	  factor	  of	  activated	  T	  cells)	  a	  factor	  that	  has	  a	  pivotal	  role	  in	  
activation	  of	  the	  immune	  response	  in	  T	  and	  B	  cells	  (Serfling	  et	  al.,	  2000;	  Bhattacharyya	  et	  
al.	  2011),	  was	  enriched	  at	  the	  promoters	  of	  Myc-­‐dependent	  and	  independent	  LPS	  induced	  
genes.	  Among	   the	  motifs	  enriched	   in	   the	  Myc-­‐dependent	   LPS	   repressed	  genes,	  we	  also	  
found	  zinc	  finger	  proteins	  (such	  as,	  Zfp410)	  and	  Smad	  proteins.	  Smad2	  and	  3	  are	  known	  
to	   form	   a	   stable	   complex	   with	   Myc	   on	   the	   p15	   and	   p21	   promoters,	   blocking	   Sp1	  
dependent	  transcriptional	  activation	  of	  these	  genes	  (Feng	  X.	  et	  al	  2002).	  	  The	  distribution	  
of	   cofactors	   and	   TFs	   in	   the	  Myc-­‐regulatory	   network	   remains	   to	   be	   completely	   clarified	  
and	  a	  deeper	  analysis	  of	  the	  motifs	  listed	  in	  this	  work	  will	  be	  needed	  in	  order	  to	  validate	  
candidate	  co-­‐regulators.	  
	  
5.6	  Myc	  binding	  to	  enhancers	  	  
	  
Whereas	   the	   role	   of	   Myc	   at	   promoters	   has	   been	   extensively	   studied,	   Myc	   binding	   to	  
enhancers,	  which	  was	  observed	  in	  different	  systems	  and	  cell	  lines	  (Shi	  et	  al.,	  2013;	  Lin	  et	  
al.2012;	   Sabò	   et	   al	   2014),	   still	   lacks	   clear	   functional	   consequences.	   We	   found	   that	   in	  
activated	  B	  cells	  a	  vast	  portion	  of	  Myc	  peaks	  falls	  in	  distal	  regions	  with	  the	  characteristic	  
features	  of	  enhancers,	  in	  particular	  high	  H3K4me1	  and	  low	  H3K4me3	  content.	  These	  sites	  
showed	  a	   lower	  Myc	  binding	   intensity	  compared	  to	  the	  ones	  on	  promoters	  but	  showed	  
similar	  E-­‐box	  frequencies.	  By	  associating	  enhancers	  and	  genes	  based	  on	  linear	  proximity	  
in	   the	   genome,	   we	   concluded	   that	   Myc	   binding	   to	   enhancers	   in	   Eµ-­‐myc	   B	   cells	  
strengthens	  the	  regulation	  of	  the	  associated	  genes,	  whether	  induced	  or	  repressed	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(Pelizzola	   M.	   and	   Sabò	   A.,	   unpublished).	   A	   more	   extensive	   picture	   of	   the	   enhancer	  
repertoire	   in	   B	   cells	   will	   be	   possible	   through	   the	   analysis	   of	   long-­‐range	   conformation	  
capture	  experiments	  already	  published	  in	  B	  cells	   (Lin	  YC.	  et	  al.,	  2012)	  and/or	  ongoing	   in	  
the	  lab	  in	  the	  Eμ-­‐myc	  model,	  allowing	  a	  more	  precise	  assignment	  of	  enhancers	  to	  specific	  
genes.	  
	  
5.7	  Myc-­‐regulated	  transcription	  is	  associated	  with	  changes	  in	  both	  RNAPol2	  
recruitment	  and	  elongation	  
	  
In	   order	   to	   understand	   if	   there	   is	   a	   relationship	   between	   Myc	   binding	   and	   RNAPol2	  
recruitment	   and/or	   elongation,	   we	   profiled	   RNAPol2	   by	   ChIP-­‐seq	   in	   wt	   and	   c-­‐myc∆/∆	  
B	  cells	   before	   and	   after	   LPS	   treatment.	   We	   observed	   that	   most	   of	   the	   Myc	   bound	  
promoters	   are	   not	   only	   actively	   marked	   by	   H3K4me3	   and	   H3K27ac	   but	   are	   also	   pre-­‐
loaded	  with	  RNAPol2,	  a	  common	  behavior	  observed	  in	  several	  systems	  (Guccione	  et	  al.,	  
2006;	   Lin	   C	   et	   al.,	   2012;	   Nie	   et	   al.,	   2012;	   Sabò	   et	   al.2014;	  Walz	   et	   al.,	   2014).	   Besides	  
H3K4me1,	  RNApol2	  was	  also	  found	  at	  distal	  Myc-­‐binding	  sites.	  The	  absence	  of	  RNApol2	  
peaks	   on	   promoters	   and	   enhancers	   that	  were	   not	   targeted	   by	  Myc,	   together	  with	   the	  
absence	   of	   active	   histone	   marks,	   further	   consolidated	   the	   concept	   that	   Myc	   does	   not	  
access	  inactive	  chromatin.	  
	  With	  our	  knockout	  model,	  we	  were	  in	  principle	   in	  the	  best	  situation	  to	  investigate	  how	  
Myc	  affects	  the	  transcription	  via	  RNAPol2.	  In	  this	  regard,	  quantitative	  analysis	  of	  ChIP-­‐seq	  
reads	  on	  TSS	  and	  gene	  bodies	  and	  their	  ratios	   (also	  known	  as	  the	  Stalling	   Index)	  before	  
and	  after	  LPS	  stimulation	   in	  wt	  and	  c-­‐myc∆/∆	   	   	   cells	   showed	  different	  effects	  on	  RNAPol2	  
distribution	  in	  Myc	  dependent	  and	  independent	  genes.	  However,	  our	  data	  pointed	  to	  a	  	  
	   131	  
	  
general	   increase	   in	   Pol2	   loading	   on	   promoters	   in	   LPS-­‐stimulated	   cells,	   this	   effect	   being	  
partially	   Myc-­‐dependent.	   The	   nature	   and	   validity	   of	   this	   phenomenon	   remain	   to	   be	  
addressed.	   The	   roles	   of	   RNAPol2	   loading	   or	   elongation	   in	   Myc-­‐regulated	   transcription	  
remain	   a	   matter	   of	   debate.	   In	   human	   B	   cells	   for	   example,	   activation	   of	   a	   tet-­‐Myc	  
transgene	  was	   shown	   to	   induce	   Pol2	   loading	   at	  Myc-­‐induced	   genes	   (Martinato	   F	   at	   al.	  
2008).	   c-­‐Myc	   inhibition	   with	   drug	   instead	   was	   described	   to	   affect	   indiscriminately	  
transcription	   at	   the	   pause-­‐release	   step	   (Rahl	   et	   al.,	   2009;	   Lin	   C.	   et	   al.,	   2012;	   Nie	   et	  
al.,2012;	   Rahl	   PB	   &	   Young	   R.	   2014).	   On	   this	   basis	   Myc	   was	   described	   as	   a	   universal	  
potentiator	  of	  pause-­‐release	  at	  all	  actively	  transcribed	  promoters	  via	  recruitment	  of	  the	  
P-­‐TEFb	  complex	  (cyclin	  T1	  and	  Cdk9).	  However,	  our	  data	  and	  the	  already	  published	  one	  
(Sabò	  et	  al.,	  2014),	  clearly	  show	  that	  no	  such	  global	  role	  could	  be	  attributed	  to	  Myc.	  Given	  
the	   binding	   of	  Myc	   to	  multiple	   types	   of	   co-­‐regulators,	   including	   histone	  modifiers	   and	  
remodelers	   (Hann	  SR.,	  2014),	  we	  surmise	  that	  diverse	  mechanisms	  are	   likely	  to	  account	  
for	  its	  transcriptional	  activity,	  most	  likely	  in	  a	  gene-­‐	  and	  context-­‐dependent	  manner.	  	  
	  
5.8	  General	  vs	  specific	  mode	  of	  transcriptional	  regulation	  by	  Myc	  
	  
The	  genome	  of	  naïve	  B	  cells	  is	  poised	  for	  rapid	  activation.	  In	  particular,	  90%	  of	  promoters	  
from	  genes	   in	  GO	  lymphocytes	  are	  polymerase	   loaded	  but	  un-­‐melted	  with	   low	   levels	  of	  
TFIIH	   supporting	   only	   basal	   transcription	   (Kouzine	   et	   al	   2013).	   Myc,	   trough	   its	  
transactivation	  domain,	  may	  promote	  unwinding	  by	  recruiting	  or	  activating	  TFHII	  (Cowling	  
et	  al.,	  2007).	  One	  effect	  may	  be	  a	  global	   increase	  in	  global	  phosphorylation	  of	  RNAPol2,	  
with	  widespread	  effects	  on	  transcription	  activation	  and	  mRNA	  metabolism.	  This,	  together	  
with	  the	  observation	  that	  Myc,	  in	  recruiting	  p-­‐TEFb,	  affects	  the	  pause	  release	  of	  all	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activated	   genes	   (Rahl	   et	   al.,	   2010)	   depicts	   the	   generic	   mechanism	   of	   transcriptional	  
amplification	  by	  Myc	  (Nie	  et	  al.,	  2012;	  Lin	  C.	  et	  al.,	  2012).	  Our	  data	  support	  an	  opposing	  
view,	  pointing	  to	  Myc-­‐specific	  mechanism	  of	  transcriptional	  regulation	  (Sabò	  et	  al.,	  2014;	  
Walz	  et	  al.,	  2014)	  with	  RNA	  amplification	  occurring	  as	  a	   secondary	  event.	  Therefore,	  at	  
the	   moment,	   the	   only	   unifying	   model	   that	   consistent	   with	   all	   available	   data	   is	   the	  
differential	   gene	   regulation	   by	   Myc;	   direct	   transcriptional	   amplification	   remains	   to	   be	  
formally	   proven	   and	   is	   not	   closely	   required	   to	   explain	   any	   of	   the	   existing	   experimental	  
observations.	  In	  conclusion,	  our	  evidences	  show	  indeed	  that	  Myc	  regulates	  selective	  gene	  
expression	   programs	   in	   B	   cells	   affecting	   mainly	   RNAPol2	   recruitment	   of	   these	   specific	  
genes	  and	  leading	  to	  a	  cellular	  metabolic	  remodelling.	  	  
	  
5.9	  A	  core	  of	  Myc	  target	  genes	  involved	  in	  metabolism	  and	  RNA	  biogenesis	  	  
	  
As	  already	  discussed,	  Myc	  regulates	  specific	  gene	  programs	  which	  are	  mainly	  involved	  in	  
growth,	  cell	  cycle,	  energy	  metabolism,	  mitochondrial	  biogenesis,	  nucleotide	  biosynthesis	  
and	  RNA	  biogenesis,	  and	  maybe	  feed	  back	  on	  global	  RNA	  production.	  	  We	  thus	  proposed	  
that	  Myc	  can	  induce	  RNA	  amplification	  indirectly	  (Sabò	  et	  al.,	  2014;	  Kress	  et	  al.,	  2015)	  but	  
how	   Myc	   target	   genes	   may	   lead	   to	   these	   physiological	   changes	   in	   activated	   B	   cells	  
remains	  to	  be	  addressed.	  Through	  comparison	  of	  our	  data	  in	  LPS-­‐stimulated	  B	  cells	  with	  
the	   Eμ-­‐myc	   transcriptional	   dataset	   (Sabò	   et	   al	   2014)	   and	   serum	   activated	   fibroblasts	  
(Perna	  et	  al.,	  2012)	  we	  could	  identify	  a	  core	  of	  Myc	  dependent	  genes,	  which	  are	  probably	  
required	   for	   metabolic	   activation	   and	   growth.	   For	   testing	   the	   indirect	   model	   of	   RNA	  
amplification,	  therefore,	  we	  could	  functionally	  characterize	  these	  putative	  target	  genes	  or	  
pathways	  using	  RNA	  interference	  or	  chemical	  drugs	  in	  order	  to	  un-­‐couple	  Myc	  binding	  to	  	  
	   133	  
	  
the	  genome	  from	  increase	  in	  cell	  growth	  and	  proliferation.	   	  Recently,	  the	  importance	  of	  
these	  Myc	  dependent	  pathways	  involved	  in	  metabolism	  and	  translation	  was	  underlined	  in	  
a	  successful	  pharmaceutical	  treatment	  of	  Eμ-­‐myc	  lymphomas.	  The	  combined	  targeting	  of	  
ribosomal	   DNA	   biogenesis	   and	   mTOR	   protein	   translation	   has	   provided	   remarkably	  
therapeutical	  benefits	  in	  the	  treatment	  of	  Myc-­‐driven	  cancer	  (Devlin	  et	  al	  2015).	   	   In	  this	  
regard,	  the	  strategy	  of	  targeting	  downstream	  regulators	  of	  Myc	  both	  in	  physiological	  and	  
pathological	   contexts	   may	   still	   represent	   a	   useful	   way	   to	   truly	   understand	   Myc	  
physiological	  mechanisms	  of	  action	  and	  overcome	  Myc-­‐driven	  tumors.	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